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Foreword
This workshop, Recent Developments in the Research and Control of Theileria
annulata, is the first of two that the International Laboratory for Research on Animal
Diseases (ILRAD), located in Nairobi, Kenya, has convened to assist it in research
planning for the quinquennium 1993–1997. ILRAD has a global mandate for the
improvement of livestock production in tropical and sub-tropical areas through
developing better methods of disease control. The focus of its research since its
inception in 1973 has been theileriosis caused by Theileria parva and tsetse-fly-trans-
mitted animal trypanosomiasis. A method of immunization against T. parva, based
on infecting animals with live parasites and simultaneous treatment with tetracyclines
to control the severity of the infection, was already available when ILRAD was
established. ILRAD has worked to improve the infection-and-treatment method of
immunization by developing new methods of characterizing the antigenic diversity
of T. parva stocks and strains in the field and by characterizing immunizing parasite
stocks in several countries. To define the tick-borne disease (TBD) environments in
which infection-and-treatment immunization is being used, ILRAD has also de-
veloped more sensitive and specific assays for the diagnosis of TBD.
A novel non-living vaccine would be a great improvement over the current live
vaccine.  Development of  such a sub-unit vaccine  must be  based  on  a  detailed
understanding of the important protective immune responses of cattle to T. parva and
of  the antigens that provoke them; this  has  been  the  major  focus  of  ILRAD’s
Theileriosis Research Program. In the longer term, the development of an antigen-
based, vector-delivered vaccine for T. parva will have to be considered in parallel
with other TBD pathogens as these parasites are frequently considered a single
disease complex for control purposes. The progress made in research on T. parva at
ILRAD, particularly in defining the nature of immune responses to this parasite, is
of direct relevance to T. annulata research. ILRAD’s establishment of a vaccine
development project within its Theileriosis Program, for the purpose of investigating
the induction of protective responses using different vector and adjuvant systems in
cattle, provides another important opportunity for future ILRAD work on other TBDs
in collaboration with other laboratories.
With these facts in mind, ILRAD hosted this workshop to discuss the magnitude
of the T. annulata disease problem, the methods currently being used to control T.
annulata infections, the problems encountered with these control methods, results of
recent research on the epidemiology and molecular biology of T. annulata infections
and developments towards new vaccines against this parasite. It is hoped that these
discussions will help ILRAD to identify areas where its research program may
contribute to research on T. annulata, and, should funding and mandate allow, to
establish collaborations that will contribute towards the improvement in control of T.
annulata and other TBDs using non-living, easily delivered vaccines.
I would like to thank Dr. Jim Lenahan and Mr. Kepher Nguli for their assistance
in planning, organizing and running this workshop. Several ILRAD colleagues acted
as rapporteurs and prepared the summaries around which the `Concluding discussion’
was written. The original summary of the concluding discussion was prepared by Ms.
Susan MacMillan and Dr. Subhash Morzaria. Ms. Doris Churi and Ms. Susan Nduta
retyped the manuscripts and Mr. William Umbima checked and corrected the refer-
ences. The map showing the distribution of T. annulata was prepared by Mr. Russ
Kruska and Mr. Joel Mwaura. Drs. Noel Murphy and Alan Young read and corrected
the drafts. I am particularly grateful to Mr. Peter Werehire for proofreading and
preparing the layout for these proceedings.
Thomas T. Dolan
International Laboratory for
Research on Animal Diseases
Nairobi, June 1992
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Opening address
A.R. Gray
Director General
International Laboratory for Research on Animal Diseases
P.O. Box 30709
Nairobi, Kenya
It is my pleasant task to welcome you all to ILRAD as we convene this workshop on
Recent Developments in Research and Control of Theileria annulata. A number of
you have visited ILRAD previously and others are here for the first time. I hope you
will take the opportunity during your visit to establish or renew friendships with
ILRAD staff to learn what progress we are making, and perhaps also find time to see
Nairobi and some of Kenya’s other attractions. For the moment, though, I would like
to say a few words about why we have invited you here this week.
As most of you know, ILRAD’s task as an institution belonging to the Consultative
Group on International Agricultural Research is to identify improved methods for
alleviating the adverse effects of livestock diseases on the use of animals for food
production and agricultural purposes in developing countries. For the past 15 years,
the Laboratory has concentrated its research on African trypanosomiasis and East
Coast fever caused by Theileria parva. Both disease complexes continue to cause
substantial losses in livestock productivity over wide areas of the African continent.
In common with many other scientific organizations, ILRAD periodically revises
its long-term strategic plan (on a ten-year horizon) and prepares program and budget
proposals to prioritize and put the strategic plan into effect (on a five-year horizon).
ILRAD’s next planning quinquennium is 1993–1997. It is quite possible that most
of ILRAD’s proposals for the five-year period starting in January 1993 will be a
continuation of current activities on tsetse-transmitted trypanosomiasis and East
Coast fever, with associated socioeconomic studies and a cooperative research and
training program. However, we have to remain alert to the possibility that other
inadequately controlled disease complexes such as cowdriosis, anaplasmosis, babe-
siosis and streptothricosis, or parasites related to those we are already working on,
such as Trypanosoma evansi and Theileria annulata, may qualify on various grounds
for some of the Laboratory’s attention, through cooperative programs, sharing of
materials, or even core programs and staffing changes.
In the next 18 months or so, ILRAD will be taking a look at progress being made
in research on improved control of some of these disease conditions. We will do this
through a series of literature reviews and workshops like this one, concerned with
research on Theileria annulata. While ILRAD has been concentrating on Theileria
parva, your organizations have been working on control of Theileria annulata, which
is globally a more widespread parasite.
Our proposals for the next five years of work at ILRAD will also eventually be
considered by the next major external review of the Laboratory scheduled for early
1992. Because all of you are distinguished scientists in the field of Theileria annulata,
we  would  like your input into this  review and planning  process, through your
participation in this workshop.
The objectives of the workshop are to review the following:
• the present distribution and economic importance of tropical theileriosis
• the current state of control measures for this disease, including use of acaricides,
immunization and chemotherapy
• the state of development of improved epidemiological, preventive and diagnostic
tools
• how ILRAD might contribute either directly to research in these areas or indirectly
by provision of reagents or transfer of technologies
I encourage your full participation in the meeting and urge you to strive for a useful
outcome in the form of a high-quality position paper on recent developments in the
research and control of Theileria annulata.
I wish you a successful workshop.
OPENING ADDRESS
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COUNTRY REPORTS
Theileria annulata and its control in China
Z.H. Zhang
Science and Technique Development Company of Ningxia
Animal Husbandry and Veterinary Institute of Ningxia,
Academy of Agricultural and Forestry Sciences
Yinchuan, Ningxia
People’s Republic of China
Theleriosis is an epidemic disease recorded in ancient China. In this country, it kills
cattle during the wheat harvesting season. The clinical signs are a continuous fever
and an immediate loss of appetite and condition followed by death. Because of poor
laboratory diagnostic techniques, the causative agent was not identified until the
1950s when a series of  investigations showed  that  this disease was caused by
Theileria annulata and transmitted by Hyalomma detritum detritum. In the 1960s,
we began research into drug treatment and immunization methods. The `Bovine
Theileria annulata Vaccine’ and `Bovine TheilerioCide’ were applied with great
success in the 1970s. The application of these two specific measures and elimination
of the ticks basically controlled theileriosis in China in the 1980s.
SYMPTOMS IN THE INFECTED CATTLE
The prepatent period from the attachment of infected ticks to the onset of fever is
10–13 days. For the first five days of the disease, the fever is high and continuous. A
remittent fever follows for another five days, followed by a fall in body temperature
before death. The prescapular and precrural lymph nodes are enlarged. The mucous
membranes of the eyelid, anus and vagina develop hyperemia and pinpoint haemor-
rhages or petechiae appear. In some cases, jaundice and papular urticaria of skin
lesions have been observed. The cattle show decreased rumination, reduced rumen
peristaltic movement and occasionally a depraved appetite. There is constipation or
diarrhoea with occult blood in the faeces, but no haemoglobin is detected in the urine.
Lactation is reduced or ceases and abortion can occur. The animal becomes emaciated
and often lies with the neck curved back to the shoulder. The animal becomes weak
and is reluctant to move. The course of the disease from fever to death ranges from
one to two weeks. The mortality rate is over 33% and survivors take a long time to
recover.
PATHOLOGICAL CHANGES
On postmortem examination, numerous ulcers are detected in the mucous membrane
of the abomasum of one to two millimetres diameter. Some ulcers are linked together
to form wide, shallow lesions that may penetrate to the muscle layer. New ulcers are
red and older ones grey in colour. The spleen is enlarged with subcapsular haemor-
rhages. The cut surface bulges with a soft pulp. The liver is swollen with a brittle
texture. The gall bladder is covered by serosal haemorrhages and distended with bile.
Some of the lymph nodes in the thoraxic, abdominal and pelvic cavities are haemor-
rhagic. The cut surface of the nodes is purple in colour and very moist. Ecchymotic
haemorrhages are distributed in the serosal surface of the large and small intestines.
Some ecchymotic haemorrhages appear on the surface of the heart and the blood is
thin. The lungs are congested and there are small haemorrhages throughout the
kidney.
HAEMATOLOGICAL CHANGES
The erythrocyte count is decreased to below 3 million per cubic millimetre and the
haemoglobin count to less than 3 grams per 100 ml.
ETIOLOGY
The life cycle of T. annulata includes the following stages.
Sporozoite stage: When infected adult ticks attach to cattle, the sporozoites
develop in the tick salivary gland and are injected with the tick saliva. The sporozoites
invade the lymphoid cells and schizonts are detected in 10–13 days. This is the
prepatent period of the disease.
Schizont stage: The schizont-parasitized lymphocytes proliferate and invade and
damage the lymphoid system and produce lesions in the abomasum and skin, liver
and spleen.
Piroplasm stage: The piroplasm parasitizes the erythrocytes and causes destruc-
tion of these cells with a decrease in the erythrocyte count and haemoglobin level.
The parasitaemia pattern (infected erythrocytes per 1000) can be divided into two
types causing different disease syndromes. The peracute form in which an initial rapid
rise in parasitaemia to approximately 30% erythrocytes infected over three days is
observed and the cattle die without a fall in parasitaemia. The cattle showing this
syndrome are difficult to cure. The second is the acute form in which the parasitaemia
does not rise as rapidly as in the peracute form and does not exceed 30%. The
parasitaemia then falls slowly to below 1% over one to two weeks. A large number
of these cattle could be cured by treatment, but usually only a few cases recover
spontaneously. When ticks feed, they ingest piroplasms, which differentiate to
gametocytes, fuse to form zygotes and then kinetes, which enter the tick gut cells and
finally penetrate the salivary gland cells and develop to sporozoites. Theileria
annulata completes its sexual generation in ticks and its asexual generation in cattle.
VECTOR TICKS
Hyalomma ticks carry and spread T. annulata in China. In Ningxia, the important
species is H. detritum detritum. The life cycle of this tick is divided into four
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stages—adult, egg, larva and nymph. During the summer season in China, the adult
ticks emerge from holes and cracks in the walls and floors of cattle sheds and attach,
feed and mate on cattle. The females fall off and lay eggs in the holes and cracks.
They die after oviposition. The males die after mating on the cattle. In autumn, the
eggs hatch to larvae under suitable conditions of temperature and humidity. In early
winter, the larva infest cattle to feed and keep warm through the winter. When spring
comes, the larva moult to nymphs. Once engorged, the nymphs drop off, crawl into
holes and moult to adults under suitable conditions. At each stage the tick plays a
role in spreading T. annulata. The larvae and nymphs are infected by the blood in
which the gametocytes are contained. The adult transmits the sporozoites, which
cause disease in susceptible cattle.
EPIDEMIOLOGY
The disease is endemic in northern China, the region in which Hyalomma species
exist. The disease is seasonal, being prevalent from June to September, with peaks
in July and August when the adult ticks are active.
TREATMENT
Effective drugs for the treatment of theileriosis caused by T. annulata are available
(Zhang, 1980, 1987). Primaquin phosphate is an effective drug which eliminates
the causative agent. It was identified in our institute and has been used success-
fully for 15 years in China. The effective dose is as low as 0.75 mg/kg body weight
given orally for three days. It is completely safe as the toxic dosage is 20 times
greater than the effective dosage. The efficacy rate is 100%. The parasites in red
blood cells begin to be destroyed within a few hours of administration and are
eliminated totally at the end of the course of treatment. Primaquin phosphate not
only eliminates the erythrocytic stage of T. annulata but also those of T. sergenti
and of T. hirci in sheep and goats and Babesia caballi in horses.
Supportive treatment to arrest capillary bleeding is usually given in the form of
calcium chloride (10%) solution at 50 to 100 ml intravenously in two doses at a
48-hour interval. The petechiae begin to discolour soon after injection. As treat-
ment for anaemia, a chemical compound of iron and cobalt, together with liver
extract and vitamin A, D, and B12, have been used, but satisfactory results have
not been obtained. The most effective treatment is blood transfusion, but this is
expensive and is usually only given to very valuable imported animals. Encourag-
ing results have been obtained with a Chinese drug named `millettia’ which showed
an effect on increasing the haemoglobin, but more research is required to evaluate
its activity. To restore the rumen and intestinal motility, a mixture of 10% sodium
chloride solution (50–100 ml), 10% vitamin C (10–50 ml) and 10% sodium
benzoate caffeine solution (5–10 ml) is prepared and administered twice intravenously
at a 48-hour interval.
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TABLE 1. Number of cattle receiving Theileria annulata vaccine in 12 provinces of the People’s Republic of China from 1975 to 1990.
Province 1975 1976 1977 1978 1979 1980 1981 1982
Ning 987 838 550 1,904 640 3,972 1,356 4,975
Meng 0 124 43 57 4,961 160 10,567 2,000
Xin 0 0 0 0 615 366 550 1,041
Gan 0 0 0 0 0 0 0 1,060
Shan 0 0 0 0 0 0 0 0
Yu 0 0 0 0 0 0 957 3,833
Ji 0 0 0 0 0 0 0 0
Lu 0 0 0 0 0 0 0 0
Jin 0 0 0 0 0 0 327 0
E 0 0 0 0 0 0 0 0
Liao 0 0 0 0 0 0 0 0
Wan 0 0 0 0 0 0 0 0
Annual total 987 962 593 1,961 6,216 4,498 13,757 12,909
Cumulative total 987 1,949 2,542 4,503 10,719 15,217 28,974 41,883
Province 1983 1984 1985 1986 1987 1988 1989 1990 Total vaccinated
Ning 1,387 10,300 45,760 13,390 20,000 20,700 1,000 0 127,759
Meng 13,581 55,000 30,400 32,240 120,000 137,013 93,920 153,680 653,746
Xin 1,114 2,000 1,600 17,460 2,500 37,540 2,500 2,200 69,486
Gan 2,565 3,600 1,200 600 0 0 0 0 9,025
Shan 0 0 3,867 96,280 50,000 90,100 50,700 45,420 336,367
Yu 15,000 50,300 91,600 78,300 25,000 30,340 12,200 1,000 308,530
Ji 117 3,600 3,500 0 0 0 0 120 7,337
Lu 0 0 0 800 1,000 1,100 400 0 3,300
Jin 0 0 84,200 82,160 500 600 0 0 167,787
E 0 0 24,000 22,920 30,000 33,080 30,000 35,620 175,620
Liao 0 0 0 0 500 2,000 400 25,300 28,200
Wan 0 0 0 0 500 0 0 0 500
Annual total 33,764 124,800 286,127 344,150 250,000 352,473 191,120 263,340
Cumulative total 75,647 200,447 486,574 830,724 1,080,724 1,433,197 1,624,317 1,887,657 1,887,657
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VACCINATION
China has successfully produced a bovine T. annulata vaccine, which is highly
effective in preventing disease. The safety coefficient is 100%, the prevention rate is
over 99% and the duration of immunity is over one year. The Chinese Ministry of
Agriculture has ratified the Animal Husbandry and Veterinary Research Institute of
Ningxia Agriculture and Forestry Academy to set up a new laboratory to produce this
vaccine and supply it to all the epidemic areas of China and to offer it for sale
elsewhere in the world.
By 1990, 1.9 million cattle had been treated with the vaccine (Table 1) and
disease losses have decreased to a very low level. The practical results are very
noticeable. In 1985, a patent for the preparation technique of the vaccine was
TABLE 2. The protection rate of Theileria annulata-vaccinated cattle in 28 epidemic areas
of the People’s Republic of China (1975–1988).
Epidemic Vaccinated Protected Protection
area Year cattle (head) cattle (head) rate %
NP 1975–1976 1,930 1,919 99.43
NHQ 1975–1983 3,587 3,578 99.75
MW 1976–1983 875 861 98.40
NH 1977 550 541 98.36
NHQ 1973–1983 14,197 14,197 100
MZ 1979 4,700 4,636 98.64
XH 1979–1983 3,701 3,699 99.95
MXZ 1981 1,542 1,532 99.35
HL 1981 957 949 99.16
SR 1981 327 327 100
MA 1981–1983 570 570 100
GJ 1982 92 92 100
GCH 1982 976 976 100
HS 1982 3,833 3,818 99.61
MS 1982 134 134 100
MSH 1983 1,359 1,352 99.48
HX 1983 117 115 98.29
MW 1983 9,370 9,315 99.41
MX 1984 8,860 
MX 1985 9,711  41,305 98.59
MX 1986 23,324 
SF 1985 1,400 1,400 100
SB 1985–1986 52,506 52,484 99.96
S 1986–1988 191,809 190,849 99.50
MS 1987 27,906 27,906 100
XH 1987–1988 4,400 4,400 100
MX 1988 37,775 37,775 100
MX 1988 22,340 22,340 100
1975–1988 428,848 427,070 99.59
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granted in the People’s Republic of China. The technical regulations for the
manufacture and examination of the vaccine have been approved by The National
Control Institute of Veterinary Bio-Products and Pharmaceuticals of China. Field
applications of the vaccine in the 1.9 million cattle in China for more than 16 years
have shown that it is very safe and effective. A transient mild fever has been
detected in only a few cattle in the second week following the injection of the
vaccine. Vaccination generally does not produce any clinical signs. It does not
cause abortion or a reduction in milk production. A most important factor is that
the  vaccinated cattle  do not act as a  source of infection to ticks because the
erythrocytic parasites are not produced.
Clinical trials before the vaccine was marketed showed that all vaccinated calves
were fully protected against lethal challenge with 50 infected ticks. The vaccinated
cattle were widely distributed over the northern half of China and were of various
TABLE 3. The incidence rate of clinical Theileria annulata in non-vaccinated cattle in 28
epidemic areas of the People’s Republic of China (1975–1988).
Epidemic Non-vaccinated Diseased Incidence
area Year cattle cattle rate %
NP 1975–1976 243 33 13.58
NHQ 1975–1983 45 12 26.67
MW — — — —
NH — — — —
NHQ — — — —
MZ — — — —
XH 1979–1983 144 14 9.72
MXZ 1981 332 158 47.59
HL 1981 355 33 9.30
SR — — — —
MA 1981–1983 34 17 50.00
GJ — — — —
GCH — — — —
HS 1982 317 191 60.25
MS — — — —
MSH 1983 64 34 53.12
HX — — — —
MW — — — —
MX 1984 150 40 26.67
MX 1985 182 43 23.63
MX 1986 590 65 11.02
SF 1985 178 16 8.99
SB 1985–1986 3,047 453 14.87
S 1986–1988 364 63 17.31
MS 1987 100 70 70.00
XH 1987–1988 348 44 12.64
MX 1988 18 7 38.89
MX 1988 1,996 114 5.71
1975–1988 8,507 1,407 16.54
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breeds, age and usage. Nevertheless, the protective rate was never below 98% and
the average is 99.59% (Tables 2 and 3). The dose of vaccine is 1 ml intramuscularly
for each animal irrespective of breed, sex, age or body weight. The vaccine can be
stored in 4 °C in a refrigerator for two months or at room temperature for three days.
For delivery, the vaccine can be kept in an ice bag in an insulated box for three days.
Dry ice or liquid nitrogen containers are not needed. The immunity induced by the
vaccine is maintained for over 13 months in cattle kept in isolation.
CONTROL MEASURES
• One injection of `Bovine Theileria annulata Vaccine’ should be given for all the
susceptible herds in April or May, one to two months before the disease season
each year.
• Ticks can be controlled by the use of organophosphorous or arsenical compounds
in summer and autumn. The cattle should be examined frequently to ensure that
there are no ticks on them.
• At the end of the epidemic season in September, cement or mud should be used to
cover the crevices and holes in the walls of cattle sheds in order to kill the old
adults, new eggs and larvae of ticks.
• The `TheilerioCide’ and other medicines described should be available for the
treatment of sick animals such as unvaccinated cattle, newborn calves and recently
imported cattle.
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Recent developments in research and control
of Theileria annulata in India
D.K. Singh
Animal Disease Research Laboratory
National Dairy Development Board
Anand 338 001, Gujarat, India
During the first two decades of this century, theilerial organisms were regularly
recorded in the blood of cattle maintained at Muktheswa, Uttar Pradesh. Since then,
several reports describing the detection of theilerial piroplasms in the blood of cattle
have appeared in the literature. Acute clinical cases of theileriosis were first recorded
on 12 June, 1922,  in hill  bulls. From  1923 to 1924, the presence  of theilerial
piroplasms was reported in the blood smears of 1,368 out of 5,158 cattle examined.
In 1930, outbreaks of clinical theileriosis were recorded in imported herds maintained
at Lahore, Bangalore, Allahabad and Kirkee. Since then, occasional outbreaks of
theileriosis have been recorded, mainly in cross-bred and exotic cattle. The disease
signs recorded in these animals were high fever, lymph node enlargement, anaemia,
petechiae of the mucous membranes and various degrees of jaundice.
Indigenous cattle and buffaloes (Bubalus bubalis) have an inherent resistance to
disease and harbour theilerial piroplasms in their erythrocytes as symptomless
carriers. Until the mid-1960s, theileriosis was enzootically stable. This stability was
upset with the large-scale introduction of exotic (taurine) cattle and with the advent
of extensive cross-breeding programs for the improvement of milk production. Today,
India has approximately 200 million cattle, of which 10 million are either pure-bred
or taurine crosses. With the establishment of many Bull Mother Farms of exotic
breeds, there has been a rapid increase in the taurine blood in dairy cattle, which show
a high degree of susceptibility to theileriosis. India has approximately 26,000 artifi-
cial insemination stations and several embryo transfer centres actively engaged in
upgrading the existing 82% nondescript cattle. With the rapid increase in the number
of cross-bred cattle, the previous enzootic stability of theileriosis has been upset and
outbreaks of acute disease with 30 to 60% mortality have been recorded.
Because of the importance of tropical theileriosis, several research schemes were
initiated in agricultural universities and other research institutes in India. Serological
screening, organized under different programs sponsored by the Indian Council of
Agricultural Research (ICAR), indicated that 30 to 60% of cattle maintained at
organized farms had antibodies to Theileria annulata. Various species of Hyalomma,
H. anatolicum anatolicum, H. dromedarii, H. marginatum isaaci and H. detritum are
potential vectors of T. annulata in India. Epidemiological studies conducted in Kheda
District of Gujarat during 1989 indicated that 26.3% of males and 39.1% of females
of H. a. anatolicum ticks feeding on cattle and buffaloes had T. annulata in their
salivary glands. Screening of blood smears collected from apparently normal indige-
nous and cross-bred cattle and buffaloes in village conditions indicated that 45.95%,
61.77% and 10.82%, respectively, were  positive  for piroplasms of T. annulata.
Serological screening  using  the  indirect immunofluorescent antibody (IFA) test
showed that 6.18%, 72.68% and 21.13% of local and cross-bred cattle and buffaloes
had mean titres of 172.50, 694.60 and 113.17, respectively.
Considerable immunological overlap was observed amongst the isolates of T.
annulata from different geographical regions of the country and all were found to be
immunogenically related. Most of these isolates were found to be highly pathogenic
and their pathogenicity was dose dependent. In Kheda District alone, where the
cross-bred and exotic cattle population is 40,000, a total of 3,800 acute cases of
tropical theileriosis were recorded during the year 1988–1989. Considering the
average cost of treatment at US$4.75 per visit and that each case involved an average
of four visits, the total expenditure on treatment of these cases would be US$72,000.
An additional attributed loss of US$173,780.50 would be incurred in the loss of milk
by females at an average of four litres per day for an estimated three months. If there
were a 5% mortality in the affected animals, an additional loss of US$57,926.80
would accrue assuming the value of an individual animal to be US$304.80. Using
these figures as the base, the total losses due to theileriosis in India would be
approximately US$77 million.
Drugs such as tetracyclines, halofuginone (Terit, Hoechst), parvaquone (Clexon,
Coopers Animal Health) and buparvaquone (Butalex, Coopers Pitman-More) have
been used for the treatment of clinical theileriosis. Buparvaquone is reported to be
the most effective and safe drug when used at 2.5 mg/kg body weight on day 3 after
detection of theilerial schizonts in biopsy smears. However, the drug is reported to
be expensive and is presently not available commercially. Under these circumstances,
in most cases, a combination therapy using tetracyclines, anti-malarials and antipy-
retics is practised. No organized program of any size is being operated in India for
the control of ticks using acaricides. Only a few farmers maintaining valuable exotic
cattle  spray their  animals  with  organochlorine  or organophosphorous acaricidal
compounds.
Many research centres established  under an  All  India Coordinated  Research
Project are engaged in developing diagnostic, chemotherapeutic and prophylactic
measures for control of theileriosis. A dot enzyme-linked immunosorbent assay
(DOT-EIA) using piroplasm antigen has been developed by the Punjab Agricultural
University, which awaits evaluation under field conditions. It is expected that the test
will facilitate large-scale epidemiological studies.
Attempts have been made at different institutions to develop immunization as a
control measure. Initial immunization using the infection-and-treatment method with
tick stabilates and tetracyclines has been tried. However, this method has not been
used outside the laboratories. Haryana Agricultural University, Hisar; the Indian
Veterinary Research Institute, Izatnagar; the Punjab Agricultural University,
Ludhiana; and the Madras Agricultural University, Madras, have all reported the
development of tissue-culture  attenuated schizont vaccines, which await testing
under field conditions.
The Animal Disease Research Laboratory of the National Dairy Development
Board, Anand, has developed a tissue-culture vaccine using the ODE (Anand) isolate
of T. annulata at 150 passages. The vaccine has been extensively studied for safety
and  potency under  laboratory and  field  conditions.  Several  experiments on  the
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standardization of dose, cross-protection against various isolates, storage, transpor-
tation, reconstitution and application of the vaccine to different categories of suscep-
tible animals have been completed. The government of India has cleared the vaccine
for large-scale production and Indian Immunologicals, a unit of the National Devel-
opment Dairy Board, began commercial production and marketing in February 1989
under the trade name `Rakshavac-T’. More than 100,000 pure-bred and cross-bred
cattle over two months of age and at different stages of pregnancy and lactation have
been vaccinated. These include immunization of several thousands of pure-bred
Holstein-Friesian heifers in advanced stages of pregnancy. Serological screening and
clinical observations of these vaccinated animals indicate that the vaccine provides
protection against lethal tick challenge for a period of more than one year. The vaccine
has been well received by veterinarians and farmers and the returns on investment
for the mass vaccination program in a developing country are quite encouraging.
Following vaccination of these susceptible animals in villages and on organized
farms, a marked reduction in the incidence of theileriosis has been reported. In Kheda
District alone, where 20% coverage has been achieved during the last three years, a
marked reduction in the incidence of the disease has been recorded. Extensive use of
this vaccine is likely to reduce the problem of theileriosis considerably in India.
It is essential to undertake extensive epidemiological surveys in countries where
T. annulata is prevalent. The presently available complement fixation and IFA tests
are cumbersome and there is an urgent need for a cheap, simple and reliable
diagnostic test, such as the DOT-EIA, and the transfer of the technology to affected
countries. Attenuated schizont-infected cell-culture vaccines have shown promising
results wherever they have been used. There is a need to evaluate the usefulness of
these vaccines in countries where they are not available. The existing culture-derived
vaccines have to be stored and transported in liquid nitrogen, which increases their
costs considerably and there is always the risk of failure of the cold chain. Research
should be directed at developing genetically engineered vaccines so that cheaper
alternative vaccines are available that eliminate the need for a cold chain. Efforts
should be made to understand the mechanism of attenuation/selection of virulent
clones and the possible reversal of the virulence of culture-derived vaccines.
In tropical countries, cattle and buffalo are frequently heavily infested with many
genera of ticks, which, apart from transmitting diseases such as theileriosis, babe-
siosis and anaplasmosis, also cause extensive damage to the health of these livestock.
Research should be directed towards developing vaccines against ticks in view of the
rapidly developing resistance to commonly used acaricides.
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Theileriosis due to Theileria annulata in Iran
R. Hashemi-Fesharki
Department of Protozoology and Entomology
Razi State Serum and Vaccine Institute
P.O. Box 11365-1558, Tehran, Iran
Theileriosis caused by Theileria annulata is the most economically important cattle
disease in Iran, causing major losses in livestock production. It is a serious constraint
to the cattle breeding programs established to increase milk and meat production in
the country. Research towards the control of this protozoan parasite has been in
priority at the Razi Institute for a long time.
IDENTIFICATION, VECTORS AND
DISTRIBUTION OF THEILERIA PARVA
Most of the early pure-bred cattle introduced into Iran became infected with T.
annulata and many of them died. The first cases were recorded in 1935 when the
government imported 16 pure-bred cattle from France, 12 of which died. Investiga-
tions into the deaths of these imported animals indicated that they had contracted
theileriosis on arrival and that the species causing the mortality was T. annulata. The
study also showed that the distribution of the protozoan in Iran broadly coincided
with that of its ixodid tick vectors, the Hyalomma excavatum group and H. detritum.
These ticks are the predominant species throughout the country. There are other
species such as H. savigny, H. rufipes-glubrum and H. dromedarii that can transmit
the disease, but their distribution is more limited. In the northern part of Iran,
particularly the northwest and parts of the west, the winter is longer and the season
of tick activity is short-lived. Thus the mortality and morbidity rate, in comparison
to that of other parts, is lower.
SUSCEPTIBILITY OF CATTLE
Imported non-immune cattle are very susceptible to theileriosis, with a mortality rate
of more than 70% in pure-breds, while cross-bred cattle have a mortality rate of less
than 45%. In enzootic areas, indigenous calves become infected in early life and
following recovery are immune. The mortality rate among these indigenous calves
is approximately 15–20%. In 1988, the cattle population in Iran was eight million.
Of the exotic cattle, 90% are Holstein-Friesian and the rest are Shitz, Red-Danish
and Jersey. Among these cattle, the Holstein and Red-Danish are more susceptible
than the others. A cattle improvement program is now under study to reduce reliance
on imported meat and dry milk. Vaccination against theileriosis is the most important
strategy to reduce the incidence of the disease.
STORAGE AND DELIVERY OF VACCINE
Studies of the pathogenicity and immunizing capacity of different strains of T.
annulata maintained at −70 or −196 °C for periods lasting more than 10 years have
shown that no changes occurred. Storing the vaccine at −70 °C and transporting it to
the field in liquid nitrogen has proved more practical than other methods and has
become routine. Although the transportation of the vaccine to distant parts of the
country is possible, difficulties sometimes occur due to shortages of liquid nitrogen.
Therefore, other delivery methods are being studied to facilitate transportation in case
there are liquid nitrogen shortages.
CLINICAL SYNDROME
Clinical theileriosis due to T. annulata in Iran is similar to that in neighbouring
Turkey, Iraq and Pakistan. During the past two decades, we have observed some
unusual cases and clinical syndromes such as skin theileriosis presented as nodules
spreading over the body. Biopsy smears from these nodules revealed more than 15–20
schizonts per microscopic field. In these cases, the pathological changes in internal
organs were negligible. These nodules were observed only in calves less than two
months old. Further studies are being undertaken on the pathogenesis of these lesions.
CELL-MEDIATED IMMUNITY
Delayed-type hypersensitivity and migration inhibition tests have been performed.
These studies indicated that delayed-type hypersensitivity in cattle with febrile and
parasitic reactions was positive but the degree of skin thickening did not correlate
with the severity of the disease response. The study revealed that more than 60% of
infected or vaccinated animals showed positive skin test reactions and the thickness
of the skin reached two and a half times that of normal skin. Pathological findings
revealed that a high number  of  eosinophils  and  a  low  number  of  lymphocytes
infiltrated the site of inoculation. The positivity of skin tests showed that cell-medi-
ated immunity could have an effect on theileriosis but the degree of protection
afforded by this immunity is not clear. Whether cell-mediated immune responses
alone are effective in protecting the animal against acute theileriosis or whether these
responses, together with humoral immunity, are required is not known. Further study
of cell-mediated immunity is required.
CHEMOTHERAPY
Beginning with the importation of susceptible cattle to Iran over 50 years ago, many
different antiprotozoal drugs and antibiotics have been tested for the treatment of
pure-bred cattle that were infected naturally or experimentally with stabilates of
virulent or mild strains of T. annulata. No satisfactory results were obtained until
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recently when oxytetracycline and two naphthoquinones were used. Oxytetracycline
dihydrochloride (Terramycin, Pfizer) at high doses in cattle experimentally infected
with T. annulata was studied during the incubation period, at the onset of clinical
signs and at the height of parasitaemia and fever. It was not effective as a therapeutic.
Studies of treatment using naphthoquinones, parvaquone and buparvaquone showed
that buparvaquone, at the recommended dose of 2.5 mg/kg, was more effective. The
recovery rate of animals treated with parvaquone was 60.7% compared with 88.7%
for those treated with buparvaquone.
IMMUNIZATION
The early research on theileriosis at the Razi Institute attempted vaccination of cattle
using blood collected from sick animals at the peak of the disease reaction. The cattle
had been infected with mild strains of T. annulata that had been used by Sergent in
Algeria (Sergent, E., et al., Theileriose a Theileria dispor, Etudes sur les Piroplas-
moses Bovins, Algeria: Institute Pasteur d’Algerie, 1945). A few cattle were also
vaccinated using the Kuba strain, which had been sent to the Razi Institute by Sergent.
Later it was observed that the blood used for vaccination could transmit other
parasites, such as Babesia, Anaplasma, Eperythrozoon and other rickettsiae, and
viruses, and this approach was abandoned. With progress in the culture of Theileria,
the Institute started to grow schizont-infected lymphoid cells using the suspension
culture method. Initially, fibroblasts were used as feeder cells for growing schizont-
infected cells and then the method was changed and they were grown without feeder
layers.  There  are different  methods  of  vaccination  against T. annulata, but the
schizont-tissue-culture vaccine plays the main role in our current vaccination pro-
gram, which began in 1973. To date more than 150,000 pure-bred and cross-bred
cattle two months and older have been immunized in Iran. The vaccine being used in
various provinces, representing different climatic conditions and livestock manage-
ment practices, is prepared from local strains grown in cultured lymphoid cells and
has proved to be very effective. No reports of adverse reactions have been received
and the vaccinated cattle have shown very good resistance to challenge. We have
found that animals may not be able to tolerate the Theileria vaccine if they are already
suffering  from another infection,  especially  a  viral  one.  Similarly, the immune
reaction may be compromised if a viral vaccine such as foot-and-mouth disease is
administered during the reaction period of the Theileria vaccine. As a result, we do
not recommend vaccination of sick animals nor do we suggest concurrent admini-
stration of other vaccines. It is recommended that other vaccines be given 25 days
before or after the Theileria vaccine. A few cases of abortion in cows more than five
months pregnant have also been observed after vaccination. The cause of abortion is
not known, but the possibility exists that the vaccine may have been responsible, so
it is recommended that it should not be administered to pregnant cows. Until 1988,
two strains were used routinely but since then only one is used. More than 50,000
cattle have been vaccinated using this method and no adverse effects have been
observed and no reports of animal deaths due to theileriosis have been received.
We have attempted to vaccinate calves with up to 300 × 106 inactivated schizonts
either  alone or  with Freund’s adjuvant,  but  in all  cases  the animals  developed
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theileriosis on challenge with virulent strains. Many of our livestock centres are not
well maintained and since the whole country is infested with ticks transmitting T.
annulata, the vaccinated cattle are automatically re-exposed to the parasite. This
repeated challenge with sporozoites appears to reinforce the immunity induced by
the schizont vaccine.
In heavily tick-infested areas, the use of acaricides is required; however, spraying
cow sheds and dipping or spraying cattle with acaricides once a week or more
frequently rarely results in effective control. The schizont tissue culture vaccine is,
at present, the best means of minimizing the productivity and mortality losses in cattle
due to theileriosis. During the last 16 years, over 2000 calves have been inoculated
in an attempt to monitor the quality of the vaccine under laboratory conditions, and
over 150,000 cattle, representing eight breeds of Bos taurus cattle, have been
vaccinated and monitored in the field. Indigenous cattle (Bos indicus) are much more
resistant to T. annulata than imported cattle; nonetheless, they suffer up to 15–20%
mortality in some parts of the country and we plan to commence vaccination of these
cattle.
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Epidemiology and control
of theileriosis in Morocco
H. Ouhelli and E. Flach
Institut Agronomique et Veterinaire Hassan II
B.P. 6202
Rabat-Instituts, Morocco
Theileriosis caused by Theileria annulata is one of the most pathogenic and economi-
cally important diseases in Morocco. The mortality rate is 70% in imported breeds
and 40% in local breeds. Sera and blood were collected from 714 cattle from 130
farms in the Doukkala area after the theileriosis peak (May–August) in 1989.
Seventy-eight of the sera were positive in the indirect immunofluorescent antibody
test (at a dilution of 1/160 or more) and Theileria piroplasms were found in 55% of
blood smears. Similarly, more than 50% of animals in the Gharb region (400 km from
Doukkala) had Theileria piroplasms in their blood smears.
Twelve farms in Doukkala were chosen for a longitudinal study. A representative
number (varying from 50 to 70% of total) of mainly cross-bred cattle were examined
monthly or twice a month in the summer for ticks and symptoms of theileriosis and
were sampled for serum and blood smear examination. Prior to the disease season in
May–August, 50% of cattle had Theileria piroplasms at parasitaemias of <1% and
usually <0.1%. None of the calves born after the theileriosis season (category 1) had
piroplasms detected, whereas 39% of calves born before then (category 2) and 78%
of adult cattle showed Theileria piroplasms in their blood.
All Hyalomma species infesting cattle in Morocco (H. detritum, H. marginatum,
H. a. excavatum, H. dromedarii and H. lusitanicum) can transmit T. annulata
experimentally. However, only H. detritum is recognized as a natural vector. This
species is widely distributed in Tunisia, Algeria and Morocco. Its adult activity begins
in May, peaks in June and ends in August, corresponding to the curve of theileriosis.
Ticks infest adult cattle more heavily (X=32.5) than young animals (X=3). Hyalomma
detritum infection with T. annulata was assessed in the salivary glands of unfed ticks
(in winter) or those attached to cattle for less than 12 hours. The infection rate was
48% with 1 to 34 Theileria sporoblasts.
The control of theileriosis in Morocco is by control of H. detritum (taking into
account its biology and distribution), the use of parvaquone (Clexon, Coopers Animal
Health) as a specific treatment for T. annulata and vaccination using schizont-
infected lymphoblastoid cells. It was shown that 102 infected cells could protect cattle
and a dose of 104 cells was selected for use in vaccination. Experimental application
and large-scale field vaccination on a farm of 1,500 cattle over four years showed its
ability to protect against artificial challenge one month later, and against natural
infection. However, the  protection does not last for more than six months  and
revaccination or natural challenge is needed. The vaccine is safe. No morbidity or
mortality has been recorded in vaccinated animals and ticks do not appear to become
infected when fed on vaccinated animals. A program of meetings with cattle owners
to inform them of the efficiency and limitations of the different tick and disease
control measures has been running for several years.
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Theileria annulata in Sudan
O.M. Osman
Veterinary Research Administration
P.O. Box 8067
Khartoum, Sudan
Sudan extends across 2.5 million square kilometres in north and central Africa and
is rich in agropastoral potential. There are about 81 million hectares of arable land
together with rich pastoral land in the south and central regions of the country. Sixteen
million cattle together with sheep, goats and camels are distributed in different
agroecological zones with marked areas of overlap. Livestock are under fairly
continuous challenge with contagious and vector-borne diseases. Theileriosis due to
Theileria annulata constitutes a major obstacle to the development of the milk and
meat industry in northern Sudan.
Bovine theileriosis was first reported in Sudan in 1908 (Annual Report of Sudan
Veterinary Services) and by 1923 it was reported regularly from all over the country.
Theileria annulata piroplasms are frequently found in the blood of indigenous Zebu
cattle kept by pastoralists but the parasite is not considered to cause a major disease
problem. The piroplasms are detected in the blood of cattle especially after rinderpest
vaccination using goat-adapted virus vaccine. However, more importance is attached
to contagious killing diseases among adult cattle. There is an inherent resistance to
theileriosis among indigenous pastoral cattle. Animals that survive disease challenge
at an early age become immune and this immunity is reinforced by repeated exposure
to infected ticks. The mortality among indigenous calves is not known, although field
veterinarians attributed a high calf mortality to T. annulata infection.
The growing urban communities around the cities and towns and within large
agricultural schemes have created an increasing demand for milk. When dairy
farming was integrated with crops, exotic breeds were introduced and many local
breeds were upgraded. With the exception of government research farms in Khartoum
and Gezira, dairy producers keep either pure Friesian or their crosses with indigenous
breeds. About half a million of these animals are distributed in highly endemic T.
annulata areas where the conditions are conducive for vector multiplication.
Hyalomma anatolicum anatolicum is the major vector of T. annulata in central
Sudan. The disease vector in other parts of the country, outside the distribution of H.
a. anatolicum, are H. rufipes, H. impeltatum and H. dromedarii and H. truncatum in
the south and south central areas.
MORTALITY AND INCIDENCE RATE OF THEILERIA ANNULATA
Calf mortality due to T. annulata has been estimated at 17% in cross-bred calves.
Antibody surveys showed a prevalence rate of 46% in indigenous herds in the White
Nile area, 67% on farms north of Khartoum and 84% on dairy farms south of
Khartoum. It was generally found that antibodies appear in the blood of calves two
to seven months after birth.
There is a general awareness that T. annulata is of considerable significance in the
economy of dairy farming. The economic effects vary with the standard of hygiene,
the status of nutrition and the degree of tick challenge. Tick control using insecticides
is expensive and therefore are used at irregular intervals, in many cases after the
disease has appeared in the herds. Chemotherapy using buparvaquone (Butalex,
Coopers Pitman-More) is very expensive. Infection-and-treatment immunization has
also been tried on a very limited scale and proved effective.
Theileria annulata is a constant threat to the development and expansion of dairy
farming. Recent clinical records show a 30% calf mortality. Newly imported Friesian
cattle suffer up to 70% mortality. Ecological factors and host availability are highly
conducive for the establishment of vector tick populations in farm establishments and
vegetation cover in irrigated areas where naturally resistant indigenous cattle which
are carriers of T. annulata and infested with Hyalomma species vectors graze.
The diverse ecological environments of Sudan make it a good model in which to
study T. annulata, but such studies are not possible for national institutions because
of a lack of funds.
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Studies on tropical theileriosis in Turkey
F. Sayin, S. Dincer, Z. Karaer, A. Cakmak, A. Inci, H. Eren, B.A. Yukari and E. Kirvar
T.C. Ankara Universitet
Vetiner Fakultesi Protozoologi Entomologi
Bilim Dali Backanligi
Irfan Bastug
Caddesi Difkapi
06220 Ankara, Turkey
Theileria annulata has been reported from every part of Turkey (Lestoquard, 1931;
Samuel and Raif, 1930; Tüzdil, 1936, 1953; Kurtpinar, 1955; Göksu, 1959, 1970;
Özcan, 1961; Mimioglu et al., 1971; Ünsüren, 1976; Tasci, 1984) and is a major
threat, particularly to European and cross-bred cattle. A blood smear survey carried
out in Central Anatolia showed that 178 out of 996 cattle were infected with T.
annulata. Sixty-nine of the infected cattle showed clinical signs of tropical theil-
eriosis and 29 died. Tropical theileriosis was diagnosed in 216 out of 1,225 sick cattle
brought to the clinic of the Ankara Veterinary Faculty for treatment between 1982
and 1986 (Ünsüren, 1986). Of the 216 infected cattle, 191 were European breeds. In
a serological survey conducted in Beytepe Village, Ankara, high titre antibodies
against T. annulata were detected in the sera of 12 out of 185 cattle examined using
the indirect fluorescent antibody (IFA) test (Cakmak, 1987). During the summer
seasons in 1989 and 1990, nearly 11% of the sick cattle brought to the Ankara
Veterinary Faculty for treatment suffered from tropical theileriosis. All the cattle with
tropical theileriosis were of European breeds.
Several species of ixodid ticks have been reported from Turkey and they were
found all over the country (Mimioglu, 1954; Merdivenci, 1969; Hoffman et al., 1971;
Karaer, 1983; Sayin and Dumanli, 1982). In the last few years, 7,029 cattle and sheep
were examined for ixodid ticks at 42 collection points in Central Anatolia. A total of
11,586 ticks, composed of 15 species, were collected. Potential vectors of T. annulata
such as H. anatolicum anatolicum and H. detritum were commonly present in the
collections. Hyalomma a. excavatum and H. detritum were also observed in the
shelters of livestock. The mean infestation percentages of cattle and sheep with ticks
were 46 and 50, respectively (Sayin and Karaer, unpublished).
The Parasitology Section of the Pendik State Veterinary Institute is responsible for
the production of 70,000 doses of live, attenuated T. annulata cell-culture vaccine a
year. The vaccination program is aimed at protecting the large number of highly
susceptible cattle being imported into Turkey from Europe and North America (with
World Bank funds). However, despite these efforts to control the disease, the impor-
tance of tropical theileriosis in Turkey is increasing. The inability to control the disease
by conventional methods is probably related to the lack of epizootiological knowledge
and the lack of regular acaricide application to control the vector ticks.
Currently a joint project is being carried out by the Faculty of Veterinary Medicine
(Ankara), the Centre for Tropical Veterinary Medicine (Edinburgh) and Pendik State
Veterinary Institute (Istanbul) to investigate several aspects of tropical theileriosis in
Turkey. These are to define the epidemiology of tropical theileriosis using sero-
epidemiological methods to study tick transmission patterns, to characterize stocks of
T. annulata using immunological, biochemical and molecular biological methods and
to establish the value of the Pendik tissue-culture vaccine in laboratory and field trials.
Ankara had already initiated cell cultures of T. annulata, established colonies of
H. detritum and H. a. excavatum, built large and small animal isolation facilities,
isolated local stocks of T. annulata in ticks and cell culture, established a liquid
nitrogen cryobank to store the above stocks as stabilates of infected blood, cell
cultures and sporozoites and set up the IFAT for serodiagnosis of T. annulata. During
this project we have collected infected blood from cattle with tropical theileriosis in
the field and inoculated 15 susceptible calves of two to three months old with the
infected blood in the laboratory. Eight calves developed severe tropical theileriosis.
Blood stabilates were obtained from these calves and cell cultures were isolated to
study the characteristics of T. annulata. Nine stocks were isolated from Ankara
County as tissue culture stabilates, of which blood stabilates have been prepared from
eight and tick stabilates from three.
Uninfected nymphs of either H. a. anatolicum or H. detritum or both were fed on
infected calves. After moulting, the adult ticks were fed on rabbits for four days and
dissected to assess the infection rate. In Table 1, the tick species, their infection rate
and mean number of infected acini are shown. The ticks fed on calves with high
parasitaemia had a higher percentage infection and an increased number of infected
acini.
Sera were collected from six calves 17, 28, 35 and 42 days after inoculation and
tested with piroplasm and schizont antigens using the IFAT (Cakmak, 1987). Positive
and negative sera were obtained from the Parasitology Institute, Hannover Veterinary
School, Germany. Rabbit antibovine 1gG FITC (Sigma) was used in the test. Schizont
and piroplasm antigens were produced in our laboratory from cell cultures and
infected blood obtained from experimental calves.
Antibodies were detected in the sera from infected calves 17 days after innoculation
and increased by 28, 35 and 42 days after inoculation. Antibody titres against
TABLE 1. The infection rates and mean number of infected acini of tick species engorged
on different Theileria annulata stocks.
Infection Mean number
Stocks Engorged ticks rate % of infected acini
T. annulata Hidirsih H. a. anatolicum 100 410
T. annulata Eryaman-i H. a. anatolicum 17 2.1
T. annulata Balçikhisar H. a. anatolicum 75 7.5
T. annulata Gülseren H. a. anatolicum 78.5 11
T. annulata Balçikhisar H. detritum 75 8.8
T. annulata Eryaman-2 H. detritum 60 23.3
T. annulata Sarioba-1 H. detritum 100 160
T. annulata Akdere H. detritum 100 159.2
T. annulata Mamak H. detritum 100 114.5
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piroplasm antigen were high when compared with titres against schizont antigens.
Serological cross-reactivity among T. annulata isolates obtained from different
villages of Ankara was studied using the IFAT. All the isolates cross-reacted with
each other.
Serum samples were collected from a calf infected with the T. annulata Gülseren
stock at different times over a year and tested with homologous schizont and
piroplasm antigens in the IFAT (Table 2). Antibody titres against piroplasm antigen
and schizont antigen appeared 17 days after innoculation of the calf and persisted for
347 and 270 days, respectively. The peak antibody titres against schizont (1:10240)
and piroplasm (1:10240) antigens were detected 50 days after innoculation.
Three stocks of T.  annulata identified as Mamak, Akdere and Sarioba were
characterized using glucose phosphate isomerase (GPI) isoenzyme electrophorosis
(Melrose and Brown, 1979; Melrose et al., 1980, 1981). The stocks were isolated
from the Ankara areas and grown as bovine lymphoblastoid cell lines. Lysates of the
parasitized cells were examined using thin-layer starch-gel electrophoresis for GPI
patterns. The isoenzyme patterns associated with each stock were different. Lysates
prepared from the salivary glands of H. detritum ticks engorged on the three stocks
of T. annulata were also examined for GPI patterns and different bands of enzyme
activity were detected in each stock. The isoenzyme patterns of different life cycle
stages of T. annulata also differed in the same stock. Piroplasms from three cattle
infected naturally in the field were isolated and characterized and the isoenzyme
pattern of each isolate was also different.
Two years earlier, three farms (Ortaköy, Saray and Igmir) in Ankara Province were
selected as trial sites. A total of 38 imported European breed cattle were introduced
TABLE 2. The IFAT titres in serum collected from a calf experimentally infected with
Theileria annulata Gülseren at different times throughtout the year and tested with homolo-
gous schizont and piroplasm antigens.
Days Schizont Piroplasm
0 — —
17 1:1280 1:2560
28 1:5120 1:5120
35 1:5120 1:5120
42 1:5120 1:5120
50 1:10240 1:10240
68 1:10240 1:5120
115 1:5120 1:2560
176 1:640 1:2560
216 1:320 1:2560
236 1:160 1:2560
270 1:160 1:1280
311 1:20 1:320
325 1:10 1:320
347 1:10 1:320
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to the farms (10, 15 and 13 cattle in each farm, respectively) and examined for the
development of antibodies to T. annulata at three-month intervals. Thick and thin
blood smears were prepared at each visit and the animals were examined for ticks.
The results of examination of cattle for T. annulata infection in Ortaköy, Saray and
Igmir farms are shown in Table 3. Theileria annulata was observed microscopically
TABLE 3. The results of examination of cattle for Theileria annulata in Ortaköy, Saray and
Igmir farms, Ankara.
Number of cattle Number of cattle infected with T. annulata
Date Farm examined Microscopic diagnosis Serologic diagnosis
February 88 Ortaköy 10 0 3
March 88 Saray 15 11 6
April 88 Igmir 13 1 8
May 88 Ortaköy 10 1 9
June 88 Saray 15 3 12
July 88 Igmir 13 0 11
August 88 Ortaköy 10 0 10
September 88 Saray 15 14 10
October 88 Igmir 13 4 11
November 88 Ortaköy 10 0 10
December 88 Saray 14 1 11
January 89 Igmir 12 0 9
February 89 Ortaköy 10 0 10
March 89 Saray 14 4 12
April 89 Igmir 12 2 9
May 89 Ortaköy 10 2 10
June 89 Saray 13 2 13
July 89 Igmir 11 2 4
August 89 Ortaköy 10 1 10
September 89 Saray 13 0 12
October 89 Igmir 8 2 5
November 89 Ortaköy 10 1 2
January 90 Igmir 8 3 1
TABLE 4. The results of examination of cattle for ticks in Ortaköy, Saray and Igmir farms.
Number of cows infested with ticks
Tick species Ortaköy Saray Igmir
Hyaloma detritum 0/10 0/15 3/13
Hyaloma anatolicum anatolicum 0/10 1/15 1/13
Hyaloma anatolicum excavatum 0/10 1/15 1/13
Dermacentor marginatus 0/10 1/15 1/13
Rhipicephalus bursa 0/10 2/15 0/13
Rhipicephalus turanicus 0/10 1/15 0/13
Haemaphysalis otophila 0/10 0/15 2/13
Haemaphysalis punctata 0/10 0/15 1/13
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in few animals, although many of them developed high antibody titres during the two
years of observation. No clinical cases of theileriosis were recorded on the farms
during this investigation.
Table 4 shows the tick species detected and the number of cattle infested with these
ticks on the farms. The number of the cattle infested with ticks was low but severe
tick infestations with Rhipicephalus bursa, R. turanicus, H. a. anatolicum, H. a.
excavatum, Haemaphysalis otophila and Haemaphysalis punctata were observed on
sheep and goats on the farms or on cattle in nearby areas.
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Specific prevention of bovine
theileriosis in the USSR
V.T. Zablotsky
The All-Union Institute of Experimental Veterinary Medicine
Viev, Kuzminki 109472
Moscow, USSR
Tropical theileriosis is one of the most important protozoan diseases of cattle. It
causes considerable economic losses in herds located in areas where the tick vectors
Hyalomma detritum and H. anatolicum are present. The disease is reported from
many countries of Africa, Central and Southeast Asia and southern Europe. Losses
due to theileriosis include high mortality (from 30 to 90%), abortion, infertility,
reduction in milk yield, loss of body weight, deterioration of meat quality of slaughter
cattle and the cost of keeping and treating affected cattle. The upgrading of local
cattle through cross-breeding with high-producing imported stock is greatly hindered
because of susceptibility of the imported stock to theileriosis. Regular acaricide
treatment of cattle no longer gives the expected results because of the occurrence of
acaricide-resistant tick populations. Following many years of research conducted in
the Protozoology Laboratory of the All-Union Institute of Experimental Veterinary
Medicine, in Moscow, on the protective properties of Theileria annulata schizonts
grown in bovine lymphoid cell cultures, a cell-culture vaccine against theileriosis
was developed and evaluated in the field.
An important point in the specific prevention of theileriosis was to evaluate the
efficiency of the vaccine in different climatic regions of the country where parasites
with different biological properties occur. Opinions vary as to the immunogenic
identity of different strains of T. annulata isolated in different regions. Some inves-
tigators believe that animals that recover from theileriosis acquire immunity only to
homologous strains and they have partial or no immunity to heterologous strains.
According to another opinion, Theileria strains originating from different geographic
regions are immunogenically identical and induce cross-immunity in vaccinated
cattle. Our studies showed that strains isolated in various infected regions of the
country were immunogenically related and were cross-protective. In addition, a
single inoculation of susceptible calves with attenuated cell-culture vaccine protected
them from infection with highly virulent heterologous field strains. Because of these
findings, a vaccine prepared from a single attenuated T. annulata strain is used to
immunize cattle in all Theileria-affected regions.
It has been shown by many investigators that the great majority of European cattle
breeds are highly susceptible to theileriosis, suffer severe disease and usually die (up
to 90% or more). Zebu and Zebu cross-bred cattle, which are bred mostly in tropical
and subtropical countries and in southern USSR, are generally resistant to piroplas-
moses, including theileriosis. For these reasons, we studied the susceptibility to
infection and the safety and immunogenic properties of the theileriosis vaccine in
naive calves of different breeds. Calves of Black-and-White, Red Latvian, Red
Estonian and Boushouyev (mixed Zebu-like and Dutch cattle) breeds were used.
There were no significant differences in the response to vaccination between calves
of these breeds. Experimentally immunized and control non-vaccinated calves were
kept on tick-infested pastures in a theileriosis-infected region to evaluate their
immunity. All control calves became ill with theileriosis and 33% of them died. The
disease was as severe, and caused losses just as high, in Boushouyev calves and in
calves of other local breeds. None of the vaccinated calves became ill with theileriosis.
Thus all experimental calves acquired a strong immunity to theileriosis.
Host age is an important factor on which parasite development and manifestation
of its pathogenicity depend. Because of contradictory evidence about the effect of
host age on the severity of the disease, we studied the post-vaccinal responses of
calves of various ages from one month to two years. These age groups were chosen
because vaccination was being planned for theileriosis-affected regions where the
adult cattle populations were already immune. Therefore, only young animals that
had not yet had contact with tick vectors were to be vaccinated together with newly
introduced animals usually no more than two years of age. It was demonstrated that
post-vaccinal responses were more pronounced in animals two years old than in
calves from two to seven months old. The main difference was in the duration of
temperature response, which was one or two days longer in the former group.
Insignificant differences in the response to vaccine application subsequently allowed
us to vaccinate young cattle two months to two years old using the same vaccine dose.
Our studies showed that humoral and cellular immune responses in calves of various
ages differed. One-month-old calves had the lowest responses. Two-month-old calves
reacted to inoculation of the vaccine with an increase in T lymphocytes in blood of up
to 12% and of B lymphocytes up to 19%; whereas one-month-old calves had consid-
erably fewer T and B lymphocytes than their older counterparts. The calves vaccinated
at one month of age showed a peak complement fixing antibody response on day 65
after vaccination that was never higher than 1:40–1:80, whereas older calves had the
maximum titre of 1:80–1:320 35 days after vaccination. All calves vaccinated at one
month of age fell ill with theileriosis following tick challenge.
The prophylactic efficacy of the cell-culture vaccine was evaluated from 1976 to
1989. Altogether over 2.5 million animals were vaccinated in the Caucusus and
central Asian areas of the USSR. Breeding females usually introduced as calves from
disease-free parts of the country late in autumn or in winter were the largest group
of vaccinated cattle, together with young stock born to introduced cattle that had not
yet had any contact with tick vectors. Vaccinated and non-vaccinated animals were
kept on tick-infested pastures in summer and autumn and were not subjected to
treatment with acaricides. The studies revealed that all control non-vaccinated ani-
mals became ill with theileriosis at different times after returning to pasture, with a
mortality rate of 27 to 40% or more. One hundred and ten cases of theileriosis were
recorded among vaccinated calves. During long periods of observation it was estab-
lished that immunity in once vaccinated calves persisted for their lifetime if animals
were attacked by Theileria-infected ticks each year. Field evaluation of the theil-
eriosis vaccine showed that it possessed high prophylactic efficacy and gave animals
full protection against the disease.
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The vaccine is manufactured on a commercial scale at a plant using a Soviet
nutrient media. The delivery of the product by aircraft and vehicles has been
organized to the zones of its application where storage and distribution centres have
been established. Scientifically substantiated principles for the product application
in the field were developed, including the route of inoculation, time and regimen of
vaccination, dose of the product and the duration of immunity. Annual vaccination
has led to the establishment of Theileria-immune cattle populations in infected zones
of the country. It has also allowed the introduction of high-producing animals and a
reduction to a minimum in the frequency of treatments with acaricides.
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Modelling
G. Gettinby
Department of Mathematics
University of Strathclyde
Livingstone Tower
26 Richmond Street, Glasgow G1 1XH, UK
INTRODUCTION
This paper presents an overview of modelling and will be based around a descrip-
tion of the development and uses of ECFXPERT, a computer model for tick
populations and East Coast fever (Theileria parva infection) at sites throughout
Africa. It will also discuss modelling concepts and future trends.
ECFXPERT
ECFXPERT is a model of the interaction of Rhipicephalus appendiculatus ticks,
cattle and T. parva developed at Strathclyde University, UK. It has been developed
to run on an IBM microcomputer or compatible with VGA graphics. Incorporated
into the model are help and dictionary facilities which aid the user both in using
the model and understanding the disease complex it models. The model is based
largely on empirical data taken from over 80 years of published literature and on
observations of experts in the field. Using these data, mathematical algorithms
were formulated and rules based on the expert knowledge were built into the
model. Since climatic factors are important to the survival of the tick, mean
monthly temperatures and rainfall inputs were of primary importance in ECFX-
PERT.
The model actually comprises four models: a tick, disease, dipping and chemo-
therapy model. These are interconnected to provide a model for the disease
complex. Output is graphically displayed and includes numbers of larvae, nymphae
and adult ticks, numbers of cattle infected and uninfected and other data. As
ECFXERT is stochastic, it gives different outputs for each run, thus providing
confidence limits.
It was found that rules for superinfection need to be better researched to
describe the course of the disease. In addition, it would appear that at most sites,
carrier cattle with a persistent transmissible infection are necessary for disease
maintenance.
ECFXPERT was tested on several published data sets, and broad agreement on
many was found although further investigation is needed. An important use of
ECFXPERT is that it provides a tool for undertaking computer experimentation.
This allows `what if’ questions to be investigated. For example, if temperature
were to either increase or decrease, what impact would this have on tick
development?
MODEL BUILDING
To build a model, say for T. annulata, one should consider the following:
Taxonomy Precision Scale Level Goal Customer
index deterministic global DNA explore researcher
analytical stochastic continental gene explanation planner
empirical regional host/herd prediction farmer/producer
intelligent site
In a model taxonomy, index models are the simplest and rely on statistical
techniques to establish cause and effect relationships. More recently, artificial
intelligence (AI)/expert systems use the expert opinions of people. Other consid-
erations are whether the model should be deterministic or stochastic, the scale of
the model—ranging from global to site—and the level, which may be at the DNA
or the herd. The goal of the model is usually predictive, although it can be a tool
to understand relationships. The end user of models has often been the researcher.
However, as models become easier to use and change, they can be aimed at planners
and managers.
Once the above points have been considered, the typical model building cycle is:
The final step, maintenance, is often overlooked and the model should be flexible
enough to be changed easily. As new developments/discoveries are made, these need
to be implemented in the model.
FUTURE TRENDS
As computing technology delivers more easily usable power, modelling will be taken
to new horizons. One of these will be merging geographical information systems
(GIS), which are databases containing spatial referenced data such as climate and
vegetation, with classical modelling techniques. This will lead to integrated geo-
graphical information systems. Within the next two decades, models could attain a
predictive power close to 90%.
Another development is the discovery that biological systems are not always linear
and that non-linear phenomena can lead to chaos. Chaos highlights the effects of
small changes in starting values which then ripple through and can cause very
different results to be obtained. An example of this is in the epidemiology of disease
(W. Byrom, unpublished data), where a given number of infected ticks can produce
very different outcomes for the disease. For one year there may be many occurrences
of the disease and a few the following year. This could be because of the chaotic
nature of the disease under observation.
formulate—calibrate—validate—implement—maintain
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DISCUSSION POINTS
Carrier status
It was noted that the lack of a carrier state disrupted the course of the disease. In the
model, ticks did not become infected if the carrier state was absent. Also, buffalo
provide a major reservoir for the disease, which would be impossible to control.
Wildlife is an accepted part of the epidemiology of disease caused by T. parva.
Chaos
The difficulties in determining whether a system is chaotic or not were discussed.
One way to determine this would be to vary inputs and see how these affect the
outputs.
Models
Is a model only as good as the weakest part? It may be necessary to adjust some
parameters to obtain better fit to certain data. In building a complex model, all the
pieces have to be validated and tested. One of the major problems of ECFXPERT is
in making radical changes, which would involve altering the computer code. It is
hoped that the newer generation of expert systems/AI and simulation models will
enable such changes to be made much more easily.
Parasitaemias
The parasitaemia level in relation to tick infection needs better understanding for
incorporation within infection models.
Get t inby, MODELLING
37
CURRENT METHODS OF
DIAGNOSIS AND CONTROL
Research developments in diagnosis and control
of bovine tropical theileriosis in India
A.S. Grewal
Tick-Borne Diseases Research Laboratory
Department of Immunology
College of Veterinary Science
Punjab Agricultural University
Ludhiana 141 004, India
In developing countries such as India, which have introduced mass cross-breeding
between native low-milk-yielding cattle (Bos indicus) and imported high-milk-yield-
ing cattle (Bos taurus), bovine tropical theileriosis has emerged as a clinical entity
of economic significance for the dairy industry. India is importing both live animals
and frozen semen for mass cross-breeding schemes.
IMMUNODIAGNOSIS
The development of a Theileria annulata dot enzyme-linked immunosorbent assay
(DOT-EIA) for detection of antibodies in bovine species is a major achievement for
control of bovine tropical theileriosis. The test has been developed by the Punjab
Agricultural University (PAU), Ludhiana. The antigen used in the test is derived from
erythrocytic piroplasms. Preparation of good-quality antigen material free of host
cell contaminants (leukocytes and erythrocytes) is critical for the specificity of the
test. In contrast to the tube method of DOT-EIA, we designed comb-type multiple-
spot dipsticks suitable for conducting the test in 96-well microtitre plates. The
advantages of this system are conservation of reagents and fast processing for mass
screening of samples.
Sera from cattle vaccinated with T. annulata schizont parasitized lymphocyte cell
culture become antibody positive after three to four weeks using the DOT-EIA, with
titres of up to 1:256,000, but always higher than 1:3,200. Pre-vaccination sera from
these calves were negative even when tested undiluted. Sera from Anaplasma- or
Babesia-infected calves did not cross-react in the T. annulata assay. It will be of
interest to do cross-reaction studies with sera from cattle infected with other Theileria
species. The assay was found useful even for screening of hybridoma culture
supernates with traces of antibodies to T. annulata piroplasm antigens. In February
1990, a workshop co-sponsored by the Indian Council of Agricultural Research
(ICAR) and the PAU was organized by our department to transfer the T. annulata
DOT-EIA to some 35 participants representing research centres and universities from
all over India. The ICAR has recommended PAU to produce standardized antigen
material for use by the participating stations. This is being done to collect informa-
tion, over the next few years, on the following aspects of bovine tropical theileriosis:
to determine the incidence/prevalence of theileriosis in cross-bred cattle, to assess
the role of water buffalo and indigenous cattle as reservoirs of infection, to monitor
field vaccination trials and to estimate the effect of infection on the productivity of
animals.
EPIDEMIOLOGY
In India in recent years, the occurrence of clinical theileriosis in new-born calves of
one to six weeks of age has been recorded as an emerging epidemiological feature in
endemic herds. The disease occurrence in young calves is in significant numbers of
not less than 40%, leading to a mortality of approximately 33%. The dams of these
calves do not always suffer from theileriosis. On farms with large numbers of cattle,
groups of new-born calves have been affected. Random serum samples from cows
whose calves become infected were consistently DOT-EIA antibody positive. Pre-
viously unexposed adults are an equally susceptible group. Recurrence of clinical
theileriosis in carrier adults under stress conditions needs to be studied. An obvious
explanation for these observations is that in endemic herds new-born calves, espe-
cially those born in the peak tick season, become infested with ticks from birth.
Passive immunity through colostrum is not beneficial as cytotoxic T lymphocyte
immunity is of prime importance in protection against theileriosis. Also, endemic
stability alone may not be effective in preventing clinical theileriosis in highly
susceptible breeds of cattle.
An important issue in India is the successful immunization of young calves. Will
field vaccination of new-born calves be feasible and, if so, will the vaccine be
effective in preventing disease in the face of simultaneous natural exposure to ticks,
as cell-culture vaccine requires two to three weeks to induce immunity? On top of
these difficulties, the commercially available vaccine recently introduced by India
Immunologicals, Hyderabad, is not recommended for use in calves under four months
of age (see vaccines and vaccination approaches discussed below). The majority (up
to 80%) of cattle are likely to be already exposed to the parasite and to be carriers at
the time of adult vaccination.
A few sera tested in the DOT-EIA showed that some buffalo sera contain T.
annulata antibodies.  A  large sampling survey  is  under  way to assess  the  inci-
dence/prevalence of infection in different types of animals (discussed above under
DOT-EIA immunodiagnosis).
Immunization with T. annulata cell-culture vaccine leads to a carrier state. It is of
great importance to understand the nature, of the carrier state with regard to the
epidemiology of the disease. Important questions to be addressed are the transmission
potential and virulence, as well as the antigenic nature, of carrier state parasites. We
have examined vaccinated calves for the carrier state by feeding clean Hyalomma
anatolicum nymphs. The moulted adult ticks were activated to examine their salivary
glands for infected acinii, and by the inoculation of ground-up tick stabilates (GUTS)
into susceptible calves. The tick pick-up infection, however, was too low to cause
clinical disease on sub-inoculation of GUTS. In a separate experiment, we observed
a linear relationship between the degree of piroplasm parasitaemia in calves and the
infectivity of fed ticks. The ticks fed on calves with higher parasitaemia (10–40%)
were more potent than those fed on lower (1–2%) parasitaemia. The carrier state
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parasitaemia in vaccinated calves was rare, varying from negligible to 0.01%. The
inability of ticks fed on vaccinated calves to transmit clinical theileriosis cannot be
interpreted as a qualitative change in virulence; it was more likely due to a low
parasite challenge. The carrier state parasite given at a higher infection dose could
be pathogenic. The vaccine-induced carrier state could be seen as beneficial for
maintaining immunity both in the vaccinated animals and by tick transmission to the
rest of the cattle population.
IMMUNIZATION WITH THEILERIA ANNULATA-PARASITIZED
LYMPHOCYTE CELL-CULTURE VACCINE
Two strategies for immunization are suggested. Immunization with cell-culture
vaccine alone is recommended during the winter months when the tick vector is
inactive. A number of cell-culture vaccines are now available, developed by different
centres to meet the regional needs of their respective State Animal Husbandry
Departments. In the past, cross-protection trial studies reported full cross-protection
between isolates from distant regions. However, a report from the Indian Veterinary
Research Institute (IVRI), Izatnagar centre, describes an isolate (Parbhani) against
which the standard vaccine stock does not protect. Cross-protection between different
isolates (cultures) is being studied further this year. Secondly, the ICAR is aiming at
further evaluation of the efficacy of vaccines in new-born calves (as discussed earlier
under the Epidemiology Section). Two such effective vaccines (PAU, Ludhiana, and
IVRI, Izatnagar) are at different stages of testing in the field. In laboratory testing it
was observed that with high passage cultures (more than 300 days), the post-vacci-
nation reaction consisted of mild fever for a day in some calves and no parasitaemia,
but challenge produced 1–7% parasitaemia with fever lasting for two to four days.
On the other hand, with the lower passage cultures (100 days), mild post-vaccination
reactions were produced with transient fever of one to three days, very low and
irregular parasitaemia, varying between negligible to <0.05%, but the calves were
fully protected against challenge with no fever and no change in the parasitaemia
profile from that of the vaccination phase. All calves survived in both the vaccinated
groups and became DOT-EIA antibody positive three to four weeks after vaccination.
The control calves suffered clinical theileriosis with parasitaemias of 40–85% and
100% mortality, respectively, within two to four weeks. These high challenge infec-
tions are unlikely to be encountered under field conditions. Even so, it would be safer
not to use the higher passage cultures and accept a mild reaction after vaccination
with the lower passage cultures that ensure solid immunity to heavy challenge. It was
also demonstrated that vaccination (300 days culture) of Anaplasma-infected calves
showed higher Theileria parasitaemias of 5–15% on subsequent challenge.
Immunization with cell-culture vaccine in conjunction with buparvaquone (Bu-
talex, Coopers Pitman-More) is recommended during the peak tick vector season
(summer months), since some of the animals may be incubating the disease at the
time of vaccination. Depending on the time of exposure to infected ticks, prior to
vaccination, it is likely that such animals could succumb to clinical theileriosis
because the vaccine takes two to three weeks to induce protective immunity. Our
recent findings confirm that the use of Butalex, which has a prolonged antitheilerial
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activity in cattle, in conjunction with cell-culture vaccine ensures safety against any
likely tick exposure while the vaccine induces immunity. Butalex, although reported
to be an anti-schizontal drug, did not interfere with the efficacy of schizont parasitized
lymphocyte cell-culture vaccine. The mechanism of the drug’s action in this applica-
tion is not fully understood. Neither attenuated parasitized lymphocytes nor unat-
tenuated parasitized lymphocytes, in conjunction with Butalex, produced clinical
disease, but they did induce immunity to sporozoite challenge infection. The control
calves treated with drug alone were fully susceptible to challenge infection four
weeks after treatment. The drug was effective in reducing the virulence of unattenu-
ated parasitized lymphocytes but it did not reduce the immunogenicity of the
attenuated parasitized lymphocytes. The parasitized schizonts from allogeneic lym-
phocytes in the vaccine transfer to the lymphocytes of the vaccinated animals in order
to induce recipient host MHC compatible cytotoxic T lymphocytes. Since Butalex in
conjunction with the parasitized lymphocyte cells could induce solid immunity, as
do the sporozoites when used with the drug, the transfer of infection from the
allogeneic cells to the lymphocytes of vaccinated animal was not inhibited.
The modified approach to infection-and-treatment immunization using cultured
parasitized lymphocytes in place  of tick sporozoites has other advantages. The
reproducibility of infective dose can be more easily obtained than with sporozoites;
infected lymphocyte culture can be scaled up more easily and economically than bulk
sporozoites for large-scale field immunization. In situations where new strains
appear, against which the existing vaccine may fail to protect, it is even safer to use
the unattenuated parasitized lymphocyte cultured in vitro. This offers the obvious
advantage of avoiding the long time required to achieve optimal attenuation of the
culture for use as vaccine. In India, as discussed above, our aim is to vaccinate cattle
when young; the amount of drug required would be small, which minimizes the cost
of vaccination with Butalex plus cell-culture vaccine. Young calves are also easier to
handle.
INFECTION AND IMMUNITY STUDIES WITH
THEILERIA ANNULATA PIROPLASMS
Preparation of erythrocytes by centrifugation and removal of the buffy coat from
infected calf blood still leaves mononuclear cells as contaminants. These erythrocyte
preparations induce clinical Theileria infections. Parasitized erythrocytes, freed of
mononuclear cells by repeated centrifugation on Lymphoprep (Nygaard) gradients,
did not set up active infections, even with 2 ml of packed red cells from blood with
70–80% parasitaemia. Pre- and post-inoculation (four weeks) sera from these calves
were negative for antibodies to T. annulata using the DOT-EIA. Blood smear
examinations revealed extremely low parasitaemia that may be of inoculum origin.
Inoculation of purified freshly released piroplasm preparations also did not establish
infections.
Immunization by injecting piroplasms emulsified with adjuvants into calves and
subsequent boosting at four weeks induced high DOT-EIA antibody titres of up to
6,400–512,000. However, on sporozoite challenge, these calves developed typical
clinical theileriosis with high erythrocytic parasitaemias and died at the same time
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as control calves. These results suggest that the merozoites from lymphocytic schi-
zogony were not blocked by antibodies to the intra-erythrocytic piroplasms. Sec-
ondly, trasfer of infection from one erythrocyte to another is an uncommon event or
is too limited to be a suitable vaccine target. These suggestions, of course, do not
exclude that intra-erythrocytic multiplication of the parasite can take place, as
reported convincingly by other workers. The parasitaemia is most likely to be a direct
reflection of merozoites produced by lymphocytic merogony. Research on merozoite
invasion of erythrocytes will be of great interest as an alternative vaccine target. In
our experience with experimental infections in more than 200 calves (accumulated
data), development of erythrocytic piroplasms was associated with the severity of
illness, and death occurred after piroplasm development.
CONFLUENT MONOLAYER CULTURES OF ADHERENT
MONONUCLEAR CELLS FROM PERIPHERAL BLOOD
OF THEILERIA ANNULATA-INFECTED CATTLE
Mononuclear cells from venous blood of infected animals were isolated on Lympho-
prep gradients and cultured. The non-adherent cells were removed, initially at three
hours, then daily for four days, until no non-adherent cells were seen. At five to seven
weeks a few small foci of dividing adherent cells, forming epithelial-like cell
monolayers, were noticed, which by 8–12 weeks became confluent monolayers. At
this time, small numbers of floating refractile dividing cells, seen mostly in pairs or
small clumps, also began to appear. The number of these non-adherent dividing cells
increased rapidly. Stained cytospin preparations revealed that all the non-adherent
cells were parasitized with Theileria schizonts and had a lymphocytic morphology.
Transfer of the non-adherent cells using selective trypsination allowed the estab-
lishment of pure adherent cell monolayer cultures. The adherent cell monolayers
could be subcultured at 1:3 split ratio and became confluent again in one to two
weeks. Cytospin-stained smears of these adherent cells revealed no parasite forms
and they were macrophage-like in morphology. The adherent cells injected into
calves did not produce Theileria infection and the calves were fully susceptible to
sporozoite challenge. The susceptibility of bovine monocyte/macrophages as targets
for T. annulata-infection needs to be studied further because it had been reported that
these cells are susceptible to infection and transformation. The non-adherent, actively
dividing Theileria parasitized cells in the primary adherent cell cultures most likely
represented a few passively attached lymphocytes that had not been removed initially,
rather than monocyte/macrophage cells that had been infected and transformed by T.
annulata.
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Vaccination of cattle against Theileria
annulata using culture-derived schizonts
E. Pipano
The Kimron Veterinary Institute
Beit-Dagan, 50 250, Israel
Theileria annulata (Dschunkowsky and Luhs, 1904) has a complex life cycle involving
Hyalomma spp. ticks and cattle (Mehlhorn and Schein, 1984). Three of the develop-
mental stages—sporozoites, schizonts and erythrocytic merozoites—are infective for
cattle. The clinical manifestations and pathological alterations are mainly associated
with the presence of microscopically detectable schizonts in the infected animals.
Theileria annulata has been diagnosed in North Africa, southern Europe, the Near and
Middle East, southern USSR, India and southern China (Dolan, 1989). The geographi-
cal distribution of T. annulata in the Far East is not yet completely known.
HISTORICAL REVIEW OF VACCINATION
AGAINST THEILERIA ANNULATA
During the 1920s and 1930s an intensive study of theileriosis caused by T. annulata
in the Mediterranean Basin was carried out in Algeria by a team of French investiga-
tors headed by Edmond Sergent. The results of their work were summarized in a
classic monograph (Sergent et al., 1945), which provided the fundamental charac-
terization of T. annulata that has been the basis for all subsequent studies. Based on
the observation that blood from cattle acutely infected with T. annulata was invariably
infective for susceptible cattle, the French investigators proceeded to select field
isolates of natural low virulence. The low-virulence isolates were maintained in the
laboratory by passage through susceptible calves, and this eventually resulted in loss
of the capacity of the schizonts to yield erythrocytic parasites (Sergent et al., 1945).
Such a strain was used for vaccination of field cattle in North Africa for a period of
10 years (1929–1938).
This method of vaccination was investigated by the Israeli scientists Adler and
Ellenbogen (1934), with the aim of protecting Friesian-type cattle imported from
Europe  to  improve  local breeds. Since they could not isolate  an indigenous T.
annulata strain with low virulence for mass vaccination of cattle, they acquired a
mild strain sent by Sergent and his collaborators. However, this exotic strain provided
poor protection against the local virulent strains (Adler and Ellenbogen, 1934, 1935,
1936). To circumvent this obstacle, the Israeli investigators adopted a two-step
vaccination procedure: first inoculating the mild exotic strain, and two months later
inoculating a local strain to reinforce the partial immunity induced by the exotic
strain. After 420 passages, the latter failed to infect susceptible calves and, by that
time, no other low virulence strains were available (Pipano, 1966).
The successful cultivation of T. annulata schizonts in plasma clot cultures by Tsur
(1945) was another major step in the progress of research in theileriosis. This line of
investigation was pursued in the search for an immunizing agent against this disease.
The achievement of mass propagation of schizonts in monolayer cultures (Tsur et al.,
1964) and the fact that the pathogenicity of the parasite decreased after prolonged
cultivation in vitro (Pipano and Tsur, 1966) provided the basis for development of a
safe cell-culture-derived vaccine.
SCHIZONT VACCINE
The process of producing an antitheilerial schizont vaccine begins with the isolation
of T. annulata parasites to initiate cultures. Blood from acutely ill cattle drawn during
the period when schizonts are detected in smears from lymph node or liver biopsy
usually induces theileriosis when inoculated into susceptible animals. A few ml of
blood drawn into a non-toxic anticoagulant are enough to cause infection, even after
storage for several days at 4 C (Sergent et al., 1945).
Hyalomma ticks from theileriosis enzootic areas are also a reliable source of
parasites since field studies have shown that a considerable percentage of such ticks
carry T. annulata infections (Walker et al., 1983). Adult ticks feeding on cattle or
water buffalo can be carefully detached and allowed to complete their blood meal on
susceptible calves in the laboratory. Most of the ticks will re-attach and transmit
theileriosis to susceptible calves. Infected adult ticks can also be obtained in enzootic
areas by collecting engorged nymphs from cattle and allowing them to moult, or by
collecting moulting nymphs or unfed adults from cracks and crevices of barns. The
adults can then be fed on cattle with a high probability of producing infections, or
they can be macerated after stimulating the development of sporozoites and the
suspension inoculated into calves (see sporozoite vaccine).
Establishment of schizont cultures
The techniques for establishing cultures of T. annulata schizonts have been described
by Brown in three comprehensive reviews (Brown, 1979a, 1980, 1983). Cultures are
initiated by incubating schizont-infected cells collected from cattle suffering from
theileriosis. Although schizonts are scarce in blood smears of such animals, incuba-
tion of peripheral blood leucocytes results in a high percentage of schizont-infected
cultures (Pipano et al., 1989). Similarly, schizont-infected cells obtained by trypsini-
zation of aseptically removed pieces of lymph node, liver or spleen can be used for
initiating cultures. An elegant technique for initiating cultures was developed by
Brown (1979b) and collaborators. Peripheral blood leucocytes of healthy cattle were
infected in vitro with sporozoites obtained from infected ticks. This technique opened
important experimental possibilities to the in vitro study of T. annulata.
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Attenuation of schizonts
In vitro cultivation of T. annulata-infected lymphoid cell lines for months or years
results in an attenuation of their pathogenicity for cattle. Schizont-infected cells are
subcultured by transfer every three to four days in small culture vessels (Pipano,
1989a). A portion of every tenth passage is stored frozen. The degree of attenuation
is assessed by periodic inoculation of 2  104 to 3  104 infected cells into susceptible
calves. Pathogenicity is evaluated according to the response of the inoculated calves.
During the early period of cultivation, the schizonts produce clinical theileriosis in
most calves and kill some of them. Later, milder clinical reactions, accompanied by
rare schizonts in lymph nodes and liver, are observed (Tsur et al., 1964; Zablotsky,
1967; Gill et al., 1976). Attenuation is complete when inoculated calves show no
clinical symptoms, schizonts or erythrocytic merozoites (Pipano and Israel, 1971;
Pipano et al., 1973).
We know too little about the phenomenon of attenuation. It may be that attenuated
schizonts derived from culture undergo only a few replication cycles when inoculated
into cattle (Pipano, 1977). Consequently, they may never reach the minimum number
of parasites needed to provoke a rise in temperature, nor the lower limit of infected
lymphocytes that can be detected by microscopic examination of tissue smears. There
are no indications that the time needed for attenuation is proportional to the initial
virulence of the schizonts (Ozkoc and Pipano, 1981; Pipano, 1971). Moreover, the
same theilerial isolate may become attenuated after different periods of cultivation
(E. Pipano, unpublished data).
Production of schizont vaccine
Production of a batch of schizont vaccine begins with the retrieval of an aliquot of
frozen, infected seed cells. For initiating the culture, 25 cm2 plastic flasks are usually
used. The cells are further passaged, transferred and expanded into larger vessels
until the  desired number of cells has been obtained (Pipano, 1989a). Theileria
annulata-infected cells have been grown as monolayers (Zablotsky, 1967; Tsur and
Adler, 1962) or as suspension cultures (Hooshmand Rad and Hashemi-Fesharki,
1968; Van den Ende and Edlinger, 1971; Mutuzkina, 1975). For monolayer cultiva-
tion, large vessels such as Roux or Blake bottles are used. These yield about 108 cells
per bottle. Monolayers can also be grown in roller bottles that may generate 30 to
40% more cells than the static vessels with the same amount of medium (Pipano,
1989a). The schizont-infected cells are harvested and concentrated by centrifugation.
The vaccine can be used directly as a fresh suspension of infected cells but in most
cases doses of vaccine are cryopreserved in liquid nitrogen (Pipano, 1989a; Wathanga
et al., 1986).
Protection engendered by the schizont vaccine
Completely attenuated schizonts do not induce any clinical response and no
parasitaemia is detected (Pipano et al., 1973). When attenuated schizonts retain the
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ability to produce erythrocytic merozoites, the latter can be detected on peripheral
blood smears from a portion of the vaccinated cattle. In these cases, a few schizonts
probably also occur in the lymph nodes or liver, but mass needle biopsy of
vaccinated animals cannot be considered a practical means for evaluating the
response to the vaccine. On the other hand, even when schizonts are completely
attenuated, specific antibody can be detected (Pipano et al., 1973, 1969; Frank et
al., 1971; Mutuzkina, 1983). The presence of antibody during the post-vaccination
period implies that some multiplication of schizonts in the vaccinated animals has
occurred. Challenge of vaccinated animals with virulent blood-derived schizonts
is not of great practical value, but may be useful as a preliminary indication of the
protective capacity of the attenuated schizonts. There is good evidence that the
main targets of the immune response to T. annulata are the schizont-infected cells
(Hall, 1988). However, cattle recovered from schizont infection possess a stronger
immunity to reinfection with schizonts than to infection with sporozoites (Sergent
et al., 1945; Pipano, 1974).
Infection of schizont-immune cattle with T. annulata sporozoites has yielded
variable results.  In  India, 14  out  of  15 schizont-vaccinated  calves  were  totally
protected against challenge with infected ticks and only one showed mild parasitae-
mia (Gill et al., 1976). In the USSR, seven vaccinated calves were challenged by
ticks; five exhibited transient fever and all of them showed a mild rise of parasitaemia
above that resulting from the vaccine (Zablotsky, 1967). In Israel, 7 out of 22 calves
vaccinated with completely attenuated schizonts remained asymptomatic and 15
exhibited low parasitaemia and mild fever after sporozoite challenge (Pipano, 1981).
In all these trials, control susceptible cattle challenged together with the vaccinated
cattle showed severe clinical theileriosis and a considerable portion of the animals
succumbed to the challenge.
In the past, vaccination-challenge trials using blood-derived parasites from various
isolates have shown that different immunogenic properties may exist among the
isolates (Adler and Ellenbogen, 1936; Pipano et al., 1974; Sergent et al., 1935; Gill
et al., 1980). Cattle vaccinated with culture-derived schizonts and then infected with
sporozoites from remote geographical areas were well protected in some cases
(Preston and Brown, 1988) but poorly-protected in others (Ozkoc and Pipano, 1981).
To reinforce the immunogenic property of the schizont vaccine, a combination of
schizonts from isolates obtained in different geographical regions was proposed
(Stepanova and Zablotsky, 1989).
Field observations have confirmed the efficacy of the schizont vaccine in inducing
immunity against natural infection. In a large field trial in the USSR, 410 vaccinated
and 66 susceptible calves were introduced into theileriosis enzootic pastures. None
of the vaccinated animals showed clinical theileriosis, while all control calves
contracted the disease and 33% of them died (Stepanova et al., 1977). A summary of
field trials in Uzbekistan showed that 98 to 100% of schizont-vaccinated cattle were
protected against clinical theileriosis when grazing in infected pastures (Stepanova
et al., 1986). Similar results were obtained in Turkmeenia where 397 calves were
protected by the schizont vaccine when kept in barns infested by T. annulata-infected
ticks. Thirteeen out of 20 non-vaccinated calves contracted theileriosis (Divanov and
Khudainazarova, 1988). In Israel, about 3,000 bulls imported from theileriosis-free,
western European areas survived in theileriosis-enzootic pastures when protected by
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vaccination with schizonts. Non-vaccinated local or imported cattle exposed acci-
dently on these pastures have invariably contracted theileriosis (Pipano, 1989b). In
Iran, observations of about 100,000 cattle showed that mortality caused by field-ac-
quired theileriosis was around 0.04% in schizont-vaccinated cattle versus up to 80%
in non-vaccinated ones (Hashemi-Fesharki, 1988). Under experimental conditions,
the immunity conferred by the vaccine lasted for at least three and a half years
(Zablotsky, 1983).
Although the schizont vaccine decreases considerably the economic loss from
theileriosis, there is no evidence, for the time being, that it has an influence on the
epizootiology of the disease. Cattle vaccinated with completely attenuated schizonts
do not provide a source of infection for ticks (Samish et al., 1984). On the other hand,
even when complete protection is conferred, the immunity does not prevent the
appearance of erythrocytic merozoites resulting from the bites of infected ticks.
Although it has not yet been proven experimentally, it is likely that ticks engorging
on such cattle will become infected. Consequently, the use of schizont vaccine does
not result in the eradication of theileriosis in enzootic areas.
Testing the schizont vaccine
The nomenclature used below follows that employed in the United States Code of
Federal Regulations (1989). The use of schizont vaccine has already reached the stage
of commercial production in several countries. However, little has been done to
establish standard requirements for testing and use of this vaccine. It would be
desirable for an ad hoc committee of representatives from vaccine-producing centres
to elaborate a standard protocol covering production, testing and application of the
vaccine, rather than having each centre follow its own procedures. The basic tests
that a veterinary vaccine produced in cell culture should undergo are for purity, safety,
sterility, potency and efficacy. At present, perhaps with a few exceptions, a master
seed (a) is kept in the production centres and most use a working seed (b) as a stock
material. Since the parasite is incorporated in the cells used for its propagation,
several consecutive batches of vaccines are produced from cells obtained from the
previous production cycle. This means that the production seed (c) is used as working
seed.
The following is the testing procedure for schizont vaccine used in the Kimron
Veterinary Institute. It should not be considered a final recommendation for other
centres but rather a provisional protocol that should be completed and improved
according to the experience gathered in other production centres.
(a) Master Seed. An organism at a specific passage level that has been selected and
permanently stored by the producer from which all other seed passages are derived.
(b) Working Seed. An organism at a passage level between Master Seed and
Production Seed.
(c) Production Seed. An organism at a specified passage level that is used without
further propagation for initiating preparation of a fraction.
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Testing for sterility
A sample from each batch of frozen vaccine is thawed and 0.2 ml of concentrated
vaccine is introduced into 120 ml of Soybean Casein Digest Medium and incubated
for 14 days at 35 °C to test for bacterial contamination. To test for fungi, a separate
vaccine sample is incubated with the same medium at 25 °C for 14 days.
Testing for specific infections
The vaccine seed is free from common viral infections such as bovine virus
diarrhoea, infectious bovine rhinotracheitis, Blue tongue virus, bovine leucosis
virus, Mycoplasma and Clamydia, having  been  tested  for  these  agents before
storage. On the other hand, another biological product is used in the production of
the vaccine, namely bovine serum, all other medium components being of synthetic
origin. Therefore, the use of serum certified to be free of potential contaminants
of bovine origin is an acceptable, practical measure in producing the vaccine.
However, whether this type of procedure is entirely adequate is a subject for further
elaboration.
Testing for purity (freedom of extragenous organic or inorganic material) is not
performed with this type of vaccine. It is not clear how the presence of the large
volume of bovine lymphoid cell material should be regarded.
Testing for safety as a practical matter is simply the testing for pathogenicity to
cattle. It appears from presently accumulated experience that no reversion to viru-
lence occurs during further subcultivation of attenuated schizonts. Furthermore, the
frozen vaccine is prepared in relatively small batches, so that testing samples from
each batch of vaccine in cattle is economically unpractical. However, for legal
purposes, two susceptible calves are inoculated once a year from a batch of vaccine
chosen at random.
Testing for potency is in effect a determination of the number of viable schizonts
(infected cells) included in a dose of vaccine necessary to induce a serological
response in cattle. If fresh vaccine is used, a constant decrease of viable schizonts
occurs, proportional to the time of storage and temperature. Because such vaccine is
subjected to variable ambient conditions, it is difficult to standardize.
With frozen vaccine, the time of storage in the frozen state does not play a major
role in the survival of the schizonts, but the freezing-thawing process does. With this
in mind, and considering the possible environmental conditions in the field after
thawing and diluting the vaccine, the number of infected cells per dose is fixed at 10
million.
The plating efficiency of the infected cells after thawing may represent a
potential test for potency (Wathanga et al., 1986). However, there is no evidence
that multiplication of schizont-infected cells in culture is equivalent to infectivity
for cattle. The serological response is assessed by measuring the antibody level
in vaccinated cattle using the indirect fluorescent antibody test (Pipano et al.,
1969).
CURRENT METHODS OF DIAGNOSIS AND CONTROL
52
Testing for efficacy is performed by challenging vaccinated and susceptible cattle
with sporozoites. Challenge is performed about six weeks after vaccination using a
suspension of macerated T. annulata-infected adult H. excavatum ticks that has been
stored as a stabilate in liquid nitrogen. A dose containing the equivalent of five ticks
is inoculated subcutaneously. Usually, the two calves used earlier for safety tests, and
a susceptible calf, are inoculated with the challenge stabilate. A considerable percen-
tage of challenge calves show a few parasites and a rise in body temperature (see
protection engendered by the schizont vaccine). However, no criteria for a stand-
ardized objective evaluation of the severity of response to challenge with sporozoites
have yet been elaborated.
SPOROZOITE VACCINE
A technique for vaccinating against T. parva theileriosis using sporozoites to
infect the cattle and chemotherapy to mitigate the clinical response was developed
during the late 1960s and early 1970s (Cunningham, 1977; Purnell, 1977; Radley,
1981). This technique was tried also with T. annulata and research in this field
was recently summarized in a comprehensive review (Pipano, 1989a).
The main stages in preparation and use of a sporozoite vaccine are as follows.
Breeding and infecting ticks. To maintain a tick colony, non-infected Hyalomma
ticks are reared on rodents. To prepare the vaccine, preimaginal stages are allowed
to engorge on cattle infected with erythrocytic merozoites of T. annulata (Samish et
al., 1983). A high parasitaemia in the donor calf is more likely to ensure a high yield
of sporozoites in the engorged ticks. Adult ticks developing from infected preimagi-
nal stages are fed on cattle, goats, rabbits or other mammals for a period of three to
five days to stimulate maturation of sporozoites in their salivary glands (Samish and
Pipano, 1976; Singh et al., 1979). Incubation at 37 °C at high humidity (Samish,
1977) may also stimulate maturation of parasites without a blood meal, but fed ticks
provide a higher number of sporozoites (Walker and McKellar, 1983; Reid and Bell,
1984).
Preparation, storage and testing of sporozoite suspension. The adult infected
ticks are removed from the host, washed free of host tissue exudate, then triturated
manually (Brown, 1983) or by means of a homogenizer (Samish et al., 1983; Food
and Agriculture Organization, 1984) in the liquid phase of cell culture medium
complemented with bovine plasma albumin. The supernatant, containing infective
sporozoites, is decanted and cryoprotectant is added (Samish et al., 1983). The
suspension is distributed in aliquots of 1.0 to 1.5 ml and preserved in liquid
nitrogen. Infectivity of the vaccine is tested by inoculating susceptible cattle with
serial dilutions of thawed suspension (Pipano et al., 1982).
Controlled infection and treatment of cattle. Vaccination is performed by
subcutaneous  inoculation of  a  thawed  suspension of  sporozoites  followed by
treatment with tetracycline or naphthoquinone derivates. Tetracyclines should be
administered during the early prepatent period to have the required effect. To
reduce the number of treatments, one or two inoculations with long-acting
oxytetracyclines have been applied (Gill et al., 1977, 1978; Pipano et al., 1981;
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Khanna et al., 1980). Naphthoquinones are administered simultaneously with the
tick suspension (Dhar et al., 1987) or at a later stage of infection (Bansal and
Sharma, 1989).
As far as T. annulata is concerned, this technique of vaccination has not passed
the stage of laboratory trials. A procedure that involves infecting cattle with highly
virulent parasites and then preventing severe disease by chemotherapy cannot be
considered safe. It appears, also, that the cost of preparing the sporozoite vaccine
plus the cost of the drugs needed for treatment is considerably higher than that
required for producing cultured schizont vaccine. It follows then that, aside from
experimental purposes, the sporozoite vaccine has no practical application in T.
annulata theileriosis.
FUTURE PROSPECTS
At present there are two effective tools available for control of T. annulata theil-
eriosis, a completely safe and relatively efficient vaccine for preventing the disease,
and an efficient chemotherapeutic agent (Bansal and Sharma, 1989) to decrease
losses in sick animals. Further studies should be directed towards improvement of
the existing vaccine and development of techniques for assessing the epizootiological
situation and hence evaluation of the need of vaccination.
Little has been done in defining the antigenic complexity of T. annulata, or
concerning the immunological responses of cattle to the different developmental
stages of this parasite. More information may lead to improvement in the protective
capacity of the vaccine.
A knowledge of the mechanism of attenuation of the schizonts in culture may
shorten the period required for obtaining avirulent schizonts. If a gene for virulence
was identified in the schizonts, the determination of virulence or avirulence using a
DNA hybridization probe might be feasible. This would replace the need for
inoculation of cattle in assessing the degree of attenuation.
It is not yet clear whether prolonged cultivation in vitro reduces the immunogenic
capacity of schizonts, and therefore decreases the efficacy of the vaccine. This
information would be indispensable for determining the optimal time for cultivation
in vitro in order to obtain maximal safety with maximum immunogenicity of the
schizonts.
The response of cattle to revaccination needs further clarification. To induce
immunity, the schizonts should become established when inoculated into cattle. If
the basic immunity conferred by an initial vaccination prevents the establishment of
schizonts on a subsequent vaccination, no reinforcement of immunity will occur. It
is likely that the use of vaccine prepared from antigenically different strains might
help circumvent the elimination of the schizonts used for revaccination.
A specific serological test that would allow rapid screening of large numbers of
samples is required to assess the need for vaccination of exotic cattle to be introduced
in regions where local breeds enjoy enzootic stability. In addition to the indirect
fluorescent antibody technique (Pipano et al., 1977), the enzyme immunoassay (Gray
et al., 1980) should be adopted and expanded for use for this purpose.
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Restricted preliminary trials have shown that immunization with non-viable anti-
gens of T. annulata engenders weak or no protection against natural infection
(Hashemi-Fesharki, 1988). It follows, therefore, that, for the present at least, the
schizont vaccine remains the method of preference for preventing losses from T.
annulata-theileriosis.
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Butalex (buparvaquone): A new
therapeutic for theileriosis
N. McHardy
Coopers Pitman-Moore,
Berkhamsted Hill
Berkhamsted, Hertfordshire, HP4 2QE, UK
INTRODUCTION
Buparvaquone is a second-generation hydroxynaphthoquinone with outstanding ac-
tivity against Theileria spp. and some small Babesia spp. Formulated as a 5% solution
for injection (Butalex, Coopers Pitman-Moore), it achieved an overall cure rate of
92% against 1,800 field cases of theileriosis, caused by Theileria annulata and T.
parva, in independent trials. High cure rates were achieved with a single intramus-
cular injection at a dose rate of 2.5 mg/kg buparvaquone, particularly against T.
annulata infections, though supportive therapy to control anaemia and pulmonary
oedema was found beneficial in advanced cases. Butalex is an extremely safe product,
and has a recommended milk-withhold period of only two days. Work is progressing
on several possible uses for Butalex in addition to the treatment of clinical cases of
theileriosis. These include its use as a `blocking’ drug in immunization procedures
against both T. annulata and T. parva, using, respectively, cultured schizonts and
sporozoites as the infective material, and as a strategic therapy in the face of severe
challenge among young calves in T. annulata-endemic areas. Several studies have
examined the effect of Butalex treatment on the milk productivity of cattle with latent
T. annulata infections, with encouraging results, and studies are in progress to
confirm the ability of Butalex to eliminate latent infections of B. equi in horses and
to treat the clinical disease. Its highly specific action against Theileria, allied to its
very low mammalian toxicity, could make it an excellent tool in investigations on the
nature of the immune response to Theileria spp. Cost efficacy analyses indicate that
Butalex will play an important role in increasing productivity and profitability,
particularly of `improved’ dairy cattle, in Theileria-endemic areas.
THERAPY OF CLINICAL THEILERIOSIS
Independent trials in at least 12 countries have demonstrated the efficacy of Butalex
in curing field cases of theileriosis caused by both T. annulata and T. parva. A total
of more than 1,800 cases have been treated with an overall cure-rate of 92%. Cure
was achieved in around 80% of cases of T. annulata infection with only one
intramuscular injection of 1 ml Butalex per 20 kg (2.5 mg buparvaquone/kg) (Table
1). Cure rates were particularly impressive when early or moderately severe cases
were treated, but some advanced cases required a second, similar treatment 40 hours
after the first to effect a cure. Dhar found that supportive treatment with B vitamins
and iron were beneficial in cases of T. annulata infection in which the haemoglobin
concentration was below 68% (Table 1). When it was below 38%, the prognosis was
poor, even with supportive therapy.
It was generally observed that, following treatment of T. annulata infections with
Butalex, clinical signs of disease were resolved in 24–48 hours and productivity was
generally restored within days or weeks, depending on the severity of the disease at
the time of treatment. `The completeness of cure’ was commented upon by many
triallists, in marked contrast to their results when using tetracyclines together with
supportive therapy. No signs of drug toxicity were reported from any of the trials.
Field trials against T. parva infections have been fewer and more mixed in their
design. However, high cure rates with a single dose were reported from Zambia
(Musisi et al., see Table 2) and Uganda (Otim, see Table 2). In Tanzania, Mbwambo
et al., see Table 2) reported excellent results, though they routinely used two doses.
They reported that use of a diuretic in any case showing respiratory distress was very
beneficial. In Kenya (Dolan et al., see Table 2), around 40% of cases required a second
injection of Butalex, and several `cured’ cases developed into chronic theileriosis.
The reasons for this relatively disappointing result are not known.
The overall cure rate of field cases of theileriosis of 92% with Butalex combined
with the frequent need for only one injection and the milk withhold time of only two
days indicates that its performance as a treatment for theileriosis is clearly superior
to that of either Clexon (parvaquone) or Terit (halofuginone).
LABORATORY STUDIES WITH BUPARVAQUONE
In an in vitro drug screen, buparvaquone was shown to have an EC50 of 0.0004 mg/L(ca. 10–9M) against T. parva, (Muguga E174) but its specific activity against T.
TABLE 1. Results of representative trials with Butalex in the treatment of field cases of
theileriosis caused by Theileria annulata infection.
No. of cases treated No. No.
Country Trial Total 1 Dose 2 Doses cured excluded* % Cured
India S. Dhar 19 19 — 19 0 100.0
India B.B. Verma 41 36 5 36 4 97.3
India R.D. Sharma et al. 95 95 — 89 0 93.7
India P.K. Banerjee et al. 15 10 5 15 0 100.0
India U.V. Shastri 17 17 0 10 3 71.4
Iran R. Hashemi-Fesharki 66 54 12 58 0 87.9
Iraq N. Hawa et al. 23 23 — 22 1 100.0
Pakistan M.A. Choudhry et al. 596 540 56 586 0 98.3
Turkey H. Unsuren et al. 35 32 3 27 3 84.4
Soviet Union V. Zablotsky et al. 402 310 92 346 0 86.1
Total 1,309 1,136 173 1,208 11 93.1
A standard dose of 1 ml Butalex per 20 kg body weight was used throughout.
*Cattle that died of causes other than theileriosis or that died within 12 hours of treatment are excluded
from the results.
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annulata was rather less (around 10–8M). This compares with an EC50 of 0.006 mg/L
against T. parva (Muguga E174) for both parvaquone and halofuginone (McHardy
et al., 1985).
Electron microscopic studies on the effect of buparvaquone on cultured T. parva
showed a rapid and specific effect on schizonts, but no adverse effects on host cells,
or host cell mitochondria. This conforms with the suggested mode of action of
buparvaquone as a specific inhibitor of parasite mitochondrial electron transport (Fry
et al., 1984). The principal schizont lesion was progressive cytoplasmic vacuolation,
while membranes and nuclear structure remained unaffected during 48 hours
exposure. Similar lesions were seen in buparvaquone-treated piroplasms of T. parva.
Bioassay of the plasma concentration of buparvaquone following intramuscular
injection into cattle of Butalex at the standard dose of 2.5 mg buparvaquone/kg
showed that concentrations peaked at around 0.2 mg/L (300  EC50) three hours after
injection, then fell steadily to low concentrations by around day 7. This observation
is in close agreement with HPLC assay by Kinabo and Bogan (1988), which suggests
that plasma binding of buparvaquone is relatively low.
STUDIES IN ARTIFICIALLY INFECTED CATTLE
Studies in calves infected with sporozoite stabilates of either T. annulata (Ankara)
or T. parva (Muguga) indicated an optimum dose of 2.5 mg/kg of buparvaquone,
as Butalex, injected intramuscularly for both infections. As in field studies, clinical
signs were generally controlled within 24–48 hours, while schizonts were clearly
damaged within 24 hours. Their numbers then fell to undetectable levels, usually
within two to seven days. Damage to schizonts took two forms. Either they became
more densely staining, and progressively smaller, or they became more diffuse in
appearance and progressively more difficult to identify. It is suggested that the
former changes were due to the direct effects of buparvaquone, while the latter was
TABLE 2. Results of representative trials with Butalex in the treatment of field cases of
theileriosis caused by Theileria parva infection.
No. of cases treated No. No.
Country Trial Total 1 Dose 2 Doses cured excluded* % Cured
Kenya T.T. Dolan et al. 167 44 123 136† 0 81.4
Tanzania H.A. Mbwambo et al. 68 9 59‡ 67 0 98.5
Uganda C. Otim et al. 51 42 9 46 0 90.2
Zambia F.L. Musisi et al. 68 68 0 62 1 92.5
Total 354 163 191 311 1 88.1
A standard dose of 1 ml Butalex per 20 kg bodyweight was used throughout.
*Cattle which died of causes other than theileriosis or which died within 12 hours of treatment are
excluded from the results.†Includes 12 `chronic’ cases.‡Two doses were given routinely except to nine early cases.
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due to an immunological effect. A low-level recrudescent schizont parasitosis was
sometimes observed following treatment of either T. annulata or T. parva infection.
This invariably resolved without the need for further buparvaquone treatment. It
emphasizes, however, that treatment with buparvaquone is unlikely to eliminate
Theileria infections totally.
Piroplasms became densely staining and `anaplasmoid’ in form within 24 hours
of buparvaquone treatment. They then showed a progressive decline in numbers over
the subsequent seven days or so, but then small numbers of piroplasms of normal
appearance were sometimes seen. In cattle treated before patent piroplasm parasitae-
mia was observed, no piroplasms were subsequently seen in blood smears. Similarly,
when advanced cases with large numbers of schizonts detected were treated, micro-
schizonts were seldom observed, suggesting that buparvaquone is particularly
effective against this stage of the life cycle.
In calves infected with T. annulata and showing a declining haematocrit at the time
of treatment, the fall was generally halted within 24 hours, before showing a slow
but progressive increase. These observations (McHardy et al., 1985) generally
parallel those seen when field cases of theileriosis are treated with Butalex. This
indicates that buparvaquone is effective against all theilerial life cycle stages in cattle,
permitting rapid resolution of clinical symptoms and return to normal productivity,
particularly when cattle are treated early in clinical disease.
In a small trial, McHardy and Wekesa (1984) showed that buparvaquone may be a
good candidate drug for use in the infection-and-treatment method of immunization
against Theileria. In ten cattle injected with 2.5 mg/kg buparvaquone as Butalex at the
same time that they were infected with a sporozoite stabilate of T. parva (Muguga), a
very mild episode of theileriosis ensued, and no piroplasms were seen in blood smears.
Ten untreated cattle developed typical fatal theileriosis, characterized by large num-
bers of both schizonts and piroplasms (Table 3). This encouraging lead has been
pursued by various workers with both T. parva and T. annulata with some success.
In a second trial, Butalex was administered at the same dosage to groups of five
calves, either seven days before infection, at the same time as infection, or ten
days afterwards. All treated calves survived to day 28 after infection, but two of
those treated seven days before infection had died by day 35. All five untreated
calves had died by day 22. The weight changes up to day 28 are shown in Table
4. Clearly, treatment seven days before infection afforded only partial protection
against severe challenge, but demonstrates that Butalex does exert a significant
TABLE 3. Effect of simultaneous administration of buparvaquone at 2.5 mg/kg body weight
intramuscularly and infection of calves with Theileria parva (Muguga) stabilate.
Untreated controls Treated
10 calves/group mean ± s.e. mean ± s.e.
Survival 0 10
Days to first schizonts 8.2 ± 0.9 9.7 ± 1.6
Days of `healthy’ schizonts 12.8 ± 1.3 0
Days of damaged schizonts 0 6.5 ± 1.9
Maximum % piroplasms 57.7 ± 10.9 0
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prophylactic effect against theileriosis, which could be beneficial in the endemic
situation. This observation is in close agreement with the pharmacokinetic findings
reported above, which showed that buparvaquone persists at schizont-inhibitory
concentrations in plasma for at least seven days after injection.
SAFETY OF BUTALEX
Extensive studies of the safety, metabolism and residues of buparvaquone, conducted
in support of the registration dossier of Butalex, show that the production is remark-
ably safe. They support a two-day withhold period for milk, but 42 days for meat.
The relatively long recommended meat withhold period is due solely to persistent
residues at the intramuscular injection site in some cattle. Residues in other tissues
reach low levels long before this.
In overdose studies, a single intramuscular injection of five times the recom-
mended therapeutic dose (12.5 mg/kg buparvaquone) or of the recommended dose
(2.5 mg/kg) on six occasions at two-day intervals caused no adverse effects beyond
transient  local  painless  swelling  at  the  injection site in some cases. Studies in
laboratory animals and using various in vitro tests show that buparvaquone is not
carcinogenic, mutagenic or teratogenic.
FURTHER STUDIES WITH BUTALEX
Infection-and-treatment immunization
Studies have been conducted with both T. parva and T. annulata. Mutugi et al. (1988)
obtained initially very encouraging results against cattle-derived T. parva type
infections, but more equivocal effects against buffalo-derived T. parva. They also
highlighted the difficulty of obtaining a satisfactory balance between dose of sporo-
zoite stabilate and blocking dose of Butalex. Musisi et al. (1990) also obtained
equivocal results, possibly because injection of Butalex shortly before the stabilate
may have interfered with establishment of the infection.
Studies with T. annulata have been conducted in India. Dhar et al. (1987) obtained
excellent results, using either sporozoite stabilate or schizont cultures as the infective
material, even in very young calves, in which a cultured schizont `vaccine’ alone was
TABLE 4. Prophylactic effect of Butalex at 2.5 mg buparvaquone/kg body weight in groups
of five calves infected with Theileria parva (Muguga).
Treatment, relative Mean % weight change
to time of infection Day 0−14 Day 0−28
Day −7 −9.2 −20.6
Day 0 −2.0 +3.5
Day +10 −3.9 +5.9
Infected, untreated −9.2 —
Not infected, untreated −1.2 +6.8
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of low efficacy. Grewal and co-workers (personal communication) have conducted
large trials in very young calves in which Butalex was used simultaneously with the
schizont `vaccine’. They showed excellent protection with this system, where `vac-
cine’ alone was ineffective, and they are working towards a system which would be
effective in endemic areas where mortality among young calves from theileriosis is
a severe problem. Shastri (1989) has successfully used Butalex strategically in young
calves facing heavy challenge with T. annulata, indicating that, under these circum-
stances, no artificial infection may be required.
Enhancement of milk productivity in latent carriers of Theileria annulata infection
Initial study by Michael et al. (1989) in a herd of Egyptian Friesians with poor milk
productivity in the presence of a low-grade T. annulata infection showed a highly
significant improvement in milk productivity following a single injection of Butalex
(2.5 mg/kg buparvaquone). It was suggested that the effect was due to a restoration
of immune responses as a result of suppression of the Theileria infection, such that
resistance to various intercurrent infections was increased. It appeared that suppres-
sion of the very low grade Theileria infection was not likely, alone, to account for
the observed increase in milk yields. Similar studies have been conducted by D.K.
Singh and M.S. Kwatra, in India. It is speculated that, should this role for Butalex be
confirmed, then it could represent a valuable additional use for the product.
Effect of Butalex on Babesia equi infection
In a study by Zaugg and Lane (1989), it was shown that Butalex is highly effective
in curing clinical cases of B. equi infections in horses, and that multiple doses may
be capable of reliably eliminating latent infections. This role could be very useful in
facilitating the free movement of horses from B. equi-endemic areas into infection-
free areas, such as USA.
COST EFFICACY OF BUTALEX TREATMENT
The efficacy of Butalex in curing Theileria infections of cattle has been demonstrated
in independent trials in many countries in both T. parva- and T. annulata-endemic
areas. While the cost of Butalex treatment will vary between countries, because of
differences in the distributor chain from manufacturer to end-user, its cost-efficacy
is likely to be excellent for several key reasons.
• High cure rates can be expected, particularly if the disease is diagnosed and treated
relatively early in the syndrome. Overall cure rates of 92% are considerably better
than with any other therapy.
• High cure rates have been achieved with a single injection. The cost of multiple
treatments is greatly reduced, and frequently only a single attendance by the
veterinarian is necessary. The need for supportive therapy for oedema and anaemia
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is also less. Thus, both the cost and the difficulty of veterinary care are significantly
reduced in comparison to alternative treatments, all of which routinely require
repeated veterinary attendance.
• Rapid responses and restoration of productivity. Field triallists, particularly in T.
annulata areas, have been impressed by the rapid cure of disease following Butalex
therapy. They have commented that, except with the most advanced cases, normal
production of milk, meat and of recovery in calves are vastly superior to that
following any other therapy.
• The milk withhold period of only two days is remarkably short, and permits a
minimum of production loss. This feature would be of particular significance if
the treatment of apparently healthy Theileria carrier cattle was found to improve
their milk yields reliably.
CONCLUSIONS
The efficacy of Butalex in curing clinical cases of both T. parva and T. annulata
infections has been established in extensive, independent field trials. Further studies
in progress may indicate additional uses for Butalex in the infection-and-treatment
method of immunization against both T. parva and T. annulata and its ability to
protect very young calves could be particularly beneficial, since very small quantities
of Butalex are required. Development of these possible new uses for the drug,
together with its use as a safe and specific anti-theilerial tool in basic studies on the
pathology and immunology of theileriosis, make Butalex a significant advance in the
control and study of theileriosis.
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The main factors to be considered in designing effective vaccines are the identifica-
tion of relevant antigens, the identification of relevant immune responses, the meth-
ods necessary to induce and maintain these responses and the identification of
individuals likely to respond poorly to the vaccine. In host-parasite relationships it
is  unlikely  that  any one  anti-parasitic  mechanism  operates alone  to effect host
resistance. The net effect of any one component of the spectrum of immune responses
induced by the various parasite life cycle stages will either be host protective, parasite
protective, irrelevant or harmful to the host. The immune responses induced by a
vaccine need not necessarily cover the whole spectrum of immune responses; the
effects of a few `key’ responses may tip the balance in favour of the host.
Animals that recover from primary infection are immune to subsequent homolo-
gous and often heterologous challenge with various stocks of Theileria annulata
parasites and vaccination has already proved to be an effective method of control.
Current vaccination measures rely essentially on live immunization of cattle using
attenuated T. annulata-infected cell lines. However, if novel vaccines are to be
designed, characterization of relevant immune responses is essential for the identifi-
cation of appropriate antigens. The following sections review the current state of
knowledge concerning immune responses involved in T. annulata infection at each
stage of the parasite life cycle. The pathogenic stages in T. annulata infection are the
schizont-infected cell and the piroplasm-infected erythrocyte.
IMMUNE RESPONSE TO THE TICK
The host response to tick attachment and feeding involves a local inflammatory
reaction, the extent and complexity of which depends on the species of tick and on
whether or not the host has been sensitized (Allen, 1973). A study of the cellular
responses in rabbits induced by Hyalomma anatolicum anatolicum, a natural tick
vector for T. annulata, was recently reported by Gill and Walker (1985). Neutrophils,
mononuclear cells, eosinophils and basophils were present, the main effectors of
resistance to the tick being mediators released by mast cells, basophils and eosino-
phils. However, in the case of T. annulata infection, it is not known whether or not
this inflammatory response is beneficial or detrimental to the host in that it may either
facilitate or hinder establishment of the parasite in its target host cell. A novel strategy
of immunizing animals against tick gut antigens to elicit antibodies that would
damage feeding ticks has provided some very promising results against the one-host
tick, Boophilus microplus (Willadsen and Kemp, 1988). The application of such a
strategy to other tick species is presumably possible although, as discussed by
Morrison (1989), in the case of two- and three-host ticks, the immunity would have
to be effective against different tick stages and over a shorter time period.
IMMUNE RESPONSE TO THE SPOROZOITE
Despite the fact that the sporozoite stage of the parasite, which is innoculated by ticks
and infects the host cell, is only exposed to the host’s immune system for a very short
time (Brown et al., 1978), it is possible to generate immune serum, in vivo, that will
inhibit the penetration of sporozoites into uninfected host leucocytes in vitro (Gray
and Brown, 1981; Preston and Brown, 1985; Ahmed et al., 1988). This sporozoite
neutralizing activity was found in recovery sera or sera from animals which had
experienced multiple infections and it was found to be equally effective against
different geographical isolates of T. annulata (Gray and Brown, 1981). However,
antisera raised in T. parva-infected animals did not neutralize the infectivity of T.
annulata sporozoites in vitro, implying that the neutralizing activity is parasite-
species specific. The antiparasitic activity of immune serum was investigated further
by Preston and Brown (1985). Two effects were observed; serum could inhibit
invasion of the target cell by the sporozoite and/or suppress the intracellular devel-
opment to schizont of the trophozoite stage of the parasite, depending on whether the
serum was derived from animals recovered from primary or multiple challenge
infections. The serum from the multiple challenge animals was more likely to inhibit
sporozoite invasion. In field challenge situations, where animals are presumably
exposed to repeated infection, immunity against the sporozoite may play a protective
role by reducing the number of host cells that become infected.
Monoclonal antibodies (MAbs) have been raised against the surface of the
sporozoite and two were found to neutralize sporozoite infectivity significantly for
normal peripheral blood lymphocytes (PBL) in vitro (Williamson et al., 1989).
These MAbs were used to isolate the genes coding for the antigens recognized.
Antisera raised in rabbits to a recombinant antigen encoded by a 300-base-pair (bp)
fragment of the gene was found to neutralize sporozoite infectivity in vitro.
Therefore, this antigen would seem to be a strong candidate for a sporozoite
vaccine. However, any immune response generated against the sporozoite stage
would have to be extremely efficient to completely prevent infection of host cells.
There is no evidence to date that the schizont-infected cell is susceptible to attack
by anti-sporozoite antibody. A more likely role for the anti-sporozoite response is
to reduce the infectivity of the initial sporozoite dose sufficiently to allow the host
immune system to control the infection.
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IMMUNE RESPONSE TO THE SCHIZONT-INFECTED CELL
The parasite, by choosing an intracellular location, resembles a biological Trojan
horse and is effectively protected from the humoral arm of the immune response.
Cell-mediated immune mechanisms are most likely to be effective against this stage,
as is the case with other intracellular pathogens. During intracellular replication of
the parasite, various antigens will appear on the surface of the parasite-infected cell
in association with major histocompatibility (MHC) antigens that can be recognized
by T lymphocytes. The action of the T lymphocytes may be categorized into `direct’
and `indirect’ effector mechanisms. Direct effector mechanisms involve cytolysis of
the infected cell as occurs in many viral infections (Townsend and McMichael, 1985).
Indirect effector mechanisms involve the activation of T cells to produce various
cytokines, which in turn activate other cells of the immune system.
An early study by Preston and Brown (1981) reported that irradiated T. annulata-
infected cells could induce proliferative responses in autologous peripheral blood
mononuclear cells (PBM) irrespective of the immune status of the responder animal.
It was unclear how relevant this autologous Theileria-mixed lymphocyte response
was in the induction of a parasite-specific immune response in vivo. Following the
more extensive work on the closely related parasite, T. parva, studies were carried
out to examine the in vivo generation of cytotoxic cells capable of lysing parasite-in-
fected target cells. The first study on cytotoxic responses in animals infected with T.
annulata sporozoites was reported by Preston et al. (1983). During recovery from
primary infection, two peaks of cytotoxic activity were observed. The first appeared
to be genetically restricted, the second was not. After challenge, the majority of the
cytotoxic cells were directed against the autologous T. annulata-infected cell line. A
further study examined the development and specificity of cytotoxic cells in cattle
immunized with autologous or allogeneic T. annulata-infected lymphoblastoid cell
lines (Innes et al., 1989). After primary inoculation of the infected cell lines, the two
groups showed distinct differences in both their clinical responses and the target
specificity  of  the cytotoxic cells detected. The allogeneic T. annulata cell line
recipients showed a mild clinical response, and on day 9 after inoculation a strong
cytotoxic response was detected, which appeared to be directed against the allogeneic
MHC antigens of the inoculated cell line in some form of graft rejection response.
By day 23 the predominant cytotoxic response was directed against the autologous
infected cell line. In contrast, the animals that received autologous T. annulata-
infected cells showed very severe clinical symptoms and the cytotoxic cells, although
specific for parasite-infected target cells, were not MHC restricted until day 20.
Both groups were found to be immune to a heterologous sporozoite challenge and
in both groups a peak of cytotoxicity was detected on day 10 after challenge and
was directed against the autologous infected target cell. This would suggest that the
cytotoxic response to challenge was MHC restricted and cross-reactive between the
heterologous stocks of T. annulata parasites used.
A cytotoxic T-cell line was generated by repeated stimulation of immune PBM
with irradiated autologous infected cells supplemented with a 20% T-cell growth
factor obtained as a supernatant from a transformed gibbon lymphoid cell line,
MLA-144. The functional specificity and phenotypic analysis of the CTL line
provided further evidence that the cytotoxic response to T. annulata was MHC class
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I restricted. Firstly, the CTL line recognized and killed only infected target cells that
were autologous to or shared BoLA class I specificities with itself. Secondly, the
effector cells appeared to reside in the BoT4– subpopulation. Thirdly, the effector
function of the CTL line was effectively blocked by the addition of anti-MHC class
I sera (Innes, Miller, Brown and Spooner, in preparation).
Several investigations have examined the possible role of cytokines produced by
sensitized leucocytes. Studies reported for T. annulata (Singh et al., 1977; Rehbein
et al., 1981; Ahmed et al., 1981) emphasize the presence of leucocyte migration
inhibition factor (MIF) when using immune PBM incubated in vitro with either
schizont or piroplasm antigen. The cytostatic effect on schizont-infected cells by
immune adherent cells has been reported by Preston (1981) and Preston and Brown
(1988). Cytostasis usually reached a sustained peak around three to four weeks after
primary immunization and would peak again after challenge with similar magnitude
and kinetics as in primary immunization. The pattern of adherent cell-mediated
cytostasis was consistent despite the differing immunizing material, either sporozoi-
tes or infected cell lines, and the different geographical origin of the stocks of T.
annulata used in the study. Cytostasis was apparent when using both autologous and
allogeneic T. annulata-infected target cells, although the mechanism by which the
adherent cells mediate this effect is unknown. It seems likely that adherent cells,
presumably macrophages, will play some form of immunoregulatory role during
Theileria infection, either immunopotentiating or immunosuppressive. Further stud-
ies are needed to elucidate the induction of these responses in vivo, and their potential
host protective or host damaging roles.
Circulating antibody has been detected against schizont antigen in cattle infected
with T. annulata using complement fixation, haemagglutination and immunofluores-
cence techniques (Pipano, 1974). The protective role of this antibody has not been
resolved and it has not been possible to correlate serological titres to the degree of
protective immunity (Pipano, 1981). The antibody produced in infected animals
appears to recognize the schizont antigen consistently within the cell and not an
antigen on the surface of the infected cell. In a recent study (Ahmed et al., 1988), it
was demonstrated that serum from immune cattle was not opsonic for infected cells
and would not lyse these cells in the presence of complement.
IMMUNE RESPONSE TO THE MEROZOITE AND PIROPLASM
Antibody responses to piroplasm antigen detected in cattle recovering from infec-
tion with T. annulata (Pipano, 1974). Ahmed et al. (1988), using a chemilumines-
cense technique, showed that immune serum would react with free merozoites
(produced by lysis of infected erythrocytes) but not with the surface of infected
erythrocytes. Monoclonal antibodies have been raised using piroplasm antigen
(Glascodine et al., 1990) which will react with in vitro-derived merozoites but not
schizonts. In summary, it would appear that the humoral immune response is
effective against the extracellular stages of T. annulata within the bovine host, the
sporozoite, the extracellular schizont (?) and the merozoite, whereas cell-mediated
immune mechanisms, in particular activated T cells, are effective against  the
intracellular schizont stage.
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Therefore, it would seem appropriate to identify relevant antigens of the sporozoite
and merozoite using antibody and possible protective schizont antigens using im-
mune T cells. Once appropriate candidate antigens have been identified, a major
challenge will be to present these antigens to the immune system in such a way as to
induce protective immunity. This is not a major problem in the induction of antibody
responses but very little is known about the inductive requirements for cytotoxic
T-cell responses.
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Differences in cells infected by Theileria
annulata and T. parva and some of the
immunological consequences
R.L. Spooner and E.J. Glass
Institute of Animal Physiology and Genetics Research
Edinburgh Research Station
Roslin, Midlothian EH25 9PS, UK
Theileria annnulata and T. parva have a remarkable ability to infect cells of the
immune system in cattle and to transform the cells, which proliferate rapidly together
with the parasite (Hulliger et al., 1964). There are, however, a number of important
differences between the two parasites and the diseases they cause. They are transmit-
ted by different tick species, they do not overlap geographically and, because of other
biological differences, different methods of vaccination are used. After it was shown
that cells infected by either parasite could be grown in vitro, attempts were made to
use these cells for immunization. It was possible to immunize cattle with T. annu-
lata-infected cells (Pipano, 1981) and recently it has been shown that as few as 102
allogeneic cells can be used (Ouhelli et al., 1989). There is no evidence of a major
histocompatibility complex (MHC) barrier to immunization with T. annulata (Innes
et al., 1989c). A vaccine is now in use in Morocco utilizing 104 cells per animal. In
contrast, it was found that very high cell numbers (108 cells per animal) (Brown,
1981) had to  be used  with T.  parva, and  only some animals were immune to
subsequent challenge; moreover, the `vaccine’ gave rise to fatal disease in some
animals. Subsequent experiments showed that cell lines would immunize against T.
parva at lower cell doses only if the MHC of the cell line and recipient animal were
the same (Teale, 1983; Dolan et al., 1984).
It was not known whether the difference between the two infections depended on
the inherent ability of the parasites to parasitize host cells or that only certain cells
were permissive to infection. It was shown that T. parva-infected cell lines were
positive for various T-cell markers (Lalor et al., 1986) but lacked both surface
immunoglobulin (Duffus et al., 1978) and bovine monocyte markers (Spooner et al.,
1988). They were positive for MHC class I and class II antigens (Spooner and Brown,
1980). Theileria annulata-infected cell lines were also positive for MHC class I and
class II antigens, but were negative for monocyte markers and, significantly, were
negative for T-cell makers (Spooner and Brown, 1980; Spooner et al., 1988).
It has been shown that T. parva infects T cells, B cells and null cells (Lalor et al.,
1986; Morrison et  al., 1986;  Baldwin et  al., 1988).  One report suggested that
macrophages cultured for several days could be infected by T. parva (Moulton et al.,
1984) whereas others found no evidence that this parasite could infect and transform
fresh macrophage/monocyte populations (Morrison et al., 1986; Baldwin et al.,
1988).  Preliminary evidence suggested that T. annulata might  infect mammary
macrophages (Musiime, 1983). Experiments were initiated in which different sub-
populations of bovine lymphocytes were separated and infected in vitro with either
T. annulata or T. parva sporozoites. Monoclonal antibodies to a macrophage marker,
IL-A24 (Ellis et al., 1987), sIgM, B5/4 (Pinder et al., 1980), CD4, IL-A11 (Teale et
al., 1986; Baldwin et al., 1986) and MHC class II, J11 (Baldwin et al., 1987) were
used to separate cells on a fluorescence activated cell sorter (FACS, Becton Dickson).
Theileria annulata infected and transformed macrophages and B cells but not T cells,
whereas T. parva infected T cells very efficiently and did not infect macrophages
(Spooner et al., 1989; Glass et al., 1989). Although B cells were infected by both
parasites, the relative efficiency of infection was considerably less. The non-permis-
siveness of T cells to infection with T. annulata was further confirmed when attempts
were made to infect alloreactive cytotoxic T lymphocytes (CTL) with either T.
annulata or T. parva. CTL expressing low levels of MHC class II on their surface
were not infected with T. annulata but were very efficiently infected by T. parva
(Innes et al., 1989b).
The significance of the different cell preferences for the pathogenesis of either
disease is not clear. It has been shown that T cells infected by T. parva can maintain
their function as alloreactive CTL at least for some time in culture (Baldwin and
Teale, 1987). It appears that the important protective immune response involves
MHC-restricted CTL in both T. annulata (Preston et al., 1983; Innes et al., 1989a)
and T. parva infections (Goddeeris et al., 1986), thus interference with the generation
or function of these cells would have implications for the outcome of either the
diseases themselves or intercurrent infections.
Monocytes infected with T. annulata have high levels of MHC class II expressed
on their surfaces. Thus, infection may affect their ability to present third-party
antigens. If such ability were impaired, it might have significance with regard to the
fate of secondary infections in tropical theileriosis. There are problems in studying
lymphocyte proliferation with both Theileria species because autologous mixed
lymphocytes reaction responses are generated (Pearson et al., 1979). However, these
reactions do not occur with antigen specific Th lines. Ovalbumin specific T-cell lines
have been generated in cattle (Glass and Spooner, 1990a). Ovalbumin has been
presented to these lines by uninfected antigen presenting cells (Glass et al., 1991)
and T. annulata-infected lines from animals of defined class II genotype. Theileria
annulata-infected cells present ovalbumin more efficiently than the uninfected cells
from which they were derived (Glass and Spooner, 1990b).
Thus, cells infected by either parasite appear to maintain their original function,
although in the case of T. annulata, augmented function is observed. The conse-
quences of amplifying the numbers of such cells in vivo may be related to the
pathogenesis of the two diseases.
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Theileria annulata, like many protozoan parasites, undergoes major differentiation
events during its life cycle in the insect vector and the bovine host. Previous work
has shown that differentiation of the intracellular schizont to the extracellular mero-
zoite can be induced by maintaining cultures of schizont-infected lymphoblastoid
cells at 41 °C. We have reproduced the production of merozoites in vitro to analyse
the events that take place. By carrying out this study, we hope to gain an understanding
of how this process is regulated at the molecular level.
REACTIVITY OF MONOCLONAL ANTIBODIES
Using sets of monoclonal antibodies (MAbs) raised against the schizont or the
piroplasm stages of T. annulata, we demonstrated that differentiation results in the
loss of monoclonal antibody epitopes associated with the schizont and the appearance
of epitopes associated with the piroplasm. Our conclusion was that merogony is a
major point of antigenic differentiation in the vertebrate phase of the life cycle, and
we predicted that the merozoite is more closely related to the piroplasm than the
schizont or the sporozoite (Table 1). The fact that the sporozoite and merozoite seem
to be antigenically different with respect to the MAbs used, some of which are known
to recognize surface polypeptides, suggests that it is unlikely that merozoites could
re-invade leukocytes and regenerate schizonts. Thus, the evidence points to a uni-
directional cycle of differentiation.
The qualitative patterns of reactivity of the MAbs that detected merozoites were
shown to be different. Two antibodies, 1D11 and 1C2, show a dot-like reactivity,
whereas monoclonal 5E1 reacts as a halo. We postulated that this was due to different
locations of the antigen detected and that the molecule recognized by monoclonal
5E1 is on the surface of the merozoite. To test this, immunoelectron microscopy on
cryo-ultramicrotome sections of heat-induced culture forms was carried out. Label-
ling with colloidal gold clearly occurred around the periphery of the merozoite,
demonstrating the surface location of the detected polypeptide. Whether this molecule
has any function in the merozoite invasion of erythrocytes is not known. Studies to
investigate this possibility will rely upon an efficient in vitro assay that we are
attempting to develop.
By probing Western blots with monoclonal antibody 5E1, we demonstrated that
the detected epitope is present on a 30-kDa polypeptide in both merozoite and
piroplasm extracts. No polypeptides were detected in extracts of schizont-infected
cells or the control line BL-20. In addition, polyspecific sera also detected a polypep-
tide of the same molecular weight in extracts of piroplasms and merozoites. We
conclude that the molecule can generate an antibody response in an immune animal
and it is unlikely that the stage specificity of the MAb is due to post-translational
modification but is due to the production of the complete 30-kDa molecule.
DETECTION OF NOVEL POLYPEPTIDES DURING
DIFFERENTIATION TO THE MEROZOITE
Using polypecific antisera, MAbs and a cloned schizont-infected cell line that shows
a high level of merozoite production, we have investigated at which point in the
differentiation process the expression of novel polypeptides takes place. Cultures of
schizont-infected cells were maintained at 41 °C and samples were taken every 2
days until day 8. Samples were processed and analysed in the following manner: (a)
cytospin and Giemsa-stained smears; (b) immunofluorescence assays; (c) SDS-
PAGE and Western blotting; and (d) immunoelectron microscopy at selected time
points after differentiation. From the results of these different procedures, we postu-
lated the following model for the expression of the 30-kDa molecule. For the first
four days after placing the culture at 41 °C, the schizont increases in size. By day 4,
expression of the 5E1 polypeptide occurs on a few cells and is clearly evident by day
6. The indirect fluorescent antibody (IFA) test patterns and immunoelectron micros-
copy suggest that the molecule is located on the surface of the schizont, and that its
expression is followed by major morphological changes to produce merozoite organ-
elles. These organelles then bud out of the differentiating schizont and become
TABLE 1. Reactivity of monoclonal antibodies against different life cycle stages of Theileria
annulata.
Monoclonal Sporozoite Schizont Merozoite Piroplasm
2E4 + + + +
1C7 – + – –
1C12 + + – –
1E11 + + – –
5E1 – – + +
2D5 – – + +
1D11 – – + +
1C2 – – + +
5H2 + – – –
4E5 + – – –
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surrounded by membrane containing the 5E1/30 kDa polypeptide. Merozoites are
then released upon destruction of the host cell.
In addition, we have studied the expression of the molecule detected by MAb
1D11. From quantifying the number of cells reacting with this antibody (at a fixed
time point) and comparing it to the number reacting with MAb 5E1, we believe that
the 110-kDa molecule recognized by this antibody is expressed later than the 30-kDa
antigen. This is consistent with its dot-like reactivity on merozoites, which suggests
that the molecule detects a merozoite organelle.
SEGREGATION BY LIMITING DILUTION OF CLONED
SCHIZONT-INFECTED LINES WITH DIFFERENT
ABILITIES TO DIFFERENTIATE
In vitro differentiation by culturing at 41 °C is known to be difficult to reproduce.
This, coupled to the observation that prolonged culture at 37 °C can result in reduced
ability to differentiate, and the fact that a population of cells can be maintained at 41
°C after merogony has occurred, led us to isolate clones from the T. annulata (Ankara)
stock we used in our experiments. Eight different cloned parasite lines have been
isolated by limiting dilution.
Initial studies have been confined to four clones. Each clone has been tested
subsequently for the ability to differentiate at 41 °C. Examination of Giemsa-stained
slides showed that two clones had an enhanced ability to differentiate. Merozoites
were detected at day 6 and were abundant by day 7. Continued culture resulted in the
complete destruction of all cells by about day 10. In contrast, the other two clones
showed few merozoites by day 8, and continued culture resulted in a population of
cells that survived in culture for up to six weeks at 41 °C. We conclude that the
parental stock contains at least two populations of infected cells, which can be
separated on the basis of their ability to differentiate.
ANTIGENIC DIVERSITY OF THEILERIA ANNULATA MEROZOITES
To estimate the degree of differentiation in the different, cloned schizont-infected
lines, slides were prepared from cultures after seven days at 41 °C and reacted with
the antibody. Two of the clones, C9 and D7, showed reactivity using monoclonal 5E1
with a range of 75–95% of the cells being positive. Clones D3 and E3, however,
showed no reactivity. This result did not correlate with the Giemsa-stain morphology
as clones D3 and E3 can produce merozoites. We concluded that the epitope recog-
nized by monoclonal 5E1 is polymorphic between the different clones and that the
antigenic profiles of the resulting merozoites vary. The result was confirmed by MAb
1C2, which detected differentiating cells in clones D3 and E3 but not in C9 and D7.
A third MAb (1D11) detects differentiating cells in all clones, and we used its
reactivity as an estimate of differentiation. Preliminary data indicates that the en-
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hanced clone D7 has five times more differentiating cells than clone D3 after seven
days at 41 °C.
ISOLATION AND EXPRESSION OF THE MAG 1 GENE
Screening a lambda gt11 genomic expression library with a set of MAbs resulted in
the isolation of a clone that reacted with MAb 5E1. Subcloning the 3.0-kb Eco R1
insert and expressing a fusion protein allowed the production of a polyspecific
antisera. The antisera has been shown by IFA to react with cultures undergoing
merogony and piroplasms but not schizont-infected cells. Thus, the cloned gene
seems to be expressed upon the differentiation of the schizont to the merozoite. To
determine the size of the polypeptide coded for by the gene, Western blots were
carried out. The antiserum detected multiple polypeptides, which ranged in size from
approximately 130 kDa to 40 kDa in extracts of piroplasms. As the serum did not
detect a 30-kDa polypeptide, we concluded that the cloned gene does not code for
the polypeptide recognized by MAb 5E1. From analysis of the gene sequence and
the IFA pattern, we postulate that the gene product(s) is glycosylated and has a surface
location on the piroplasm. The differential expression of the Mag 1 gene has also
been analysed by RNA slot-blot hybridizations. The results indicate that during
merogony gene expression is regulated, at least in part, at the RNA level.
CONCLUSION AND FUTURE STUDIES
With the aim of understanding how stage differentiation is regulated at the molecular
level, we have begun to analyse the events that occur upon differentiation of the
schizont to the merozoite. Differentiation clearly results in antigenic alterations, and
our results indicate that major changes in gene expression occur. It seems likely that
such changes are coordinated, and may involve a common mechanism of regulation.
For example, similar regulatory domains could exist within the promoter regions of
genes whose expression is regulated at the transcriptional level. To investigate these
possibilities, we have begun to clone and analyse genes that are differentially
expressed.
The expression of a 30-kDa molecule has been studied and we have shown that it
is expressed on the surface of the differentiating schizont. We postulate that this
expression occurs quite early on, after an irreversible chain of differentiation events
has been triggered, and is followed by the development of merozoite organelles and
the production of merozoites by a budding process. How the triggering of differen-
tiation is initiated and what molecues are involved in this process are unknown. Future
studies will have to address early events at a biochemical level if any understanding
of the triggering process is to be gained.
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The parasite Theileria parva divides rapidly in the cytoplasm of bovine lymphocytes
and simultaneously induces a massive lymphoproliferation, which, later in the
disease, is followed by lymphocytolysis and death of the animal. The proliferating
lymphocytes gradually displace the normal lymphoid tissue, resulting in a condition
similar to a multicentric lymphosarcoma. Infected lymphocytes collected by lymph
node biopsy carry T-cell surface markers and are easily established in laboratory
cultures as permanently transformed lymphoblastoid cell lines. Infected lymphocytes
can be grown in soft agar, form tumours in nude mice, and can grow in culture with
wholly artificial serum supplements. Lymphocyte transformation is dependent on the
continuous presence of the parasite in the cytoplasm. A unique and interesting
feature of these cell cultures is that their transformed phenotype can be reversed by
selective elimination of the parasite after drug treatment, leaving the host cells viable
but no longer proliferating. The reversibility of cell transformation offers unusual
opportunities in the study of cell proliferation and transformation.
Our approach to understanding the parasite-induced proliferation has been to
characterize gene expression in the parasite as well as in infected lymphocytes. A
detailed molecular analysis of the host-parasite relationship should allow the identi-
fication of important control processes used by the host and possibly modified or
interrupted by the parasite that results in uncontrolled cell proliferation.
We, along with others, have shown previously that growth of T. parva-infected cells
occurs via an autocrine mechanism (Brown and Logan, 1986; Dobbelaere et al., 1988)
involving the secretion of a growth factor with interleukin 2 (IL-2)-like activity. In
addition, it was shown that cells from a cloned T. parva-infected T-cell line, TpM(803),
constitutively express functional IL-2 receptors (IL-2R) on their surface (Dobbelaere
et al., 1988; Coquerelle et al., 1989). IL-2R expression was shown to be strictly
dependent on the continuous presence of the parasite in the host cell cytoplasm, since
elimination of the parasite by the theilericidal drug buparvaquone led to the rapid
disappearance of IL-2R expression (Dobbelaere et al., 1988; Coquerelle et al., 1989).
The constitutive expression of functional IL-2R on the surface of T. parva-infected
cells probably confers a selective advantage to the parasite-infected cells. If IL-2
were released from normal or infected T cells in the micro-environment near infected
cells, all cells in the environment carrying IL-2 receptors potentially would be
stimulated. It was therefore important to examine whether constitutive IL-2R expres-
sion was a general characteristic of all T. parva-infected cell lines. We analysed a
range of cloned and uncloned T. parva-infected cell lines of different origins and
phenotypes. We also tested cell lines infected with T. annulata, the causative agent
of tropical theileriosis, which has been reported to transform a different subset of
mononuclear cells. The continued growth of these cells also depends on the continu-
ous presence of the parasite in their cytoplasm (Rintelen et al., 1990). Our results
show that all cells infected with T. parva express IL-2 receptors on their surface. We
have been able to identify IL-2 transcripts in all T. parva cells tested. In the two lines
of T. annulata that we have tested, we have shown that IL-2 receptors are expressed
on the lymphocyte surface, although there are no identifiable IL-2 transcripts
produced.
Our interests are to determine what gene regulatory processes are influenced by
the presence of the parasite that result in uncontrolled cell growth. Regulatory
processes in gene expression, including IL-2R gene expression, are mediated by
interaction of trans-acting protein factors of transcription that bind to cis-acting
elements of gene enhancers. Some of these trans-activating factors, such as steroid
receptors and NF-kB, are themselves activated from pre-existing pools dormant in
the cytoplasm. Recently, the nuclear factor NF-kB, crucial for expression of the kappa
light-chain immunoglobulin gene, has been shown to play a role in the expression of
IL-2R(α) chain as well as IL-2  during  activation  of  T lymphocytes. NF-kB is
important in the activation of several other eucaryotic genes as well. NF-kB binding
sequences are found in the human immunodeficiency virus (HIV) enhancer and
upstream of the major histocompatibility complex class I (Baldwin and Sharp, 1987)
and class II (Blanar et al., 1989) genes. NF-kB binding activity is constitutively
present in mature B cells and some T-cell lines and can be induced in cells of
lymphoid and non-lymphoid origin by agents such as lipopolysaccharides, phorbol
esters, and DNA-damaging agents.
The established regulatory properties of NF-kB in lymphoid cells and the
potential role of this factor in constitutive expression of the IL-2R gene in Theil-
eria-infected T cells led us to characterize the NF-kB-like proteins in parasite-in-
fected cells. We have presented data suggesting that the continuous presence of the
parasite in the cytoplasm of Theileria-infected cells results in constitutively high
levels of NF-kB activity in the nucleus as well as high levels of the inactive form
in the cytoplasm.
Using both transfection techniques with plasmids carrying a marker gene or an
enzyme under the control of the NF-kB transcription factor as well as specific
DNA-protein binding assays, we have been able to accurately detect and measure the
levels and locations of NF-kB in lymphocytes infected with Theileria. We have been
able to show that the regulatory regions of both the IL-2 and IL-2R(α) genes are
constitutively activated in Theileria-infected lymphocytes. Using the gene segment
from the HIV virus containing only the NF-kB regulatory region, we are able to show
that the increase in gene transcription from an HIV plasmid as well as the IL-2 and
IL-2R(α) in Theileria-infected cells is stimulated by the presence of NF-kB in the
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lymphocytes. The results of these functional studies focused our attention on the kB
sequence of the HIV enhancer. To measure directly the level and location of NF-kB-
like proteins in T-cells infected by T. parva, we used double-stranded oligonu-
cleotides with the HIV NF-kB sequence as radioactive probes in protein binding
assays. These binding assays measure the binding of proteins to specific oligonu-
cleotide sequences. Assays using nuclear and cytoplasmic extracts from infected
lymphocytes confirm that infected cells maintain constitutively high levels of NF-kB
in both the nucleus and the cytoplasm. Using ConA-stimulated lymphocytes as
controls, we have been able to show both a quantitative and a qualitative difference
in the infected lymphocytes. This observation suggests the indirect or possibly direct
influence of the parasite on host cell gene transcription.
We have shown that the factor is localized unevenly in both nuclear and cytoplas-
mic fractions. The nuclear form is activated, whereas the cytoplasmic form is bound
to an inhibitor. The NF-kB-like proteins in infected lymphocytes differ from those in
ConA-stimulated lymphocytes and HeLa cells because, as in purified NF-kB, pro-
teins in extracts from infected lymphocytes are stimulated to bind to their recognition
motifs by GTP, while this is  not true in extracts from ConA cells. We cannot
distinguish in these experiments whether ConA-stimulated lymphocytes and Theil-
eria-infected lymphocytes have different NF-kB-like proteins or the same proteins
in different states of modification.
Having established that Theileria-infected lymphocytes constitutively express and
activate NF-kB, we attempted to determine for what length of time the stimulatory
effect of the parasite remained after removal of the parasite by drug treatment. By
treating the Theileria-infected cells with buparvaquone, which selectively kills the
parasite leaving the host cell intact, we determined the fate of activated NF-kB. Upon
treatment with the drug buparvaquone, a marked loss of NF-kB binding in nuclear
extracts over time was observed. The loss of NF-kB closely paralleled the previously
documented loss of the parasite as well as the loss of parasite-specific transcripts. It
also paralleled the reduction in proliferation. Loss of NF-kB from the cytoplasm
occurred to a lesser extent than that from the nucleus. It appears, therefore, that killing
of the parasite by buparvaquone specifically decreased NF-kB binding in nuclear
fractions and at the same time decreased the size of the cytoplasmic precursor pool.
We conclude that the presence of T. parva not only activates NF-kB but also increases
the synthesis of NF-kB such that an excess of precursor is maintained in the cytoplasm.
In turn, the activation of the IL-2 and IL-2R control regions by NF-kB results in rapid
lymphocyte proliferation via an autocrine stimulated growth mechanism.
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INTRODUCTION
The life cycle of organisms of the genus Theileria presents the biologist with a
fascinating array of topics, many of which are of interest to the core of biology.
Coupled with these interests is the more practical aspect of using knowledge gained
from their study to provide improved control measures against the diseases they
cause. Considering solely the mammalian stages of the life cycle in Theileria
annulata, there are three main areas of interest, parasite/host cell recognition and
invasion, schizont-induced host cell proliferation and parasite development. Our
research has been aimed at understanding the molecular interactions and mechanisms
involved in these areas.
GENE STRUCTURE
Compared to a number of parasites, our knowledge of T. annulata gene structure and
organization is very limited, as is our knowledge of the karyotype and ploidy of each
nucleus. We have no evidence supporting diploidy and assume that the nuclei are
haploid. To date four genes have been isolated and characterized by sequence
analysis: a sporozoite surface antigen gene (Spag 1), a differentially expressed
merozoite/piroplasm gene (Mag 1), a cognate hsp70 gene and the 16s RNA structural
gene. In addition, an episomal element and a large RNA species have been identified
and partially characterized. A number of other gene clones have been isolated but
currently await characterization. The main features of the characterized genes are
briefly described below.
Spag 1. A 300-bp fragment was initially isolated from a genomic expression
library, constructed in lambda gt11, by screening with a monoclonal antibody (1A7)
recognizing the surface of the sporozoite (Williamson et al., 1989). This insert was
used to screen a size selected partial Sau3A library constructed in EMBL 3. A clone,
containing a 12.4-kb insert, was isolated and a 3.4-kb Eco RI fragment (containing
the 300-bp sequence) sub-cloned and sequenced. In addition, a sporozoite cDNA
library was constructed and a series of clones isolated (by screening with sub-clones
of the 3.4-kb genomic fragment) and sequenced. Southern blots of genomic digests
of the Hisar strain of the parasite, together with similar blots from cloned lines of the
parasite, establish that there are three `alleles’of the Spag 1 gene. Further alleles have
been identified in other strains of the parasite. The three alleles in the Hisar strain
show Eco RI fragments of 3.4, 4.8 and 6.0 kb in Southern blots. The genomic clone
isolated and sequenced corresponds to the 3.4-kb allele, while the cDNA corresponds
to one of the other alleles.
Sequence analysis of the cDNA clone shows an open reading frame containing the
300-bp sequence originally isolated. Two main features of interest shown are firstly
a high proline content in portions of the sequence and secondly a series of repeats
that correspond exactly to the repeats of elastin, a protein found in connective tissue
(Blood, et al., 1988). The biological significance of this sequence in terms of acting
as the basis of host cell recognition and in terms of co-evolution between host and
parasite is of considerable interest.
Mag 1. A lambda gt11 genomic expression library was screened with the mono-
clonal antibody 5E1, which recognizes the surface of the merozoite (and piroplasm),
and a cloned sequence isolated. The clone has a 4.5-kb insert and an internal Eco RI
site. The 3.0-kb Eco RI fragment was sub-cloned in pGEM and the induced fusion
protein was shown to react weakly with the MAb 5E1. Sera to the fusion protein were
raised in rabbits and Western blot analyses of piroplasm and infected lymphocytes
showed that the antibody recognized a complex of polypeptides that were stage-spe-
cifically (piroplasm) expressed. These antibodies recognize the merozoite and piro-
plasm giving a characteristic surface pattern. Surface probability plots of the translated
sequence show that the repeat sequences have a high surface probability (K. Hussain
and co-workers, unpublished data). By means of slot-blot analysis of RNA isolated
from piroplasms, schizont-infected cell lines and merozoites, it has been shown that
the steady state levels of mRNA are increased in the piroplasm and merozoite stage.
Sequence analysis of the 3.0-kb sequence shows an open reading frame of 272 bp.
In the central portion of the gene, flanked by multiple Hinf l sites, is a block of
complex repeat sequences. There are three motifs: a 14-bp sequence, a 75-bp
sequence (K repeat) and 72-bp sequence (Z repeat); each Z or K repeat is flanked by
the 14-bp repeat and a total of 9Z and 4K repeats are found within this block. Although
there is some sequence divergence between repeats, in general they are highly
conserved. Southern blots of restriction digests of genomic DNA show that the gene
is polymorphic between strains of the parasite and that at least two `alleles’ are found
within the Hisar strain. In addition, from such restriction digests, there is tentative
evidence that there are two copies of this gene/haploid genome.
Hsp70. A heat shock protein gene has been isolated by screening genomic libraries
of T. annulata with a Drosophila cDNA clone under reduced stringency (Mason et
al., 1989). Sequence analysis shows this gene to have 65% homology with the
Drosophila sequence at the amino acid level. Upstream of the transcription start
(determined by S1 mapping) is a sequence (TAAATAA) similar to a TATA box and
two sequences (CAGAAAGTTGCCA and GCTTAAGTGTCAA) with homology to
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the heat shock element consensus sequence. Northern and slot-blot analyses show
that this gene is constitutively expressed in the sporozoite, schizont, merozite and
piroplasm stages of the parasite, although heat shock of schizont-infected cell lines
shows a threefold increase in RNA levels.
16s RNA. The structural gene for the 16s-like RNA has been examined by PCR
amplification using primers corresponding to 5 and 3 ends of eukaryotic 16s rRNAs
and the resulting products cloned into M13. The coding region spans 1774 bp and
has an average G/C content of 45% (Gajadhar et al., 1991). No remarkable features
are apparent from the sequence; sequence comparisons using sequences from some
23 organisms show that T. annulata has a greater similarity to Sarcocystis muris than
it does to either Plasmodium falciparium or P. berghei. At present, nothing is known
about the overall structure of the ribosomal transcription unit or the copy number of
the genes.
Extrachromosomal nucleic acid. Gel electrophoresis of high molecular weight
preparations of T. annulata nucleic acid show, in addition to nuclear DNA, two
smaller species of 6.5 and 2.6 kb respectively. Digestion with either RNase or DNase
shows the 6.5-kb species to be DNA and the 2.6-kb species to be RNA (Hall et al.,
1990). Nothing is known of the nature or structure of the latter species. The 6.5-kb
element is a linear double-stranded DNA molecule found in three geographically
distinct isolates of the parasite. Northern blot analysis using the 6.5-kb DNA element
as a probe shows that the element has three major transcripts of 2.45, 1.05 and 0.24
kb, which are expressed in sporozoites, piroplasms and merozoites. The element does
not code for sequences homologous to mitochondrial rDNA (a larger species of
molecule does), but sequence analysis suggests that the element contains the struc-
tural gene for cytochrome b (F.R. Hall, unpublished), suggesting that it is an element
contained within the mitochondrion. The existence of the cytochrome b gene on the
element suggests that it is similar to an element described in Plasmodium.
Clearly our database of T. annulata genes is small, making it difficult to draw
general conclusions. Furthermore, the Spag 1, Mag 1 and hsp70 genes represent a class
of genes that are regulated and Spag 1 and Mag 1 are a further subclass representing
surface antigens. Thus, the features of these genes may be specific in relation to their
biological roles. Two features are striking, however; firstly, both surface antigens have
repeated sequences reminiscent of similar genes from Plasmodium and, secondly, both
surface antigen genes show considerable restriction fragment length polymorphism
both between and within strains. The structure of the Spag 1 genomic clone, with two
overlapping open reading frames (one frame shifted from the other), suggest that there
is RNA processing in T. annulata, which may involve a novel mechanism.
SUB-UNIT VACCINES
We have no published experimental data on the use of recombinant antigens for
induction of protective immunity. Therefore, the use of such antigens can be consid-
ered only theoretically, apart from some data from Williamson (1989). From work
described elsewhere in this volume and from published data (Hall, 1988; Tait and
Hall, 1990), it is clear that a humoral immune response can be elicited to the
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sporozoite stage and that a cellular immune response is elicited to the schizont-in-
fected lymphocyte. These responses have been shown, in vitro, to be potentially
protective. There are four main potential targets for the immune system—the surface
of the sporozoite, the surface of the infected lymphocyte, the surface of the merozoite
and the surface of the infected erythrocyte.
Research has been directed towards identifying molecules for all these stages,
primarily with a view to understanding the interactions between host and parasite, in
the case of the surface of the infected lymphocyte and erythrocyte, or the regulation
of gene expression in the case of the surface of the sporozoite and merozoite, as the
parasite develops from one stage to another. Much of the research effort has focused
on the sporozoite surface antigen, although a series of molecules has been identified
on the surface of the infected lymphocyte (Shiels et al., 1989) and the merozoite.
Experiments using the in vitro invasion blocking assay (Gray and Brown, 1981;
Preston and Brown, 1985) have shown that sera from cattle immunized by irradiated
sporozoites and live sporozoites have blocking activity (Williamson, 1989) as do two
monoclonal antibodies (1A7 and 4B11) that recognize the surface of the sporozoite.
Western blot analysis of these sera and the monoclonal antibodies (Williamson, 1989)
show that there is considerable variation between individual animals in terms of the
antigens they recognize: the monoclonal 1A7 recognizes a complex of antigens (54,
63, 70, 85 kDa) while 4B11 recognizes a 17-kDa antigen and most of the bovine sera
recognize one or both of the antigens. Challenge experiments of animals immunized
with sporozoites show no clear evidence for protection. The gene coding for the 1A7
epitope has been cloned (Spag 1) and both genomic and cDNA sequences have been
sequenced. The largest cDNA clone (2.4 kb) has been expressed in pGEX and the
fusion protein isolated and purified. Current experiments are aimed at examining the
immune response to this molecule in cattle and mapping B- and T-cell epitopes.
Surface-labelling studies coupled with surface-specific monoclonal antibodies
have identified a series of infection-specific polypeptides on the surface of the
schizont-infected lymphocyte. A 118–120-kDa molecule has been identified and
shown to be a glycoprotein (Shiels et al., 1989). The genes coding for these polypep-
tides have not been isolated. Whether these molecules are involved in the recognition
of  the  infected  lymphocyte by  the host immune  system  or are involved in the
mechanism of transformation remains to be examined.
The merozoite is found relatively transiently in infected animals. In T. annulata it
is an important stage due to the high erythrocyte parasitaemia and the associated
anaemia. Little is known of the immune response to this stage, although, in principle,
if protective immunity could be induced against it, it would prevent erythrocyte
invasion and therefore anaemia. Experiments are currently under way to isolate the
gene coding for the 30-kDa merozoite surface antigen (Glascodine et al., 1990) and
one putative surface antigen gene (Mag 1) has been isolated. With these genes and
the ability to generate merozoites in vitro (Glascodine et al., 1990), it is now possible
to examine the role of the merozoite and its surface antigens in protective immunity;
however, no such experiments have been undertaken.
Another possible target for a protective immune response, by analogy with studies
on Plasmodium, is the surface of the infected erythrocyte. If the surface of the
erythrocyte is altered by infection, antigens could be isolated and examined for their
role in protection. No major changes have been detected using a range of surface-
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labelling and other techniques (Glascodine, 1989), although some tentative evidence
for the presence of parasite-derived molecules was obtained. Further research is
required to consolidate these findings.
Overall, some of the reagents (antibodies and gene clones) for examining the role
of surface antigens of the sporozoite and merozoite stages in protective immunity
have been generated together with the culture methods that allow examination of the
merozoite. A number of other surface proteins of both stages await further charac-
terization. These results will allow future studies on the role of the surface antigens
of these two stages in protective immunity.
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CONCLUDING
DISCUSSION
Concluding discussion
The concluding discussion was chaired by Dr. J.J. Doyle and organized around the
reports of the chairmen of each session from the summaries prepared by their
rapporteurs. Other issues that the participants felt required further discussion were
listed and are shown in Figure 1. The summaries of the sessions and the discussion
contain many references to work on Theileria parva that was presented in short
papers by ILRAD scientists in parallel with T. annulata papers. These have not been
included in the proceedings, but the main points are included in the summaries
presented below.
The Chairman (Dr. Doyle) opened the session by calling for the summaries from the
sessions on Country Reports, Current Vaccines and Immunology.
Country reports—summarized by Dr. C.G.D. Brown
Reports were presented from China, India, Morocco, Turkey, Sudan and the USSR,
representing  a  broad  cross-section  of countries in which tropical theileriosis is
endemic. In addition, two important papers from Israel and Iran were submitted in
written form. The consensus from these reports indicated that:
• the disease was only a problem in imported or improved cattle, predominantly in
European dairy breeds;
• disease control could be pragmatically and effectively implemented using a live
tissue-culture vaccine of schizont-infected lymphoid cells attenuated by long-term
passage;
1) Diagnosis
2) Early vaccination (against T. annulata and use of buparvaquone)
3) What is attenuation?
4) Carrier state:
(a) duration
(b) maintenance:
i) schizonts
ii) piroplasms
5) Genetic resistance
6) Epidemiology
7) Distribution
8) Mild strains
FIGURE 1. Issues listed by Workshop participants for further discussion.
• of the eight countries reporting, seven now produce their own vaccines with which
they have vaccinated between thousands and millions of cattle; and
• to date little emphasis has been placed on other control measures such as vector
control, chemotherapy, the  selection  and use  of resistant cattle, management
procedures or through an awareness of tick ecology and novel chemotherapeutics.
Buparvaquone has proved highly effective in the treatment of the clinical disease
throughout the T. annulata-endemic zone, while primaquin is used in China.
Chemotherapy might have a role in protecting the calf too young to immunize.
Priorities for future work would include a detailed epidemiological study of the
disease and its transmission patterns as well as cost-benefit analyses of control
measures in different husbandry and production systems. Novel vaccines would, one
hopes overcome the cold-chain and delivery problems of the current live vaccine, but
these are not expected to improve on the protection afforded. The long-term approach
may well prove to be the selection of genetically resistant, moderately productive
cattle for the smallholder dairy farm.
Current vaccines—summarized by Drs. S. Williamson
and P.R. Spooner
A general discussion was held to summarize the methods of vaccine preparation and
use against T. annulata in the different countries represented at the meeting. These
are summarized in Table 1.
STORAGE
Dr. Singh found that vaccine kept for two months at 4 °C produced variable results,
although it was agreed that short-term storage at 4 °C (1 month) was acceptable,
especially where high cell numbers are used for immunization (1–5 × 106).
TABLE 1. Details of cell dose, passage, method of delivery and duration of immunity for
different Theileria annulata cell lines.
Attenuation days
Dose in culture (medium Duration of immunity
(number of cells) changes per week) (tick-free conditions) Delivery
India 5 × 106 675 (3) 18 months Liquid N2
(D.K. Singh) linked with AI
China 1 × 106 120–320 (2) >13 months 4 °C (2 months)
(Z.H. Zhang)
USSR 0.5 × 106 Not known 42 months Liquid N2
(V.T. Zablotsky)
Turkey 10 × 106 Not known Not investigated Liquid N2
(F. Sayin)
Morocco 1 × 104 912 (2) <6 months Planned link
(H. Ouhelli) with AI service
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CROSS-IMMUNITY
Each of the countries represented used one stock in all areas without any indication
of problems with breakthrough infection. Dr. Singh had carried out cross-immunity
trials challenging the vaccine stock with six other stocks without breakthrough,
although Prof. Grewal mentioned that in one area of India one stock, known as T.
annulata Parbani, broke through the vaccine stock. Thus, there is a need for some
further cross-immunity studies.
DEFINITION OF ATTENUATION
According to Prof. Pipano’s paper, complete attenuation has been achieved when,
after inoculation of the vaccine dose, there are no clinical signs and no schizonts,
that piroplasms are detected and that there is no transmission to susceptible cattle
through ticks. Most participants agreed that piroplasms, and occasionally fever, are
observed in vaccinated animals and that a carrier state is established.
CARRIER STATE
Since piroplasms are observed by many workers in vaccinated animals, they are
potentially able  to  infect ticks. One  question raised was whether the parasite
transmitted to ticks feeding on carrier cattle (cattle carrying piroplasms from the
vaccination stock) is infective and virulent. Prof. Grewal reported the transmission
of infection from vaccinated to susceptible cattle resulted in infection but not
clinical disease. Salivary gland dissection confirmed low infection rates in ticks
fed on the vaccinated cattle.
CHALLENGE DOSE
Dr. R.L. Spooner pointed out the importance of defining the challenge dose used
to test vaccines since this often varied between research groups. Similarly, the
method used to detect carriers should be defined since the sensitivity of detection
varies between methods.
Current vaccines for Theileria parva (Dr. T.T. Dolan)
East Coast fever (ECF) is presently controlled by the application of acaricides to
control the tick vector. This method is becoming less reliable because of the high
cost of acaricides, civil unrest, poor management and illegal cattle movements.
Therefore, newer strategies are sought to control ECF and other tick-borne dis-
eases. The method of immunization available and applicable for ECF is infection-
and-treatment in which live sporozoites (stabilate) are inoculated and the animals
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are treated simultaneously with oxytetracycline. Immunized animals become
infected, develop inapparent or very mild disease and immunity and in many
instances become carriers.
Once this method has been accepted for use within a country, a decision has to
be made whether to use a locally isolated parasite (e.g., Kenya, Zanzibar, Zambia,
Zimbabwe) or to use a centrally prepared vaccine that may be a combination of
several stocks. This means that a new stock of parasite may be introduced into an
area (e.g., Malawi, Zambia). South Africa prevents the spread of T. parva from the
buffalo population by operating a slaughter policy should any cattle become
infected.
The most comprehensive and recent costing of an ECF vaccine (Mukhebi et al.,
1990, Preventive Veterinary Medicine 9: 207–219) estimates the cost per animal as
being US$0.89 for the stabilate dose and US$2.37 for the delivered vaccine. This
was estimated on the basis of a 30-year program to vaccinate 2.9 million cattle.
Tools have been developed that demonstrate the antigenic diversity among T.
parva stocks, e.g., monoclonals and DNA probes, but cross-immunity remains the
definitive test in the selection of vaccine stocks as the in vitro tests are not
correlated with the immunogenic nature of the stock.
ECF immunization is being implemented with success in Burundi as a national
program and in Zambia with donor input. Trials are currently in progress in Kenya,
Malawi, Uganda, Zanzibar (Tanzania) and Zimbabwe.
QUESTIONS
Dr. R.L. Spooner queried the low number of vaccine doses that had been applied
to date and Dr. Singh suggested that farmers were apprehensive because disease
reactions occur during immunization. Although few of cattle may react following
vaccination, this was not thought to be a main reason for reluctance to implement
ECF immunization. Dr. Dolan considered that increased application of ECF immu-
nization depended on acceptance by both governments and farmers and would
require a change in attitude concerning strict tick control policies. Dr. McHardy
pointed out that costing of ECF immunization should be more a balance between
cost of disease and cost of vaccination.
Diagnosis of Theileria annulata (Dr. A. Grewal)
The indirect fluorescent antibody (IFA) test is the standard serological test used
for detection of antibodies in most countries. A DOT-EIA has been developed in
India based on piroplasm antigen and appears both specific and sensitive; anti-T.
annulata antibodies appeared three to four weeks after immunization. A dip stick
method has been developed using the same antigen. The standardized antigen is
distributed to research centres throughout India. The test is used for epidemiologi-
cal purposes in cattle and buffalo to assess the need for immunization and to
monitor immunization.
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Prof. A. Grewal also summarized his experimental work on T. annulata immu-
nization. A novel approach in immunizing calves, designed to overcome the
possibility of field infection being contracted before effective immunity could be
established, was described. This involved simultaneous inoculation of tissue
culture vaccine and buparvaquone (Butalex) at 2.5 mg/kg.
Experiments attempting to immunize with purified piroplasms or infected
erythrocytes, with or without adjuvant, were unsuccessful.
QUESTIONS
Dr. Brown raised the concern that piroplasms occurring in an animal after bupar-
vaquone treatment could generate a buparvaquone-resistant strain of parasite. The
cost of the drug was also mentioned—it is likely to be comparable to parvaquone
(Clexon, Coopers Pitman Moore) and would depend on the marketing chains of the
companies in individual countries.
Immunology—summarized by Drs. N. Flynn and J. Naessens
Dr. Innes summarized the immune responses to the different stages of Theileria
annulata.
Tick: Whilst an inflammatory response has been described at the bite site, the
actual role that this response plays in the generation of immunity is poorly
understood.
Sporozoite: Although this stage of the parasite is exposed to the immune system
for only a short period of time, immune serum from cattle exposed to multiple
challenges has been shown to inhibit the infection of PBMs in vitro. The involve-
ment of humoral factors such as TNF or IFN may also have a role in inhibiting the
development of trophozoite to schizont stages in infected cells, but this is poorly
understood.
Schizont: Once the parasite has matured into a schizont, immunity is not
mediated by antibody but by MHC class I-restricted cytotoxic lymphocytes
(CTLs). These cells peak around day 9–10 following challenge of immune animals
and around day 16 in naive animals challenged with autologous infected cells. In
animals challenged with allogeneic cells, an anti-class I CTL response is observed,
peaking around day 9. This response does not prevent immunization, but reduces
pathogenicity of the cell line. By day 23, schizont-infected cells have the BoLA
phenotype of the recipient, indicating transfer of the parasite from donor to
recipient host cells. It is not known how these parasite-specific CTLs are induced,
which antigens are recognized, or the role of accessory cells and helper factors.
Cytokines: The possibility of the potential role of cytokines, produced by the
infected cells, in pathogenicity and development of immunity was mentioned.
Merozoites/piroplasms: Immune sera contain antibodies to merozoite/piro-
plasms and may be involved in blocking transmission. No antibodies to the surface
of infected red blood cells have been identified.
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The responses to Theileria parva (Dr. P. Toye)
Sporozoites: Sera from immune animals block in vitro sporozoite infectivity. The
major antigen recognized is a 67-kDa surface protein, which does not show
heterogeneity among different T. parva stocks.
Schizont: The response to the schizont stages in T. parva is also mediated by CD8+
class I-restricted CTLs. The arguments in favour of a major role for these specific
CTLs in protective immunity are that no correlation exists between antibody titres
and immune status, transfer of immunity can be achieved with lymphocytes, but not
with serum, appearance of CTLs coincides with remission and a correlation between
in vitro parasite specificity and ability to withstand parasite challenge in vivo.
The major task ahead is to identify the parasite antigens recognized by the CTLs.
At present no methodology exists to do this, due to the processing required of the
parasite antigens into immunogenic peptides which are presented in association with
MHC class I. It may be possible to mimic the processing by co-transfecting bovine
MHC and parasite genes into mouse L-fibroblasts, and checking them with relevant
CTLs. The choice of appropriate parasite genes could involve all schizont genes or
a selection of putative candidates: those that are recognized by antibody or T helper
cells, those present on the schizont surface. Evidence was presented that preferential
combinations of MHC products and parasite peptides drive the immune responses,
and this will complicate the search for relevant antigens.
Dr. Williams mentioned that a further complication could be the existence of
different CTL repertoires in different animals. Dr. Toye said that he was not looking
for an epitope that drives a CTL response during an in vivo infection, but for any
epitope present in all parasites.
The 67-kDa sporozoite antigen has been shown to protect against sporozoite
needle challenge in two cattle.
Dr. Spooner talked briefly on comparative aspects of T. annulata and T. parva.
Theileria annulata preferentially infects macrophages and B lymphocytes in contrast
to T. parva which infects T cells and to a lesser extent B cells, but not macrophages.
In an attempt to assess the effect of T. annulata-infection of macrophages on their
ability to process and present third party antigens, ovalbumin-specific T-cell lines
were generated. Theileria annulata-infected cells presented ovalbumin more effi-
ciently than uninfected antigen presenting cells at a constant cell ratio.
POINTS RAISED DURING DISCUSSION
In response to a question from Prof. Tait on the ability of CTLs to protect, Dr.
McKeever said that although CTL responses were `light and transient’ in the periph-
eral blood, they were quite dramatic in draining lymph. Parasite-specific CTL-
precursor frequencies rose to 1/40 cells. Transfer of these cells to non-immune
recipients gave protection from sporozoite challenge.
Dr. Brown suggested that the cellular response may be more biased to helper cells
rather than CTLs in T. annulata. He mentioned the difference in pathogenesis in the
two diseases. Dr. Dolan drew attention to the importance of humoral immunity in T.
sergenti, for which a good blood vaccine exists.
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Dr. Morzaria suggested that merozoite-blocking vaccines could disturb
epidemiological stability by removing the constant re-boosting in a field situation.
Dr. ole-MoiYoi highlighted that by selecting putative antigens for CTL recogni-
tion, one might omit potentially important molecules, such as the nuclear proteins in
influenza.
Dr. Williams said that there was growing evidence that processing of antigen and
association with MHC products can also occur on the membrane. Therefore, he found
it worthwhile to use a random pool of peptides with the right binding properties to
screen with immune CTLs.
Prof. Tait asked whether immune precipitation of class I could be used to identify
associated parasite peptides, as has been done for class II. Dr. Iams commented that
low quantities and many different peptides would be obtained.
Dr. Doyle asked what the role of the carrier state was in maintaining immunity to
T. annulata. According to Dr. Brown, immunity lasts at least 15 months  after
infection-and-treatment, and there was some evidence for a schizont-carrier state. Dr.
Doyle emphasized the importance of selecting CTLs important in maintenance of the
carrier state.
Dr. Williams said that no seroepidemiological studies have been carried out in T.
annulata-endemic areas; only experimentally infected animals had been studied. A
further discussion ensued on the mechanism of schizont transfer. No concrete data
could be given. According to one hypothesis, macrophage phagocytosis of parasite
material could explain the higher transfer in T. annulata.
Discussion of country reports,
current vaccines and immunology
Drs. Doyle and Dolan raised the issue of early vaccination and the observations of
Dr. Grewal in which very young cattle could be treated with buparvaquone (Butalex)
and immunized with cell-culture vaccine at the same time. The drug did not appear
to interfere with the take of vaccine and the animals were immune. Dr. Grewal
confirmed that this was the case, that calves of three weeks of age had been
successfully immunized and that protection had been demonstrated two weeks later
(calves were then five weeks old). These experiments used only small numbers of
calves and were often complicated by intercurrent disease, particularly diarrhoea.
More data was available on the success of this method in calves of four to six weeks
of age—still below the generally recommended age for immunization of two months
(Table 1). This work suggests a significant finding for situations where calves are at
risk to disease exposure from very early in life and Dr. Brown recommended that this
approach should be explored with different parasite stocks in different countries. This
could obviate the need to attempt to modify vaccines to cater for very young calves
in high challenge environments. Dr. Singh pointed out that in his experience calves
immunized below two months of age were susceptible on challenge. The meeting
recognized that the drug might be expensive, or unavailable, and that in a practical
immunization scheme, calves of various ages would be presented for immunization.
Nonetheless, Dr. Grewal’s 100-day vaccine stock, the drug and the immune response
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interacted in this circumstance and if it is reproducible it could greatly enhance the
effectiveness of vaccination.
Dr. Doyle then referred the workshop to the items attenuation, carrier state and
genetic resistance in Figure 1. Dr. Brown mentioned that the work of Prof. Sayin’s
group in Turkey addressed some of these questions, which would be critical in
understanding the epidemiology of T. annulata. He believed that the parasite carrier
state in cattle was maintained by the schizont, although there was no hard data to
confirm this. Prompted by  Dr. Doyle, Dr. Brown agreed that he recognized an
association between cell dose (vaccine dose) and duration of immunity. In addition,
the longer a parasite was held in culture, the more cells were required to immunize.
Dr. Singh had found that when groups of animals were immunized and held under
tick-free conditions, then subjected to challenge at 6, 12 and 18 months, immunity
was undiminished at 18 months. Dr. Ouhelli explained that in Morocco they visit
farms before the start of the theileriosis season to vaccinate calves and newly
introduced cattle, but for convenience they vaccinate all cattle. Dr. Singh followed a
similar strategy.
Dr. Doyle summarized the discussion to this point. There was likely to be a limit
on the duration of immunity and the passage and cell numbers might influence that
duration. He wondered what revaccination might do in adult immunized cattle. Dr.
Innes explained that she had encountered difficulty with revaccination and suggested
that, if the same cell line was being used, a problem of rejection might arise. Dr.
Grewal agreed that this was likely to happen. Other participants thought that this
might be the case but had no experimental evidence to support it. This was clearly
an area in which further work was required, not only to address the duration of
immunity following immunization with a particular cell line, but also to examine
declining immunity in relation to the seasonality of challenge, tick control and pick
up and transmission of the vaccine stock.
Prof. Tait outlined the variables that might be involved in attenuation. One was
the transfer of the schizont from donor to recipient cells which might be influenced
by the expression of peptides presented on the surface of the infected or recipient
cells. The second was the rate of proliferation of cells following transfer—this might
lead to attenuation. The third might be the rate of production of merozoites—could
this be down-regulated? And finally, it could be in the invasiveness of the merozoites
for erythrocytes. He did not think that anyone had looked at these factors and
wondered if it should be done. Dr. Singh commented that there was a cellular
(blasting) reaction following inoculation of the immunizing cells and a delay (incu-
bation period) before the immunizing infection could be detected. When animals were
revaccinated, the cellular response was much reduced. He believed that there was a
population of immune cells responding on revaccination and that piroplasms were
very few. Dr. Doyle wanted to know if he was rejecting all of Prof. Tait’s variables
that might influence attenuation but Dr. Singh thought that the rate of multiplication
might be affected. Dr. Ouhelli observed that following vaccination, few parasites are
seen and they persist for only about two months compared with a year following
natural infection (Dr. Pipano’s vaccine line was attenuated to the point where it did
not produce piroplasms and could not be picked up and transmitted by ticks).
Dr. Doyle then asked if it was worthwhile investigating the kinetics of the vaccine
infection, the initial delay before linear transformation of host cells. Prof. Tait thought
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that the main question was to work out what was actually happening in attenuation.
Dr. Doyle compared the immune response to that in T. parva, where there are probably
very similar cytotoxic T-cell responses. He then asked how many of the million or so
cells were functional in the vaccine and what they did. Dr. Singh thought that 25–30%
might be all that survived. Dr. Williams asked what if just 100 cells survive—what
then? Dr. Doyle wondered if these cells could be identified and why they transfer the
infection. Dr. Williams asked what you would do with that information and Dr. Doyle
replied that you could see how it relates to cell type, the numbers of cell types or clones
you have transferred infection to, then how it affects carrier state and the duration of
immunity. It might also reduce the number of cells needed to vaccinate—What do
people who use these vaccines think about these possibilities? Dr. Morzaria thought
that by maintaining cultures for a long time, you might select parasite strains that do
not produce merozoites. Dr. Doyle agreed, but most of the people at the workshop who
use vaccines reported the development of piroplasms. He asked if the technologies are
available to look at what is happening in the attenuation process and if there were
some kind of recommendation from the meeting as to whether those using vaccines
wanted to know the mechanism(s) of attenuation. Dr. Ouhelli thought that it was
academically interesting although he agreed that if we knew and could use the process,
it might speed up attenuation, which in some cases had taken three to four years to
develop. Dr. Osman considered this a viable area for research.
The Chairman then asked the following questions of those countries which might
plan to use vaccination in the future. Would they use existing vaccines from other
countries as the evidence for antigenic differences in T. annulata was not strong, or
would they envisage political problems? If they are to produce their own vaccines,
should they not start with mild strains that already exist in their country so that they
would not have to address the problem of attenuation either by passage, mutagenesis
or by the use of technologies to understand the genetic changes that are taking place?
Dr. Singh recalled literature reports that suggested that virulent strains were more
likely to provide broad protection than mild strains but he had no experience to
support this. Dr. Brown considered the political implications of live vaccines as
important. While it is relatively easy to produce a `new’vaccine, the question of safety
in moving a live vaccine from one country to another, or even within one country,
might raise important disease control issues.
Dr. Doyle summarized the three sessions and the discussion. There is a vaccine
that is effective but there are things we don’t know about it at various levels and
people are working on these, either in the countries themselves or in collaboration
with the Edinburg and Glasgow groups. There seems to be consensus that this work
is justified and should continue. The political issues and questions of safety regarding
live vaccines suggest that countries will continue to produce their own vaccines and
this work should be funded. Regarding the flow of knowledge or technologies from
work on T. parva to T. annulata, there is no advantage or special knowledge in one
parasite or the other as to why potentially susceptible cells remain uninfected in
carrier cattle. We do not know where T. annulata-infected cells are likely to survive,
although sites of low immunological surveillance have been identified for T. parva.
Therefore one can only encourage communication in these areas where progress with
one parasite might be translated to the research effort of the other.
The Chairman then called for the summary from the session on Biology.
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Biology—summarized by Drs. P. Gardiner and N. Murphy
Because of the extensive polymorphism within isolates of the T. parva species
complex at the monoclonal antibody and immunization level, it was decided to
investigate the genetic basis of this diversity (presented by Dr. S.P. Morzaria). In
restriction digests using rare cutting enzymes, it was noticed that there was a
limited number (approximately 30) of fragments. There was some correlation
between SfiI restriction patterns and previous methods of classification by immu-
nity of stocks. It was further thought that such fragments could be used to determine
the variability in antigenicity. Thus the goal was to determine the basis of the SfiI
polymorphisms, provide a set of mapped markers for genetic recombination studies
and locate the antigen genes that may  be responsible for protection  or stock
characterization. The  generation of  a  map  should  allow  for the generation of
linkage groups and then facilitate the mapping of unknown genes.
The problems in map generation were co-migrating SfiI fragments (resolved by
the use of stocks that were polymorphic at that site) and partial SfiI digestions with
preferential digestion of some sites. The use of probes helped generate the map and
determine chromosome number, which was confirmed through the use of a telomeric
probe. Polymorphisms were located predominantly in telomeric regions.
The genome size of T. parva is 1 × 107 bp. There are four chromosomes,
generating 30 SfiI fragments and 7 NotI fragments. The linkage map has been
generated but fragment 12 is still to be assigned. Mapped genes include identified
antigen genes, the actin gene, heat shock genes and cDNAs of unknown function.
Theileria annulata also has four chromosomes with a small number of SfiI
fragments and, by analogy to the above, a map of the T. annulata genome could be
generated quite readily. It was stated that from measurements of DNA content by
cytofluorimetry of sporozoites and piroplasms of T. annulata, these life cycle
stages were likely to be haploid, and this is also implied by the mapping data.
The differentiation of T. annulata in vitro from the schizont stage to merozoites
has been examined. Using a number of monoclonal antibodies (MAbs), stage-
specific antigens have been identified and the timing of their appearance determined
in the above differentiation sequence. Cloning from established cell lines infected
with T. annulata yielded two types of clones: one that showed an enhanced ability
to transform to merozoites at 41 ÉC, and another that showed a reduced ability. The
interest will be in the stage-specific expression of genes governing this transforma-
tion in the two types of cloned line. The phenotype of the original, infected cell was
unknown, but both types of cell lines responded by the induction of the hsp70
transcript by temperature stimulation. Although the high-producing line could not
be induced to produce piroplasms regularly in vitro, infection of animals with these
lines produced piroplasms very quickly, even before schizonts were detected.
This area has not been investigated in T. parva, partly because the production of
piroplasms is of lesser importance in the pathogenesis of disease caused by this
organism. Studies, if they were initiated, would probably be different in serological
reagents, although it is possible that at the DNA level useful homologies may exist.
Dr. Bishop, complementing the early approaches to differentiate parasite stocks
of T. parva, described DNA probes that have been developed and that recognize a
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variety of moderately or highly repetitive sequences. These repetitive DNA probes
(the same sequences have been identified at ILRAD and Cambridge) have been able
to distinguish T. parva from T. annulata and T. taurotragi. The highly repetitive
sequence is extremely polymorphic amongst T. parva stocks and gives each a
distinctive fingerprint. However, it is difficult to identify immunological relationships
among these stocks with these probes.
A second generation of probes was generated using primers to the original
sequence in a polymerase chain reaction. These have been used for carrier state
detection and stock-specific probes have been generated. These are now being used
to examine the occurrence of sexual recombination in T. parva. The probe sequences
detect large open reading frames (ORFS) arranged in tandem arrays and it is of
interest to identify the encoded protein and determine its function since this molecule
is so polymorphic among stocks.
Further probes have been developed that give simpler patterns on restriction
digests of various theilerial DNAs: e.g., small ribosomal subunit pattern (three RFLPs
have been identified); antisense probes to ribosomal RNA subunits have distin-
guished stocks and species (including T. annulata and buffalo-derived T. parva); and
telomeric sequences (conserved in sequence, but differing in hybridizing restriction
fragments in all stocks examined). The latter probe may be useful in examining
relatedness of isolates.
To date, such analyses have not seemed important for tropical theileriosis because
of the widespread applicability of the attenuated vaccine for T. annulata. However,
if recombinant vaccines were to be contemplated, given the individual phenotypic
heterogeneity of T. annulata isolates (see below), characterization by similar meth-
odologies would become important. At present the reagents available for distinguish-
ing stocks of T. annulata are MAbs, two stage-specific genes (Mag 1 and Spag 1)
and glucose phoshate isomerase (GPI) type. The Spag gene reveals eight alleles and
when all characteristics are combined, all isolates examined show high variability.
At ILRAD, to avoid the problems associated  with (i) multiple infections of
lymphocytes with sporozoites and (ii) more than one infected  tick acinar cell,
scientists have adopted the following cloning technique for T. parva. Sporozoites are
titrated and cultures established from a dilution of one sporozoite to at least 100
lymphocytes. Infected lymphocytes are doubly cloned by limiting dilution, then used
to infect the autologous cell donor and stabilates are made from ticks after pick-up
of the infection. The time-scale for this protocol is at least a year. It was suggested
that sufficient markers were available at ILRAD to distinguish if lymphocytes
infected with more than one schizont might contribute to inaccuracies in the more
rapid cloning of schizont-infected lymphocytes.
Differences in cloning methodology were discussed and later work (see the
discussion  of the Spag 1 gene) demonstrates the necessity of efficient  cloning
procedures when analysing polymorphic genes. In stocks of T. parva that proved to
be genotypically heterogeneous, one clonal type tended to predominate in the stock.
Despite high variability in the T. annulata stocks, cross-protection was still noted
amongst the majority of stocks except the Parbani, Razi and Tara isolates.
The subject was raised as to whether studies of differentiation, as it affected
parasite attenuation in vitro, could be valuably extended (for both species but
particularly for T. annulata). Passage number and other factors affecting attenuation
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should probably be identified for the more efficient production of the T. annulata
vaccine material. The Tova (virulent) isolate could be fruitfully examined vis-a-vis
T. parva and mild T. annulata isolates to identify such factors and possibly attenuation
markers.
Dr. Williams considered the identification of parasite factors that may govern the
transformation of the host cell by theilerial parasites upon infection. Examination of
parasites for oncogene products yielded negative results. However, cells were respon-
sive to cytokines IL-2, IL-4 and (erratically) g-interferon. The IL-2 receptor was found
to be constitutively expressed. Similarly, a protein regulating factor for expression of
the IL-2 receptor has been identified and found to be constitutively expressed.
Reasoning that other inductive factors are either secondary or membrane proteins
of the parasite, an assay has been developed to identify such proteins as direct
products of a plasmid library of T. parva. Ten such products have been identified
(many thousands of plasmids remain to be screened), but none has yet been associated
with the transformation process.
Dr. ole-MoiYoi reported that T. parva-transformed cells express elevated levels of
bovine casein kinase-II, which can phosphorylate both endogenous and exogenous
substrates, but also, probably, a similar parasite enzyme. The latter was identified
through its similarity to the Drosophila β-subunit gene, but the α-subunit has not
been detected. The β-subunit of the parasite enzyme has a unique 78 amino acid tract,
but whether this is concerned with membrane binding is unproven.
It is not clear whether the induction of the host and parasite enzymes, which may
have the ability to phosphorylate oncogene products, are related to the initiation of
the proliferative state of host cells or to the maintenance of that state. However,
phorbol-esters can activate casein-kinase II and Dr. Williams has shown that in the
presence of phorbol-esters and IL-2, the cell lines generated following the removal
of the parasite can be made to proliferate for up to six months.
In the case of T. annulata, infected-PBLs have been shown to secrete growth
factor(s) but these have not been identified. There are also infection-specific tyrosine
and serine/threonine kinases produced by the BL-20 cell line infected with this
parasite. The Tova (virulent) isolate of T. annulata has a single endogenous target of
116–120 kDa for casein kinase II rather than the five such molecules seen in T. parva.
These studies could continue in both parasites, but it might be more fruitful to choose
a single system for  such studies. The fundamental  difference  between  the  two
parasites might be either in their selection of target host cells or in their fundamental
transformation capacity in vivo; T. parva is generally found in T cells, T. annulata in
B cells and macrophages. Other cell types can take up T. parva sporozoites, but
development of the parasite in `unusual’cells is rare. B cells may develop more slowly
and it has been noted that T. parva infection of B cells leads to milder reactions on
injection into cattle.
The discussion of the points indicated that definition of host cell type and
transformation of those cells both in vitro and in the host were all areas that would
be worth studying. Similarly, it would be of interest to know whether the two
parasites both generate and react to cytokines in the same way, and whether
those induced by the other species helped determine growth and transformation
functions.
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Prof. Tait identified genes in T. annulata that were of current interest and detailed
the structure of the merozoite (Mag 1) and sporozoite-specific (Spag 1) genes as
far as they are known.
The Mag 1 gene, which is expressed in merozoites and piroplasms but not in
other stages, contains three types of repeat motif and is reminiscent of some
plasmodial genes. It may code for a surface (glyco) protein.
Spag 1 was identified from a genomic library generated from an uncloned T.
annulata parasite. The cDNA and genomic nucleotide sequences so far determined
differ, suggesting that the sequenced cDNA is derived from another, closely related
allele of the Spag 1 gene. Nothing is known about RNA processing of the transcript,
but the existence of an intron within the gene suggests that this occurs in repeats
with high homology to that found in the elastin gene. It is speculated that Spag 1
is the T. annulata surface molecule responsible for sporozoite binding to host
mononuclear cells and macrophages, but not T cells expressing elastin receptors.
The T. annulata merozoite antigen is not simply a product of in vitro cultivation
as it is recognized by infected sera. The relationship of merozoites produced in
vitro to those in vivo is not known.
Dr. Iams described antibodies that identify the major T. parva sporozoite anti-
gens. A 104-kDa molecule, the antibody to which does not neutralize sporozoite
infectivity, is a component of rhoptries. A 67-kDa molecule that induces a good
neutralizing antibody is encoded from two open reading frames separated by a
small intron and it occurs on the surface of the sporozoite.
An incomplete clone that is thought to define a 30-kDa and a 44/48-kDa
sporozoite protein is presently being sheared so that the immunogeneicity  of
peptides derived from fragments can be analysed for binding of antibody raised to
the larger molecules.
The gene for an 85-kDa antigen that is immunodominant in the induction of
`infection’ sera and monoclonal antibodies has eluded numerous library screens.
No discussion was held of possibly common `house-keeping’ genes or the
mitochondrial elements found in both species. The identified antigen genes would
appear to be quite different and this may accurately reflect the two parasites’
selection of different host cells.
Given the differences in host cell choice and production of piroplasms (and
subsequent pathology), fundamental differences in surface antigens and maturation
antigens might be expected between the two theilerial species, but it is recom-
mended that both immunologically and biologically based investigations be con-
tinued in efforts to identify alternative targets for vaccination. Such antigens are
required now for T. parva and may ultimately be required for T. annulata when
recombinant vaccines produced in bulk may supplement the attenuated vaccine for
this parasite and might surmount the problems of the cold chain requirements and
the problems of immunizing young animals.
It is clear from the work presented at this session that the approaches taken to
identify antigen genes of interest and to study parasite differentiation and transfor-
mation are similar in both parasite species. The reagents and technologies are also
similar although the states of knowledge in certain areas are different. In this context,
four areas that can be considered are genome mapping, differentiation, antigen genes
and transformation.
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There is a range of T. annulata (gene clones and monoclonals) recognizing isolates
and clones that could be developed as diagnostic and epidemiological tools. The
contributions that ILRAD could make to these studies therefore are primarly in
genome mapping and transformation, but, perhaps as importantly, ILRAD could
promote improved exchange of personnel, material, reagents and information
between the `annulata’ and `parva’ fraternities.
The Chairman thanked Prof. Tait and then called for the reports on Epidemiology
and Modelling.
Epidemiology—summarized by Dr. J. Delehanty
Dr. Perry described the mandate and the work of ILRAD’s  Epidemiology and
Socioeconomics Program. This Program was established quite recently as an adjunct
to ILRAD’s basic biological research on animal diseases and has concentrated, up
till now, on the epidemiological, socioeconomic and environmental contexts of T.
parva and its control.
The basic assumption underlying the Program’s research to date is that theileriosis
affects different regions and different production systems differently. We do not really
know the magnitude of this variable effect in different African systems, yet we ought
to. Even where we have a good idea of severity, our knowledge of disease impact,
particularly economic impact, tends to be, at best, anecdotal. It follows then that in
some systems a new method of controlling theileriosis will have profound and
positive effects while in other systems a given method will have little effect, or
actually be deleterious in one way or another. We do not really know where, in Africa,
a given control method could be applied to positive effect, and where it would be
inadvisable, yet we ought to. For this reason, much of the work of the Program, thus
far, has  been explicitly geographic. Relying heavily on geographic information
systems, an attempt is being made to assemble data and compile maps that will
describe spatial variability in disease risk, disease effect, and the potential impact of
better control. Not all variability is spatial. An integral part of this work is to index
non-spatial considerations or factors within the spatial matrix.
Work is being conducted at three levels of resolution. At the smallest scale are
farm- and district-level studies, all in Kenya. Here, detailed descriptions of disease
epidemiology, farm management, farm economics and the social context of cattle
production are being assembled in the expectation that the dynamic descriptions
assembled, and the control recommendations derived, can be projected to similar
regions elsewhere. At a middle level of resolution, country-level studies have been
undertaken in Zimbabwe to assess both the biological and the economic efficacy of
current tick-borne disease control strategies, and to determine where, and under what
conditions, these could be modified to positive effect. Finally, at a continental scale,
various geographic models of vector and disease suitability (such as CLIMEX and
BIOCLIM) have been run in order to test their predictive powers and assess their
utility for determining where improved control is warranted. These latter activities
are just a first step in a broad campaign to assemble and analyse, for Africa as a whole,
a range of data, including economic and environmental data, that will allow us to
assess patterns of current disease impact and the potential impact of control.
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Three major points of discussion were raised in response to Dr. Perry’s presenta-
tion. First, concern was raised over research costs. Can the local-level studies
described here be replicated cost-effectively in all areas, or are we not better off
abandoning concern for small-scale variability in disease risk and vaccinating every-
thing? These concerns are legitimate, but Dr. Perry stressed in response that studies
of this sort are not contemplated on a broad scale. Projections from a few carefully
chosen regions to a broader universe is precisely the point of the exercise.
Second, it was pointed out that the databases and analytical procedures being
developed in conjunction with this work will be widely applicable to studies of the
control of a host of livestock diseases. Fundamentally, these data and procedures are
not specific to theileriosis or to T. parva.
Modelling—summarized by Mr. J. Scott
A wealth of information exists on East Coast fever, which has been reported in
the literature for over 80 years. Relationships and rules can be extracted from
empirical findings and it is possible to use them to construct a model of the
interactions among ticks, cattle and T. parva. Using meteorological and other data,
a model can explain the pattern of tick population dynamics and disease outbreaks
in different areas. For example, results of computer experiments using the ECFX-
PERT model indicate that carrier state is necessary to maintain disease. Without
carrier state, ticks did not develop infection. It was noted that superinfection is
poorly reported in the literature and further information is essential for inclusion
in the model.
Models can be classified according to the type, the site, the biological level and
function and precision of the model. The use of index models and artificial intelli-
gence models should be explored for other theilerioses. Looking into the future,
geographical information systems may be combined with these classical techniques
to give rise to integrated geographical information systems that might provide a high
prediction power. Another type of mathematical model might be chaos, whereby
small changes in inputs to the model ripple through and produce very different outputs
from what we might expect.
Four main points were raised in the discussion: carrier state, models, chaos and
parasitaemia.
1) Carrier state is important in the model and wildlife provide large reservoirs for
the disease. These now appear to be accepted dogmas in the epidemiology of East
Coast fever.
2) Regarding chaos, one way to determine whether a system was chaotic or not is
to vary inputs and to see what kind of outputs are produced.
3) Regarding models, one way to try to strengthen them is to adjust parameters to
try to improve the fit to data that we are working with. With complex models, it is
also noted that one of the major problems of ECFXPERT, and other types of models,
is that if we want to make radical changes to the model, we have to change the
computer code, which is time-consuming and there is no guarantee that it will work.
It is hoped that the new generation of expert systems, artificial intelligence and
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simulation models will make such changes a lot easier and that models can be
generated a lot faster.
4) Parasitaemia in relation to tick infection needs to be much better understood
for incorporation within infection models.
Finally, how do the geographic models described by Dr. Perry fit with the
dynamic disease models developed  and  described by  Dr. Gettinby?  To  which
approach should researchers turn? On this question, Dr. Gettinby and Dr. Perry
concurred. These are two approaches to the same questions, coming from opposite
directions. Ultimately, they are reconcilable and may prove mutually dependent.
Dr. Gettinby’s models of disease dynamics are driven by the site-specific determi-
nants of parasite behaviour. Dr. Perry’s models attempt to outline the variable
contexts of disease occurrence and disease cost; in other words, what goes to
determine site-specificity. Each approach uses, and may require, the other. The
question remaining is this: what are the minimum data sets necessary to do both
well?
Dr. Gettinby commented that epidemiological data from T. annulata can be input
into a model such as ECFXPERT and many of the questions discussed such as the
consequences of carrier state or of different forms of vaccination in relation to
transmission could be addressed. He believed that it would be short-sighted to
concentrate on epidemiology and not on both epidemiology and vaccination. The
relationships of these two have to be put into empirical models if we are to link the
life cycle of the tick to the transmission of disease.
The Chairman opened the discussion on epidemiology by asking those involved
in vaccination how much they wished to know about the epidemiology of the
disease. He had heard questions raised about the detection of disease in water
buffalo and indigenous  cattle. What more did people wish to know about the
susceptibility of these animals and how did they plan to get it?
Dr. Grewal thought that PCR-based DNA probes would be extremely useful for
studying carrier state parasitaemias. Dr. Singh commented that the extent of the
disease is not known and wondered if it would be possible to distinguish between
immunizing and natural infections. Dr. Brown thought that some very detailed
studies, such as those described by Dr. Perry for T. parva (in Kaloleni in Kenya)
would be important. Such an exercise might address the problem as it affects the
poorest farmer and provides economic data. If it is shown that these very poor
farmers cannot afford vaccination, what could be done to provide vaccination for
their cattle? This could be done effectively only with efficient epidemiological and
immunological tools. Dr. Ouhelli considered that epidemiological studies should
include other tick-borne diseases and that sensitive specific tests for Anaplasma
and Babesia were essential in investigating and controlling T. annulata.
Dr. Doyle agreed with the importance of all the points raised, particularly the
identification of vaccine strains in the natural pool of parasites. This of course was
more difficult where locally produced local isolates (strains) were used for vacci-
nation.  Nonetheless, the  technologies  for  determination of genetic  changes in
vaccine strains were available. It was apparent also that many reagents were
available which might prove to be efficient epidemiological tools and the expertise
was available to develop them in a practical period of time. All that is required is
a decision that it is important and that it should be done. In Dr. Brown’s opinion,
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these were very difficult components to write up within a three-year project. These
were reasonably long-term ambitions and the question was how to persuade donors
to provide long-term support. Dr. Doyle agreed that this was a problem, but clearly
those countries applying vaccination appreciate the priority need in developing
technologies to sustain vaccine development and application.
Dr. Singh raised the suspicion that there is some degree of immunosuppression
following vaccination. It was pointed out that this could be addressed by direct
experimentation. The relationship of age, nutritional status, intercurrent disease
and vaccination with other vaccines such as rinderpest and foot-and-mouth could
be experimented upon.
Dr. Doyle then asked Dr. Spooner (R.L.) for his views on genetic resistance. Dr.
Spooner remarked that there is some evidence for genetic resistance to disease and
much more for resistance to ticks. Disease resistance may be more important in the
case of T. parva. As these diseases are dose dependent, tick resistance may have a
significant effect if ticks are not heavily infected. Together with Dr. Brown, he had
been reviewing the literature on resistance to theileriosis, which he believed was
very limited. They had made proposals to do specific experiments to look at
epidemiology and genetic resistance and to try to separate disease and vector
resistances. Dr. Brown reported that they had just completed a small experiment
with Sahiwal animals. This breed is being crossed with high-producing breeds,
particularly Jerseys, in New Zealand and then being exported to Southeast Asia.
This type of animal is what World Bank projects are planning to use for the long
term in countries such as India. The results show that Sahiwal are more resistant
than Ayshire or Holstein breeds. The literature from India reports that indigenous
cattle are resistant to tropical theileriosis but there are an equal number of reports
that describe their susceptibility. This needs to be defined for planning breeding
programs where T. annulata is a problem. Dr. Dolan pointed out that there is clear
evidence of decreased susceptibility to T. parva in endemic areas and that in the
country reports delivered at this workshop most countries reported that the cattle
at risk to T. annulata were the imported high-producing stock.
Dr. Doyle felt that this area required much more study using the best
epidemiological tools available. The suggestion that buffalo and indigenous cattle
are susceptible, or at least not as resistant as previously thought, means that the
problem may be much greater than has been assumed. The selection for resistance
and identification of the resistance trait, away from any environmental noise, will
be expensive and time consuming. ILRAD’s trypanotolerance program is an exam-
ple. The work being undertaken on mapping the bovine genome over the next five
to seven years will identify linkages which may be useful—but that is not available
now. The epidemiological research at ILRAD, developing improved epidemiologi-
cal tools, using GIS and beginning to look in depth at theileriosis in eastern and
southern Africa in different epidemiological regions and in different farming
systems, will establish methodologies that will be applicable in other disease
situations, particularly tropical theileriosis. However, our knowledge of disease
impact and its economic cost is extremely poor and ILRAD’s approach using these
newer technologies is justified in attempting to put real costs on these very
significant problems.
The Chairman then called for the summary of the session on novel vaccines
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Novel vaccines—summarized by Dr. M. Sileghem
and Mr. N. MacHugh
The need for alternative vaccine strategies has arisen because of the disadvantages
of the existing methods of immunization against T. parva and T. annulata, namely,
the viability of cells and sporozoites, the need for a cold chain system, the parasite
heterogeneity, the use of live parasites and the induction of a carrier state. In immune
cattle, both antibodies to the sporozoite stage of the parasite and cytoxic T cells
specific for schizont-infected cells can be demonstrated. Subunit vaccines could be
used to exploit either or both of these immune systems.
SUBUNIT VACCINES
The idea of constructing subunit vaccines that affect different life cycle stages of the
parasite and eventually trigger different components of the immune system was
proposed by different speakers. Immunity to sporozoites can be achieved by antibod-
ies; however, high titres are required and a low number of escaping sporozoites can
initiate infection. Therefore, a subunit vaccine affecting both sporozoites and mero-
zoites was proposed by Prof. Tait for T. annulata. With this vaccine approach, the
few sporozoites escaping destruction could still differentiate into schizonts but would
be  unable to differentiate into piroplasms. Immunity to both sporozoites and
merozoites are mainly mediated by antibodies specific for surface molecules.
Another subunit vaccine directed to sporozoites and schizonts was proposed by
Dr. McKeever for T. parva. The immunity to sporozoites would be achieved through
antibody induction whereas the immunity to schizonts would be achieved through
activation of cytotoxic T lymphocytes (CTLs).
DELIVERY SYSTEMS
It is well known that T cells do not recognize native antigen but are triggered by a
processed molecule which is co-presented with MHC molecules. The processing of
antigens that associate with the MHC class I molecules and trigger CTLs is thought
to take place in the cytosol. To trigger T cells, it is thus essential to deliver the antigen
in the correct way. This can be achieved by the use of pH-sensitive liposomes, which
dissolve after internalization and guarantee a cytoplasmic delivery, or by the use of
ISCOM particles. ISCOM particles are constructed of cholesterol, lecithin and Quil
A and have been shown to induce a strong CTL activity in other systems. Another
suitable system is the construction of lipopeptides by conjugating the peptide antigen
to a lipid `tail’. Finally, the gene encoding the antigen can be delivered after
integration in recombinant viruses or bacteria. The best known systems for this type
of delivery are vaccinia, herpes, adenoviruses, Salmonella and Escherichia coli.
Dr. McKeever gave an example of antigen delivery using a recombinant virus. The
gene encoding the 67-kDa surface protein from T. parva sporozoites was cloned and
inserted into a vaccina virus. Rabbits and guinea pigs were challenged with 106 and
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5 × 107 plaque-forming units, respectively. In both cases, a strong response to the
p67 was observed as determined by Western blotting. Both antisera were capable of
blocking the in vitro infection of lymphocytes by sporozoites. This blocking effect,
however, was only seen at high antiserum titres.
In a preliminary experiment, cattle were challenged with the recombinant virus.
The antiserum was positive for p67 recognition and blocked in vitro sporozoite
infection at a 1:4 dilution. Out of two animals, one also manifested a strong T-cell
proliferative response to the purified p67.
Both Prof. Tait and Dr. Musoke presented data on the identification and cloning
of genes encoding antigens that induce sporozoite neutralizing antibodies in cattle.
In the T. annulata study, the gene encodes a polypeptide of approximately 104 kDa.
Immunization with a recombinant antigen produced using this gene conferred pro-
tection against challenge with T. annulata in one animal. It failed to protect another.
In a further study, animals immunized with lysed sporozoites injected with either
saponin or Freunds adjuvant showed delayed onset of disease when challenged. Dr.
Musoke presented data on immunization with recombinant antigen produced using
a gene encoding a 67-kDa polypeptide. Two animals were immune to challenge with
a 1/100 dose of T. parva stabilate 3087, but one animal had a severe response to a
tenfold higher dose while the other showed a less severe reaction.
POINTS RAISED IN DISCUSSION
Prof. Tait suggested that the 104-kDa recombinant could be used to map potential B-
and T-cell epitopes. Evidence in Leishmania suggests that single epitopes can be
protective.
Closing remarks
Dr. Gray, Director General, ILRAD, thanked all the participants for their vigorous
commitment during the three days of the workshop. He felt that ILRAD had obtained
a thorough update on the extent of the tropical theileriosis problem and the current
state of research and control. This will help significantly in ILRAD’s planning for the
quinquennium 1993–1997. He recalled an EEC-funded meeting in Edinburgh a few
years ago which had addressed many of the problems discussed this week. He thought
that it would be useful for the authors of the report on this workshop to review the
conclusions of that meeting to see what progress had been made and if the recom-
mendations for future work remained the same. He was impressed with expertise on
T. annulata that existed in and around Nairobi. He thanked Dr. Doyle whom he felt
chaired the concluding discussion particularly well and he thanked the participants
once again and wished the visitors an enjoyable continuation of their stay in Kenya.
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CONCLUSIONS
AND RECOMMENDATIONS
Conclusions and recommendations
• Cell-culture vaccines for use in immunization against Theileria annulata are
effective and widely used and any novel vaccine that is developed will have to be
of comparable efficacy and as economical to produce.
• Standards are required for assessing the immunizing capacity of individual vaccine
cell lines (strains) and for ensuring that vaccine lines are free from other bovine
pathogens.
• The widespread protection provided by individual isolates suggests that antigenic
diversity is not a significant problem with T. annulata. Collaborative cross-immu-
nity studies could identify the most widely protective cell lines and the use of these
would assist in standardization, quality control and safety testing.
• The duration of immunity varies between vaccine cell lines and may be related to
passage number, cell dose, individual parasite idiosyncrasy and age or nutritional
state of the animal. Further work is required to define the duration of immunity
with important immunizing stocks, to identify the need for, and frequency of,
re-immunization and to investigate the possible rejection of the immunizing cell
line following repeated immunization.
• The mechanism(s) of attenuation is unknown and an understanding of the molecu-
lar basis of this process could facilitate the rapid production of non-virulent
parasites that would meet the strictest standards for vaccines related to immunizing
capacity, carrier state and transmissibility.
• The chemotherapeutic drug buparvaquone has an important place in integrated
control of T. annulata and its potential in protecting calves below the age of two
months from natural disease challenge, while apparently facilitating the develop-
ment of the cell-culture-vaccine-induced immunity needs thorough investigation.
• The nature of the immune responses to all stages of T. annulata requires further
elucidation to assist in the identification of the major protective antigens for
exploration in novel vaccines that will provide effective, long-lasting immunity
that rivals or exceeds that of the current live-cell-culture vaccines.
• Current research on the antigens of the sporozoite and merozoite stages of T.
annulata should be pursued and a comparison of the sporozoite surface antigen,
Spag, of T. annulata and the p67 antigen of T. parva should be undertaken.
• The epidemiology of T. annulata is poorly understood and work needs to be
undertaken to define the extent of tropical theileriosis, to measure the susceptibility
of cattle of different types and ages and Asian buffalo, to identify immunogenic
types (strains) of the parasite circulating in the field, and to study the persistence
of infection in animals and ticks and the antigenic nature and transmissibility of
these parasites.
• Although tropical theileriosis is known to extend from North Africa to China, few
studies have been undertaken of the economic importance of the disease, on the
mortality and production losses or on the cost of control. This is an important area
of study that must be addressed to determine the economic impact of tropical
theileriosis and to direct commensurate resources towards more effective control.
• ILRAD’s immunological expertise  and approaches  to molecular vaccines, its
geographical information systems and epidemiological and socioeconomic skills
are all of potential benefit to research and control of T. annulata and should be
exploited in collaboration with, and in the transfer of relevant technologies to,
national and international laboratories working on tropical theileriosis.
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